Medicare Coverage Policies May 2013 update Dear Client, This manual was developed to provide a ready reference of coverage policies so you can determine whether it is necessary to have Medicare patients sign an Advance Beneficiary Notice (ABN). Use this manual to verify the need for an ABN by checking the ICD-9 code provided by the physician against the policy for medical necessity. If the ICD-9 code is not listed (with the exception of the Blood Count policy - see below), have the patient sign an ABN before drawing the specimen. There are two types of policies located in this manual. One is the National Coverage Decisions (NCD) Uniform Lab Policies, and the other is the Local Coverage Decisions (LCDs). The policy type for each test contained in this manual can be found below and to the right of the test name: Alpha-fetoprotein Policy Type: NCD (National Coverage Decision) For each policy, you will see its CPT code(s) listed below the heading area and the ICD-9 (diagnosis) codes that are accepted for payment. There is an exception to this format: the list of covered codes for the Blood Count policy is so expansive that the non-covered codes are listed instead. Please note that this policy information is specific to the State of Oregon. The policy is regularly updated. Visit our website at www.peacehealthlabs.org/publications for the most recent update and to view or print this manual online. Medicare regulations state that it is the responsibility of the physician or an authorized representative to select the diagnosis based on the medical record, not reimbursement considerations. This manual is not meant to suggest or in any way influence the selection of an ICD-9 code. If you have questions about this manual, please call PeaceHealth Laboratories Billing at 541687-2134 or 800-826-3616. For additional copies, call Melissa Sanders at 541-349-8447. PeaceHealth Laboratories PeaceHealth Laboratories PeaceHealth Laboratories PeaceHealth Laboratories Medicare Coverage Policies Universal Policy Guidelines: NCD reasons for denial For all NCD policies, the following reasons for denial apply: Note: This section has not been negotiated by the Negotiated Rulemaking Committee. It includes CMS’s interpretation of its longstanding policies and is included for informational purposes. • Tests for screening purposes that are performed in the absence of signs, symptoms, complaints, or personal history of disease or injury are not covered except as explicitly authorized by statute. These include exams required by insurance companies, business establishments, government agencies, or other third parties. • Tests that are not reasonable and necessary for the diagnosis or treatment of an illness or injury are not covered according to the statute. • Failure to provide documentation of the medical necessity of tests may result in denial of claims. The documentation may include notes documenting relevant signs, symptoms, or abnormal findings that substantiate the medical necessity for ordering the tests. In addition, failure to provide independent verification that the test was ordered by the treating physician (or qualified non-physician practitioner) through documentation in the physician’s office may result in denial. • A claim for a test for which there is a national coverage or local medical review policy will be denied as not reasonable and necessary if it is submitted without an ICD–9–CM code or narrative diagnosis listed as covered in the policy unless other medical documentation justifying the necessity is submitted with the claim. • If a national or local policy identifies a frequency expectation, a claim for a test that exceeds that expectation may be denied as not reasonable and necessary, unless it is submitted with documentation justifying increased frequency. • Tests that are not ordered by a treating physician or other qualified treating nonphysician practitioner acting within the scope of their license and in compliance with Medicare requirements will be denied as not reasonable and necessary. • Failure of the laboratory performing the test to have the appropriate Clinical Laboratory Improvement Amendment of 1988 (CLIA) certificate for the testing performed will result in denial of claims. PeaceHealth Laboratories Medicare Coverage Policies Universal Policy Guidelines: NCD coding guidelines For all NCD policies, the following coding guidelines should be observed: 1. Any claim for a clinical diagnostic laboratory service must be submitted with an ICD–9–CM diagnosis code. Codes that describe symptoms and signs, as opposed to diagnoses, should be provided for reporting purposes when a diagnosis has not been established by the physician. (Based on Coding Clinic for ICD–9–CM, Fourth Quarter 1995, page 43). 2. Screening is the testing for disease or disease precursors so that early detection and treatment can be provided for those who test positive for the disease. Screening tests are performed when no specific sign, symptom, or diagnosis is present and the patient has not been exposed to a disease. The testing of a person to rule out or to confirm a suspected diagnosis because the patient has a sign and/or symptom is a diagnostic test, not a screening. In these cases, the sign or symptom should be used to explain the reason for the test. When the reason for performing a test is because the patient has had contact with, or exposure to, a communicable disease, the appropriate code from category V01, Contact with or exposure to communicable diseases, should be assigned, not a screening code, but the test may still be considered screening and not covered by Medicare. For screening tests, the appropriate ICD–9–CM screening code from categories V28 or V73–V82 (or comparable narrative) should be used. (From Coding Clinic for ICD–9–CM, Fourth Quarter 1996, pages 50 and 52). 3. A three-digit code is to be used only if it is not further subdivided. Where fourth-digit and/or fifth-digit sub-classifications are provided, they must be assigned. A code is invalid if it has not been coded to the full number of digits required for that code. (From Coding Clinic for ICD–9– CM. Fourth Quarter, 1995, page 44). 4. Diagnoses documented as ‘‘probable,’’ ‘‘suspected,’’ ‘‘questionable,’’ ‘‘rule-out,’’ or ‘‘working diagnosis’’ should not be coded as though they exist. Rather, code the condition(s) to the highest degree of certainty for that encounter, such as signs, symptoms, abnormal test results, exposure to communicable disease or other reasons for the visit. (From Coding Clinic for ICD–9– CM, Fourth Quarter 1995, page 45). 5. When a non-specific ICD–9 code is submitted, the underlying sign, symptom, or condition must be related to the indications for the test. PeaceHealth Laboratories Medicare Coverage Policies Universal Policy Guidelines: LCD reasons for denial For all LCD policies, the following reasons for denial apply: Medicare does not cover routine screening in the absence of signs or symptoms. Periodic monitoring of serum levels of high-risk medication is not considered screening. When the documentation does not meet the criteria for the service rendered or the documentation does not establish the medical necessity for the services, such services will be denied as "not reasonable and necessary" under Section 1862 (a) (1) of the Social Security Act. Medicare Coverage Policies Universal Policy Guidelines: LCD coding guidelines For all LCD policies, the following coding guidelines should be observed: ICD-9-CM code V82.9 (special screening of other conditions, unspecified condition) should be used to indicate screening tests performed. Use of V82.9 will result in the denial of claims as non-covered screening services. All ICD-9-CM diagnosis codes must be coded to the highest level of specificity. Reviewing results of laboratory tests, phoning results to patients, filing such results, and such activities as obtaining, reviewing, and analyzing the appropriate diagnostic tests, etc., are services which are covered by the program, and payment for these services is included in the payment for the evaluation and management (E&M) services to the patient. PeaceHealth Laboratories Medicare Coverage Policies Table of Contents Policy Name Testing Indications and Limitations Alpha-fetoprotein B-type Natriuretic Peptide (BNP) Blood Counts CA 125 CA 15-3 (27.29) CA 19-9 Carcinoembryonic Antigen (CEA) Collagen Cross Links Cytogenetics Digoxin GGT General Health Panel Genetic Testing Glucose Glycated Protein/Glycohemoglobin Gonadotropin, Chorionic (hCG) Hepatitis Panel HIV testing; Diagnosis HIV testing; Prognosis, including monitoring Iron Studies Lipid Testing Occult Blood, Fecal Partial Thromboplastin Time (PTT) Prostate Specific Antigen (PSA) Prothrombin Time Screening for Sexually Transmitted Infections (STI’s) Thyroid Testing Urinalysis Urine Culture, Bacterial/Sensitivity Studies Vitamin D Assay Additional Coding Guidelines PeaceHealth Laboratories NCD LCD N/A N/A Page i-xxxiv 1-2 3-4 5-11 12 13 14 15 16 17-21 22-24 25-28 29 30-37 38-41 42-43 44-45 46 47-51 52 53-56 57-64 65-68 69-74 75 76-83 84-89 90-94 95-116 117-119 120-121 122-126 PeaceHealth Laboratories Medicare Coverage Policies NCD/LCD Policy Updates Policy Name Alpha-fetoprotein B-type Natriuretic Peptide (BNP) Blood Counts CA 125 CA 15-3 (27.29) CA 19-9 Carcinoembryonic Antigen (CEA) Collagen Cross Links Cytogenetics Digoxin GGT General Health Panel Genetic Testing Glucose Glycated Protein/Glycohemoglobin Gonadotropin, Chorionic (hCG) Hepatitis Panel HIV testing; Diagnosis HIV testing; Prognosis, including monitoring Iron Studies Lipid Testing Occult Blood, Fecal Partial Thromboplastin Time (PTT) Prostate Specific Antigen (PSA) Prothrombin Time Screening for Sexually Transmitted Infections (STI’s) Thyroid Testing NCD LCD Urinalysis Urine Culture, Bacterial/Sensitivity Studies Vitamin D Assay 1/12 3/12 4/12 10/06 10/06 10/06 10/09 10/04 3/12 10/10 10/11 9/95 12/12 10/11 10/11 10/11 10/10 10/10 1/07 10/11 10/11 10/11 10/11 10/10 1/12 2/12 10/11 5/13 10/10 PeaceHealth Laboratories Last update 3/12 PeaceHealth Laboratories Medicare Coverage Policies Test/CPT Listing Policy Name NCD Alpha-fetoprotein B-type Natriuretic Peptide (BNP) CA 125 CA 15-3 (27.29) CA 19-9 Carcinoembryonic Antigen (CEA) Collagen Cross Links Cytogenetics General Health Panel Genetic Testing Glucose Glycated Protein/Glycohemoglobin Gonadotropin, Chorionic (hCG) Hepatitis Panel HIV testing; Diagnosis HIV testing; Prognosis, including monitoring Iron Studies Lipid Testing Occult blood, Diagnostic Prostate Specific Antigen (PSA) Prothrombin Time 86304 86300 86301 82378 82523 GGT PeaceHealth Laboratories 83880 85004, 85007, 85008, 85013, 85014, 85018, 85025, 85027, 85032, 85048, 85049 Digoxin CPT Code(s) 82105 Blood Counts Partial Thromboplastin Time (PTT) LCD 88120, 88121, 88230-88299 80162 82977 80050 81201, 81202, 81203, 81211, 81212, 81213, 81214, 81215, 81216, 81217, 81270, 81275, 81292, 81293, 81294, 81295, 81296, 81297, 81298, 81299, 81300, 81317, 81318, 81319, 81381, 81401, 81403, 81405, 81406, and 88363 82947, 82948, 82962 82985, 83036 84702 80074 86689, 86701-86703, 87390, 87391, 87534, 87535, 87537, 87538 87536, 87539 82728, 83540, 83550, 84466 80061, 82465, 83700, 83701, 83704, 83718, 83721, 84478 82272 85730 84153 85610 Medicare Coverage Policies (con’t) Test/CPT Listing Policy Name NCD LCD Screening for Sexually Transmitted Infections (STI’s) Thyroid Testing Urinalysis Urine Culture, Bacterial/Sensitivity Studies Vitamin D Assay 87086, 87088, 87184, 87186 PeaceHealth Laboratories CPT Code(s) Chlamydia (86631, 86632, 87110, 87270, 87320, 87490, 87491, 87810) (*87800 used for combined Chlamydia & Gonorrhea testing) Gonorrhea (87590, 87591, 87850, 87800*) Syphilis (86592, 86593, 86780) and Hepatitis B (Hepatitis B surface antigen) (87340, 87341) 84436, 84439, 84443, 84479 81000, 81001, 81002, 81003, 81005, 81007, 81015, 81020 82306, 82652 Indications and Limitations Test Name Indications/Limitations Alpha-fetoprotein Policy 190.25 AFP is useful for the diagnosis of hepatocellular carcinoma in highrisk patients (such as alcoholic cirrhosis, cirrhosis of viral etiology, hemochromatosis, and alpha 1-antitrypsin deficiency) and in separating patients with benign hepatocellular neoplasms or metastases from those with hepatocellular carcinoma and, as a nonspecific tumor associated antigen, serves in marking germ cell neoplasms of the testis, ovary, retro peritoneum, and mediastinum. B-type Natriuretic Peptide Policy L31568 Indications BNP measurements may be considered reasonable and necessary when used in combination with other medical data such as medical history, physical examination, laboratory studies, chest x-ray, and electrocardiography in the following two clinical situations. • Acute exacerbation of dyspnea in patients with known or suspected pulmonary or other non-cardiac causes of dyspnea to rule out CHF. Plasma BNP levels are significantly increased in patients with CHF presenting with acute dyspnea compared to patients presenting with acute dyspnea due to other causes. • Acute exacerbation of dyspnea in patients known to suffer from both chronic obstructive pulmonary disease (COPD) and CHF. The BNP level may assist the physician distinguish between an exacerbation of COPD and decompensated CHF. Plasma BNP levels are significantly increased in patients with CHF with or without concurrent lung disease compared with patients who have primary lung disease. Limitations BNP measurements must be assessed in conjunction with standard diagnostic tests, medical history and clinical findings. The efficacy of BNP measurement as a stand-alone test has not been established yet. Moreover, certain conditions such as (and not limited to) ischemia, infarction and renal insufficiency, advanced age, female gender may cause elevation of circulating BNP; obesity, upstream heart failure and other conditions lower the BNP level. These conditions confound the interpretation of BNP levels to varying extents. The efficacy and/or utility of plasma BNP level as a monitor of the degree of CHF or the efficiency of CHF treatment has not been established. Treatment guided by BNP has not been shown to be PeaceHealth Laboratories | Indications and Limitations i Indications and Limitations Test Name Indications/Limitations B-type Natriuretic Peptide Policy L31568 superior to symptom-guided treatment in either clinical or quality of life outcomes. Therefore, BNP measurements for monitoring and management of CHF are non-covered. The efficacy but not the utility of BNP as a risk stratification tool (to assess risk of death, myocardial infarction or congestive heart failure) among patients with acute coronary syndrome (myocardial infarction with or without T-wave elevation and unstable angina) has been established. However, the assessment of BNP level has not been shown to alter patient management. The BNP is not sufficiently sensitive to either preclude or necessitate any other evaluation or treatment in this group of patients. Screening examinations are statutorily non-covered. PeaceHealth Laboratories | Indications and Limitations ii Indications and Limitations Test Name Indications/Limitations Blood Counts Policy 190.15 Indications Indications for a CBC or hemogram include red cell, platelet, and white cell disorders. Examples are enumerated individually below. 1. Indications for a CBC generally include the evaluation of bone marrow dysfunction as a result of neoplasms, therapeutic agents, exposure to toxic substances, or pregnancy. The CBC is also useful in assessing peripheral destruction of blood cells, suspected bone marrow failure or bone marrow infiltrate, suspected myeloproliferative, myelodysplastic, or lymphoproliferative processes, and immune disorders. 2. Indications for hemogram or CBC related to red cell (RBC) parameters of the hemogram include signs, symptoms, test results, illness, or disease that can be associated with anemia or other red blood cell disorder (e.g., pallor, weakness, fatigue, weight loss, bleeding, acute injury associated with blood loss or suspected blood loss, abnormal menstrual bleeding, hematuria, hematemesis, hematochezia, positive fecal occult blood test, malnutrition, vitamin deficiency, malabsorption, neuropathy, known malignancy, presence of acute or chronic disease that may have associated anemia, coagulation or hemostatic disorders, postural dizziness, syncope, abdominal pain, change in bowel habits, chronic marrow hypoplasia or decreased RBC production, tachycardia, systolic heart murmur, congestive heart failure, dyspnea, angina, nailbed deformities, growth retardation, jaundice, hepatomegaly, splenomegaly, lymphadenopathy, ulcers on the lower extremities). 3. Indications for hemogram or CBC related to red cell (RBC) parameters of the hemogram include signs, symptoms, test results, illness, or disease that can be associated with polycythemia (for example, fever, chills, ruddy skin, conjunctival redness, cough, wheezing, cyanosis, clubbing of the fingers, orthopnea, heart murmur, headache, vague cognitive changes including memory changes, sleep apnea, weakness, pruritus, dizziness, excessive sweating, visual symptoms, weight loss, massive obesity, gastrointestinal bleeding, paresthesias, dyspnea, joint symptoms, epigastric distress, pain and erythema of the fingers or toes, venous or arterial thrombosis, thromboembolism, myocardial infarction, stroke, transient ischemic attacks, congenital heart disease, chronic obstructive pulmonary disease, increased erythropoietin production associated with neoplastic, renal or hepatic disorders, androgen or diuretic use, splenomegaly, hepatomegaly, diastolic hypertension.) PeaceHealth Laboratories | Indications and Limitations iii Indications and Limitations Test Name Blood Counts Policy 190.15 Indications/Limitations 4. Specific indications for CBC with differential count related to the WBC include signs, symptoms, test results, illness, or disease associated with leukemia, infections or inflammatory processes, suspected bone marrow failure or bone marrow infiltrate, suspected myeloproliferative, myelodysplastic or lymphoproliferative disorder, use of drugs that may cause leukopenia, and immune disorders (e.g., fever, chills, sweats, shock, fatigue, malaise, tachycardia, tachypnea, heart murmur, seizures, alterations of consciousness, meningismus, pain such as headache, abdominal pain, arthralgia, odynophagia, or dysuria, redness or swelling of skin, soft tissue bone, or joint, ulcers of the skin or mucous membranes, gangrene, mucous membrane discharge, bleeding, thrombosis, respiratory failure, pulmonary infiltrate, jaundice, diarrhea, vomiting, hepatomegaly, splenomegaly, lymphadenopathy, opportunistic infection such as oral candidiasis.) 5. Specific indications for CBC related to the platelet count include signs, symptoms, test results, illness, or disease associated with increased or decreased platelet production and destruction, or platelet dysfunction(e.g., gastrointestinal bleeding, genitourinary tract bleeding, bilateral epistaxis, thrombosis, ecchymosis, purpura, jaundice, petechiae, fever, heparin therapy, suspected DIC, shock, pre-eclampsia, neonate with maternal ITP, massive transfusion, recent platelet transfusion, cardiopulmonary bypass, hemolytic uremic syndrome, renal diseases, lymphadenopathy, hepatomegaly, splenomegaly, hypersplenism, neurologic abnormalities, viral or other infection, myeloproliferative, myelodysplastic, or lymphoproliferative disorder, thrombosis, exposure to toxic agents, excessive alcohol ingestion, autoimmune disorders (SLE, RA and other). 6. Indications for hemogram or CBC related to red cell (RBC) parameters of the hemogram include, in addition to those already listed, thalassemia, suspected hemoglobinopathy, lead poisoning, arsenic poisoning, and spherocytosis. 7. Specific indications for CBC with differential count related to the WBC include, in addition to those already listed, storage diseases/mucopolysaccharidoses, and use of drugs that cause leukocytosis such as G-CSF or GM-CSF. 8. Specific indications for CBC related to platelet count include, in addition to those already listed, May-Hegglin syndrome and Wiskott-Aldrich syndrome. PeaceHealth Laboratories | Indications and Limitations iv Indications and Limitations Test Name Indications/Limitations Blood Counts Policy 190.15 Limitations 1. Testing of patients who are asymptomatic, or who do not have a condition that could be expected to result in a hematological abnormality, is screening and is not a covered service. 2. In some circumstances it may be appropriate to perform only a hemoglobin or hematocrit to assess the oxygen carrying capacity of the blood. When the ordering provider requests only a hemoglobin or hematocrit, the remaining components of the CBC are not covered. 3. When a blood count is performed for an end-stage renal disease (ESRD) patient, and is billed outside the ESRD rate, documentation of the medical necessity for the blood count must be submitted with the claim. 4. In some patients presenting with certain signs, symptoms or diseases, a single CBC may be appropriate. Repeat testing may not be indicated unless abnormal results are found, or unless there is a change in clinical condition. If repeat testing is performed, a more descriptive diagnosis code (e.g., anemia) should be reported to support medical necessity. However, repeat testing may be indicated where results are normal in patients with conditions where there is a continued risk for the development of hematologic abnormality. CA 125 Policy 190.28 Indications CA 125 is a high molecular weight serum tumor marker elevated in 80% of patients who present with epithelial ovarian carcinoma. It is also elevated in carcinomas of the fallopian tube, endometrium, and endocervix. An elevated level may also be associated with the presence of a malignant mesothelioma or primary peritoneal carcinoma. A CA125 level may be obtained as part of the initial pre-operative work-up for women presenting with a suspicious pelvic mass to be used as a baseline for purposes of post-operative monitoring. Initial declines in CA 125 after initial surgery and/or chemotherapy for PeaceHealth Laboratories | Indications and Limitations v Indications and Limitations Test Name Indications/Limitations CA 125 Policy 190.28 ovarian carcinoma are also measured by obtaining three serum levels during the first month post treatment to determine the patient's CA 125 half-life, which has significant prognostic implications. The CA 125 levels are again obtained at the completion of chemotherapy as an index of residual disease. Surveillance CA125 measurements are generally obtained every 3 months for 2 years, every 6 months for the next 3 years, and yearly thereafter. CA 125 levels are also an important indicator of a patient's response to therapy in the presence of advanced or recurrent disease. In this setting, CA 125 levels may be obtained prior to each treatment cycle. Limitations These services are not covered for the evaluation of patients with signs or symptoms suggestive of malignancy. The service may be ordered at times necessary to assess either the presence of recurrent disease or the patient's response to treatment with subsequent treatment cycles. The CA 125 is specifically not covered for aiding in the differential diagnosis of patients with a pelvic mass as the sensitivity and specificity of the test is not sufficient. In general, a single "tumor marker" will suffice in following a patient with one of these malignancies. CA 15-3 (27.29) Policy 190.29 Indications Multiple tumor markers are available for monitoring the response of certain malignancies to therapy and assessing whether residual tumor exists’ post-surgical therapy. CA 15-3 is often medically necessary to aid in the management of patients with breast cancer. Serial testing must be used in conjunction with other clinical methods for monitoring breast cancer. For monitoring, if medically necessary, use consistently either CA 15-3 or CA 27.29, not both. CA 27.29 is equivalent to CA 15-3 in its usage in management of patients with breast cancer. Limitations These services are not covered for the evaluation of patients with signs or symptoms suggestive of malignancy. The service may be ordered at times necessary to assess either the presence of recurrent disease or the patient's response to treatment with subsequent treatment cycles. PeaceHealth Laboratories | Indications and Limitations vi Indications and Limitations Test Name Indications/Limitations CA 19-9 Policy 190.30 Indications Multiple tumor markers are available for monitoring the response of certain malignancies to therapy and assessing whether residual tumor exists’ post-surgical therapy. Levels are useful in following the course of patients with established diagnosis of pancreatic and biliary ductal carcinoma. The test is not indicated for diagnosing these two diseases. Limitations These services are not covered for the evaluation of patients with signs or symptoms suggestive of malignancy. The service may be ordered at times necessary to assess either the presence of recurrent disease or the patient's response to treatment with subsequent treatment cycles. Carcinoembryonic Antigen (CEA) Policy 190.26 Indications CEA may be medically necessary for follow-up of patients with colorectal carcinoma. It would however only be medically necessary at treatment decision making points. In some clinical situations (e.g. adenocarcinoma of the lung, small cell carcinoma of the lung, and some gastrointestinal carcinomas) when a more specific marker is not expressed by the tumor, CEA may be a medically necessary alternative marker for monitoring. Preoperative CEA may also be helpful in determining the post-operative adequacy of surgical resection and subsequent medical management. In general, a single tumor marker will suffice in following patients with colorectal carcinoma or other malignancies that express such tumor markers. In following patients who have had treatment for colorectal carcinoma, ASCO guideline suggests that if resection of liver metastasis would be indicated, it is recommended that postoperative CEA testing be performed every two to three months in patients with initial stage II or stage III disease for at least two years after diagnosis. For patients with metastatic solid tumors which express CEA, CEA may be measured at the start of the treatment and with subsequent treatment cycles to assess the tumor's response to therapy. Limitations Serum CEA determinations are generally not indicated more frequently than once per chemotherapy treatment cycle for patients with metastatic solid tumors which express CEA or every two months post-surgical treatment for patients who have had colorectal carcinoma. However, it may be proper to order the test PeaceHealth Laboratories | Indications and Limitations vii Indications and Limitations Test Name Indications/Limitations Carcinoembryonic Antigen (CEA) Policy 190.26 more frequently in certain situations, for example, when there has been a significant change from prior CEA level or a significant change in patient status which could reflect disease progression or recurrence. Testing with a diagnosis of an in situ carcinoma is not reasonably done more frequently than once, unless the result is abnormal, in which case the test may be repeated once. Collagen Cross Links Policy 190.19 Indications Generally speaking, collagen crosslink testing is useful mostly in "fast losers" of bone. The age when these bone markers can help direct therapy is often pre-Medicare. By the time a fast loser of bone reaches age 65, she will most likely have been stabilized by appropriate therapy or have lost so much bone mass that further testing is useless. Coverage for bone marker assays may be established, however, for younger Medicare beneficiaries and for those men and women who might become fast losers because of some other therapy such as glucocorticoids. Safeguards should be incorporated to prevent excessive use of tests in patients for whom they have no clinical relevance. Collagen crosslinks testing is used to: 1. Identify individuals with elevated bone resorption, who have osteoporosis in whom response to treatment is being monitored; 2. Predict response (as assessed by bone mass measurements) to FDA approved antiresorptive therapy in postmenopausal women; and 3. Assess response to treatment of patients with osteoporosis, Paget's disease of the bone, or risk for osteoporosis where treatment may include FDA approved antiresorptive agents, anti-estrogens or selective estrogen receptor moderators. Limitations Because of significant specimen to specimen collagen crosslink physiologic variability (15-20%), current recommendations for appropriate utilization include: one or two base-line assays from specified urine collections on separate days; followed by a repeat assay about three months after starting anti-resorptive therapy; followed by a repeat assay in 12 months after the three-month assay; and thereafter not more than annually, unless there is a change in therapy in which circumstance an additional test may be indicated three months after the initiation of new therapy. PeaceHealth Laboratories | Indications and Limitations viii Indications and Limitations Test Name Indications/Limitations Cytogenetics Cytogenetics Policy PolicyL23846 L24295 Cytogenetics is the study of chromosomes by light or fluorescent microscopy. Cytogenetic testing is used to study an individual’s chromosome makeup. The term karyotyping refers to the arrangement of nucleus chromosomes in order from the largest to the smallest to analyze their number and structure. Cytogenetic testing involves the determination of chromosome number and structure; variations in either can produce numerous physical abnormalities. With cytogenetic testing, the total chromosome count is determined first, followed by the sex chromosome complement and then by any abnormalities. A normal karyotype of chromosomes consists of a pattern of 22 pairs of autosomal chromosomes and a pair of sex chromosomes: XY for the male and XX for the female. A plus (+) or minus (-) sign indicates, respectively, a gain or loss of chromosomal material. Specimens for cytogenetic analysis can be obtained for routine analysis from the peripheral blood, in which case T lymphocytes are examined; from amniotic fluid for culture of amniocytes; from trophoblastic cells from the chorionic villus; from bone marrow; from solid tumors, and from cultured fibroblasts, usually obtained from a skin biopsy. Enough cells must be examined so that the chance of missing a cytogenetically distinct cell line (a situation of mosaicism) is statistically low. For most clinical indications, 20 mitoses are examined and counted under direct microscopic visualization, and two are photographed or digitalized and karyotypes are prepared. Observation of aberrations usually prompts more extended scrutiny, and in many cases, further analysis of the original culture. Per Medicare National Coverage Determinations (NCD) Manual, 1003, Section 190.3: “Medicare covers these tests when they are reasonable and necessary for the diagnosis or treatment of the following conditions: ● Genetic disorders (e.g., mongolism) in a fetus; (See the Medicare Benefit Policy Chapter 15, "Covered Medical and Other Health Services," 20.1) ● Failure of sexual development; or ● Chronic myelogenous leukemia. ● Acute leukemias, lymphoid (FAB L1-L3), myeloid (FAB M0-M7) and unclassified; or ● Myelodysplasia.” (End of Quote) PeaceHealth Laboratories | Indications and Limitations ix Indications and Limitations Test Name Indications/Limitations Cytogenetics Policy L24295 The above quotation obligates the carrier to cover the listed diagnoses but does not limit coverage to that list. Further, genetic disorders and failure of sexual development involve chromosomal abnormalities that are stable over time, and, accordingly, payment for cytogenetic studies for these abnormalities will be allowed once per lifetime. This is in contrast to the malignancies, where repeated cytogenetic studies may be appropriate. At the present time, it should be noted that, even in cases of genetic disorders, the general policy limitation is for once per lifetime testing. When clinicallyrelevant technological advances (such as with FISH testing), are available, and repeat testing is believed to be medically reasonable and necessary, such claims must be billed using an additional ICD-9CM code. (See the section titled ICD-9-CM Codes that Support Medical Necessity and attached Coding Guidelines for additional information.) Since “Urovysion”, a proprietary test for recurrent bladder cancer identification and monitoring, utilizes multiple probes, which are applied simultaneously, for dates of service on and after 01/01/2011, is correctly identified by two new CPT codes included in this LCD. NAS finds little evidence in the literature that consistent chromosomal abnormalities in the conditions of polycythemia vera, agnogenic myeloid metaplasia, idiopathic thrombocythemia and multiple myeloma are known, or that their identification is likely to affect patient care; consequently, these are considered to be payable diagnoses only when the medical record contains clear, unequivocal documentation that this testing is medically reasonable and necessary for the individual case under consideration. Concerning the testing of HER-2/neu antibodies, Noridian believes that current literature amply supports the notion that HER-2/neu tests on histological sections of breast cancers may, in the appropriate clinical settings, provide useful prognostic information and therapeutic indications for treating metastatic disease with antiHER-2/neu antibodies. For this or any other medically necessary use of in situ hybridization (FISH) testing, for dates of service on or after January 1, 2005, quantitative or semi-quantitative in situ hybridization (tissue or cellular) performed by computer-assisted technology should be reported as CPT code 88367 when performed by a physician (limited to M.D./D.O.). Beginning January 1, 2005, quantitative or semi-quantitative in situ hybridization (tissue or cellular) performed by manual methods should be reported as CPT code 88368 when performed by a physician (limited to M.D./D.O.). PeaceHealth Laboratories | Indications and Limitations x Indications and Limitations Test Name Indications/Limitations Cytogenetics Policy L24295 Do not report CPT code 88365 with CPT codes 88367 or 88368 for the same probe. Only one unit of service may be reported for CPT code 88365, 88367 or 88368 for each reportable probe. These codes include both a professional component and a technical component. When a test for HER-2/neu protein over expression is performed using an immunocytochemistry technique, the test should be billed as 88342, immunocytochemistry. Thus, other CPT codes listed in the CPT/HCPCS Codes section of this policy should not be used when billing for HER-2/neu antibodies. Since there is no current provider category for PhD Geneticists, notwithstanding the certainty that such providers are capable of demonstrating superb training and expertise, Medicare Contractors do not have the authority to create a provider category to allow payment for their services. We encourage these providers to continue discussion with CMS in this regard. NAS recognizes that Cytogenetic Testing is an emerging technology with rapidly expanding indications and will accept recommendations to reconsider the list of covered diagnoses. However, these requests for reconsideration must be submitted as a formal reconsideration (See www.noridianmedicare.com for the reconsideration process.) and must be accompanied by complete copies of relevant peerreviewed literature that support the recommendation. Compliance with the provisions in this policy is subject to monitoring by post payment data analysis and subsequent medical review. Digoxin Policy 190.24 Indications Digoxin levels may be performed to monitor drug levels of individuals receiving digoxin therapy because the margin of safety between side effects and toxicity is narrow or because the blood level may not be high enough to achieve the desired clinical effect. Clinical indications may include individuals on digoxin: • • • • • • With symptoms, signs or electrocardiogram (ECG) suggestive of digoxin toxicity. Taking medications that influence absorption, bioavailability, distribution, and/or elimination of digoxin. With impaired renal, hepatic, gastrointestinal, or thyroid function. With pH and/or electrolyte abnormalities. With unstable cardiovascular status, including myocarditis. Requiring monitoring of patient compliance. PeaceHealth Laboratories | Indications and Limitations xi Indications and Limitations Test Name Indications/Limitations Digoxin Policy 190.24 Clinical indications may include individuals: • Suspected of accidental or intended overdose. • Who have an acceptable cardiac diagnosis (as listed) and for whom an accurate history of use of digoxin is unobtainable. The value of obtaining regular serum digoxin levels is uncertain, but it may be reasonable to check levels once yearly after a steady state is achieved. In addition, it may be reasonable to check the level if: • Heart failure status worsens. • Renal function deteriorates. • Additional medications are added that could affect the digoxin level. • Signs or symptoms of toxicity develop. Steady state will be reached in approximately 1 week in patients with normal renal function, although 2?3 weeks may be needed in patients with renal impairment. After changes in dosages or the addition of a medication that could affect the digoxin level, it is reasonable to check the digoxin level one week after the change or addition. Based on the clinical situation, in cases of digoxin toxicity, testing may need to be done more than once a week. Digoxin is indicated for the treatment of patients with heart failure due to systolic dysfunction and for reduction of the ventricular response in patients with atrial fibrillation or flutter. Digoxin may also be indicated for the treatment of other supraventricular arrhythmias, particularly in the presence of heart failure. Limitations This test is not appropriate for patients on digitoxin or treated with digoxin FAB (fragment antigen binding) antibody. Gamma Glutamyl Transferase (GGT) Policy 190.32 Indications 1. To provide information about known or suspected hepatobiliary disease, for example: a. Following chronic alcohol or drug ingestion. b. Following exposure to hepatotoxins. c. When using medication known to have a potential for causing liver toxicity (e.g., following the drug manufacturer's recommendations). d. Following infection (e.g., viral hepatitis and other specific infections such as amoebiasis, tuberculosis, psittacosis, and similar infections). 2. To assess liver injury/function following diagnosis of primary or PeaceHealth Laboratories | Indications and Limitations xii Indications and Limitations Test Name Indications/Limitations Gamma Glutamyl Transferase (GGT) Policy 190.32 secondary malignant neoplasms. 3. To assess liver injury/function in a wide variety of disorders and diseases known to cause liver involvement (e.g., diabetes mellitus, malnutrition, disorders of iron and mineral metabolism, sarcoidosis, amyloidosis, lupus, and hypertension). 4. To assess liver function related to gastrointestinal disease. 5. To assess liver function related to pancreatic disease. 6. To assess liver function in patients subsequent to liver transplantation. 7. To differentiate between the different sources of elevated alkaline phosphatase activity. Limitations When used to assess liver dysfunction secondary to existing nonhepatobiliary disease with no change in signs, symptoms, or treatment, it is generally not necessary to repeat a GGT determination after a normal result has been obtained unless new indications are present. If the GGT is the only "liver" enzyme abnormally high, it is generally not necessary to pursue further evaluation for liver disease for this specific indication. When used to determine if other abnormal enzyme tests reflect liver abnormality rather than other tissue, it generally is not necessary to repeat a GGT more than one time per week. Because of the extreme sensitivity of GGT as a marker for cytochrome oxidase induction or cell membrane permeability, it is generally not useful in monitoring patients with known liver disease. Genetic Testing Policy L24308 Screening services, such as pre-symptomatic genetic tests and services, are those used to detect an undiagnosed disease or disease predisposition, and as such are not a Medicare benefit and not covered by Medicare. Similarly, Medicare may not reimburse the costs of tests/examinations that assess the risk for and/or of a condition unless the risk assessment clearly and directly effects the management of the patient. However, Medicare does cover a broad range of legislatively mandated preventive services to prevent disease, detect disease early when it is most treatable and curable, and manage disease so that complications can be avoided. These services can be found on the CMS website at: http://www.cms.gov/Medicare/Prevention/PrevntionGenInfo/index.html PeaceHealth Laboratories | Indications and Limitations xiii Indications and Limitations Test Name Indications/Limitations Genetic Testing Policy L24308 Any preventive services and tests not listed on the CMS Preventive Services webpage are considered non-covered screening (preventive) tests or services which are not a benefit of the Medicare program. Glucose Policy 190.20 Indications Blood glucose values are often necessary for the management of patients with diabetes mellitus, where hyperglycemia and hypoglycemia are often present. They are also critical in the determination of control of blood glucose levels in the patient with impaired fasting glucose (FPG 110-125 mg/dL), the patient with insulin resistance syndrome and/or carbohydrate intolerance (excessive rise in glucose following ingestion of glucose or glucose sources of food), in the patient with a hypoglycemia disorder such as nesidioblastosis or insulinoma, and in patients with a catabolic or malnutrition state. In addition to those conditions already listed, glucose testing may be medically necessary in patients with tuberculosis, unexplained chronic or recurrent infections, alcoholism, coronary artery disease (especially in women), or unexplained skin conditions (including pruritis, local skin infections, ulceration and gangrene without an established cause). Many medical conditions may be a consequence of a sustained elevated or depressed glucose level. These include comas, seizures or epilepsy, confusion, abnormal hunger, abnormal weight loss or gain, and loss of sensation. Evaluation of glucose may also be indicated in patients on medications known to affect carbohydrate metabolism. Effective January 1, 2005, the Medicare law expanded coverage to diabetic screening services. Some forms of blood glucose testing covered under this national coverage determination may be covered for screening purposes subject to specified frequencies. See 42 CFR 410.18 and section 90, chapter 18, of the Claims Processing Manual, for a full description of this screening benefit. Limitations Frequent home blood glucose testing by diabetic patients should be encouraged. In stable, non-hospitalized patients who are unable or unwilling to do home monitoring, it may be reasonable and necessary to measure quantitative blood glucose up to four times annually. Depending upon the age of the patient, type of diabetes, degree of control, complications of diabetes, and other co-morbid conditions, more frequent testing than four times annually may be reasonable and necessary. PeaceHealth Laboratories | Indications and Limitations xiv Indications and Limitations Test Name Indications/Limitations Glucose Policy 190.20 In some patients presenting with nonspecific signs, symptoms, or diseases not normally associated with disturbances in glucose metabolism, a single blood glucose test may be medically necessary. Repeat testing may not be indicated unless abnormal results are found or unless there is a change in clinical condition. If repeat testing is performed, a specific diagnosis code (e.g., diabetes) should be reported to support medical necessity. However, repeat testing may be indicated where results are normal in patients with conditions where there is a confirmed continuing risk of glucose metabolism abnormality (e.g., monitoring glucocorticoid therapy). Glycated Protein/ Glycohemoglobin Policy 190.21 Indications Glycated hemoglobin/protein testing is widely accepted as medically necessary for the management and control of diabetes. It is also valuable to assess hyperglycemia, a history of hyperglycemia or dangerous hypoglycemia. Glycated protein testing may be used in place of glycated hemoglobin in the management of diabetic patients, and is particularly useful in patients who have abnormalities of erythrocytes such as hemolytic anemia or hemoglobinopathies. Limitations It is not considered reasonable and necessary to perform glycated hemoglobin tests more often than every three months on a controlled diabetic patient to determine whether the patient's metabolic control has been on average within the target range. It is not considered reasonable and necessary for these tests to be performed more frequently than once a month for diabetic pregnant women. Testing for uncontrolled type one or two diabetes mellitus may require testing more than four times a year. The above Description Section provides the clinical basis for those situations in which testing more frequently than four times per annum is indicated, and medical necessity documentation must support such testing in excess of the above guidelines. Many methods for the analysis of glycated hemoglobin show significant interference from elevated levels of fetal hemoglobin or by variant hemoglobin molecules. When the glycated hemoglobin assay is initially performed in these patients, the laboratory may inform the ordering physician of a possible analytical interference. Alternative testing, including glycated protein, for example, fructosamine, may be indicated for the monitoring of the degree of glycemic control in this situation. It is therefore conceivable that a patient will have both a glycated hemoglobin and glycated protein ordered on the same day. This should be limited to the initial assay of glycated hemoglobin, with subsequent exclusive use of glycated PeaceHealth Laboratories | Indications and Limitations xv Indications and Limitations Test Name Indications/Limitations Glycated Protein/ Glycohemoglobin Policy 190.21 protein. These tests are not considered to be medically necessary for the diagnosis of diabetes. Gonadotropin, Chorionic (hCG) Policy 190.27 Indications hCG is useful for monitoring and diagnosis of germ cell neoplasms of the ovary, testis, mediastinum, retroperitoneum, and central nervous system. In addition, hCG is useful for monitoring pregnant patients with vaginal bleeding, hypertension and/or suspected fetal loss. Limitations It is not reasonable and necessary to perform hCG testing more than once per month for diagnostic purposes. It may be performed as needed for monitoring of patient progress and treatment. Qualitative hCG assays are not appropriate for medically managing patients with known or suspected germ cell neoplasms. Hepatitis Panel Policy 190.33 Indications 1. To detect viral hepatitis infection when there are abnormal liver function test results, with or without signs or symptoms of hepatitis. 2. Prior to and subsequent to liver transplantation. Limitations After a hepatitis diagnosis has been established, only individual tests, rather than the entire panel, are needed. HIV Testing; Diagnosis Policy 190.14 Indications Diagnostic testing to establish HIV infection may be indicated when there is a strong clinical suspicion supported by one or more of the following clinical findings: 1. The patient has a documented, otherwise unexplained, AIDSdefining or AIDS-associated opportunistic infection. 2. The patient has another documented sexually transmitted disease which identifies significant risk of exposure to HIV and the potential for an early or subclinical infection. 3. The patient has documented acute or chronic hepatitis B or C infection that identifies a significant risk of exposure to HIV and the potential for an early or subclinical infection. PeaceHealth Laboratories | Indications and Limitations xvi Indications and Limitations Test Name Indications/Limitations HIV Testing; Diagnosis Policy 190.14 4. The patient has a documented AIDS-defining or AIDS-associated neoplasm. 5. The patient has a documented AIDS-associated neurologic disorder or otherwise unexplained dementia. 6. The patient has another documented AIDS-defining clinical condition, or a history of other severe, recurrent, or persistent conditions which suggest an underlying immune deficiency (for example, cutaneous or mucosal disorders). 7. The patient has otherwise unexplained generalized signs and symptoms suggestive of a chronic process with an underlying immune deficiency (for example, fever, weight loss, malaise, fatigue, chronic diarrhea, failure to thrive, chronic cough, hemoptysis, shortness of breath, or lymphadenopathy). 8. The patient has otherwise unexplained laboratory evidence of a chronic disease process with an underlying immune deficiency (for example, anemia, leukopenia, pancytopenia, lymphopenia, or low CD4+ lymphocyte count). 9. The patient has signs and symptoms of acute retroviral syndrome with fever, malaise, lymphadenopathy, and skin rash. 10. The patient has documented exposure to blood or body fluids known to be capable of transmitting HIV (for example, needlesticks and other significant blood exposures) and antiviral therapy is initiated or anticipated to be initiated. 11. The patient is undergoing treatment for rape. (HIV testing is a part of the rape treatment protocol.) Limitations 1. HIV antibody testing in the United States is usually performed using HIV-1 or HIV-½ combination tests. HIV-2 testing is indicated if clinical circumstances suggest HIV-2 is likely (that is, compatible clinical findings and HIV-1 test negative). HIV-2 testing may also be indicated in areas of the country where there is greater prevalence of HIV-2 infections. 2. The Western Blot test should be performed only after documentation that the initial EIA tests are repeatedly positive or equivocal on a single sample. 3. The HIV antigen tests currently have no defined diagnostic usage. 4. Direct viral RNA detection may be performed in those situations where serologic testing does not establish a diagnosis but strong clinical PeaceHealth Laboratories | Indications and Limitations xvii Indications and Limitations Test Name Indications/Limitations HIV Testing; Diagnosis Policy 190.14 suspicion persists (for example, acute retroviral syndrome, nonspecific serologic evidence of HIV, or perinatal HIV infection). 5. If initial serologic tests confirm an HIV infection, repeat testing is not indicated. 6. If initial serologic tests are HIV EIA negative and there is no indication for confirmation of infection by viral RNA detection, the interval prior to retesting is 3-6 months. 7. Testing for evidence of HIV infection using serologic methods may be medically appropriate in situations where there is a risk of exposure to HIV. However, in the absence of a documented AIDS defining or HIV- associated disease, an HIV associated sign or symptom, or documented exposure to a known HIV-infected source, the testing is considered by Medicare to be screening and thus is not covered by Medicare (for example, history of multiple blood component transfusions, exposure to blood or body fluids not resulting in consideration of therapy, history of transplant, history of illicit drug use, multiple sexual partners, same-sex encounters, prostitution, or contact with prostitutes). 8. The CPT Editorial Panel has issued a number of codes for infectious agent detection by direct antigen or nucleic acid probe techniques that have not yet been developed or are only being used on an investigational basis. Laboratory providers are advised to remain current on FDA-approval status for these tests. HIV Testing; Prognosis Policy 190.13 Indications 1. A plasma HIV RNA baseline level may be medically necessary in any patient with confirmed HIV infection. 2. Regular periodic measurement of plasma HIV RNA levels may be medically necessary to determine risk for disease progression in an HIV-infected individual and to determine when to initiate or modify antiretroviral treatment regimens. 3. In clinical situations where the risk of HIV infection is significant and initiation of therapy is anticipated, a baseline HIV quantification may be performed. These situations include: a. Persistence of borderline or equivocal serologic reactivity in an at-risk individual. b. Signs and symptoms of acute retroviral syndrome characterized by fever, malaise, lymphadenopathy and rash in an at-risk individual. PeaceHealth Laboratories | Indications and Limitations xviii Indications and Limitations Test Name Indications/Limitations HIV Testing; Prognosis Policy 190.13 Limitations 1. Viral quantification may be appropriate for prognostic use including baseline determination, periodic monitoring, and monitoring of response to therapy. Use as a diagnostic test method is not indicated. 2. Measurement of plasma HIV RNA levels should be performed at the time of establishment of an HIV infection diagnosis. For an accurate baseline, 2 specimens in a 2-week period are appropriate. 3. For prognosis including anti-retroviral therapy monitoring, regular, periodic measurements are appropriate. The frequency of viral load testing should be consistent with the most current Centers for Disease Control and Prevention guidelines for use of anti-retroviral agents in adults and adolescents or pediatrics. 4. Because differences in absolute HIV copy number are known to occur using different assays, plasma HIV RNA levels should be measured by the same analytical method. A change in assay method may necessitate re-establishment of a baseline. 5. Nucleic acid quantification techniques are representative of rapidly emerging and evolving new technologies. As such, users are advised to remain current on FDA-approval status. Iron Studies Policy 190.18 Indications 1. Ferritin, iron and either iron binding capacity or transferrin are useful in the differential diagnosis of iron deficiency, anemia, and for iron overload conditions. a. The following presentations are examples that may support the use of these studies for evaluating iron deficiency: certain abnormal blood count values (i.e., decreased mean corpuscular volume (MCV), decreased hemoglobin/hematocrit when the MCV is low or normal, or increased red cell distribution width (RDW) and low or normal MCV); abnormal appetite (pica); acute or chronic gastrointestinal blood loss; hematuria; menorrhagia; malabsorption; status post-gastrectomy; status postgastrojejunostomy; malnutrition; preoperative autologous blood collection(s); malignant, chronic inflammatory and infectious conditions associated with anemia which may present in a similar manner to iron deficiency anemia; following a significant surgical procedure where blood loss had occurred and had not been repaired with adequate iron replacement. PeaceHealth Laboratories | Indications and Limitations xix Indications and Limitations Test Name Iron Studies Policy 190.18 Indications/Limitations b. The following presentations are examples that may support the use of these studies for evaluating iron overload: chronic hepatitis; diabetes; hyperpigmentation of skin; arthropathy; cirrhosis; hypogonadism; hypopituitarism; impaired porphyrin metabolism; heart failure; multiple transfusions; sideroblastic anemia; thalassemia major; cardiomyopathy, cardiac dysrhythmias and conduction disturbances. 2. Follow-up testing may be appropriate to monitor response to therapy, e.g., oral or parenteral iron, ascorbic acid, and erythropoietin. 3. Iron studies may be appropriate in patients after treatment for other nutritional deficiency anemias, such as folate and vitamin B12, because iron deficiency may not be revealed until such a nutritional deficiency is treated. 4. Serum ferritin may be appropriate for monitoring iron status in patients with chronic renal disease with or without dialysis. 5. Serum iron may also be indicated for evaluation of toxic effects of iron and other metals (e.g., nickel, cadmium, aluminum, lead) whether due to accidental, intentional exposure or metabolic causes. Limitations 1. Iron studies should be used to diagnose and manage iron deficiency or iron overload states. These tests are not to be used solely to assess acute phase reactants where disease management will be unchanged. For example, infections and malignancies are associated with elevations in acute phase reactants such as ferritin, and decreases in serum iron concentration, but iron studies would only be medically necessary if results of iron studies might alter the management of the primary diagnosis or might warrant direct treatment of an iron disorder or condition. 2. If a normal serum ferritin level is documented, repeat testing would not ordinarily be medically necessary unless there is a change in the patient's condition, and ferritin assessment is needed for the ongoing management of the patient. For example, a patient presents with new onset insulin-dependent diabetes mellitus and has a serum ferritin level performed for the suspicion of hemochromatosis. If the ferritin level is normal, the repeat ferritin for diabetes mellitus would not be medically necessary. PeaceHealth Laboratories | Indications and Limitations xx Indications and Limitations Test Name Indications/Limitations Iron Studies Policy 190.18 3. When an End Stage Renal Disease (ESRD) patient is tested for ferritin, testing more frequently than every three months requires documentation of medical necessity (e.g., other than chronic renal failure or renal failure, unspecified). 4. It is ordinarily not necessary to measure both transferrin and TIBC at the same time because TIBC is an indirect measure of transferrin. When transferrin is ordered as part of the nutritional assessment for evaluating malnutrition, it is not necessary to order other iron studies unless iron deficiency or iron overload is suspected as well. 5. It is not ordinarily necessary to measure both iron/TIBC (or transferrin) and ferritin in initial patient testing. If clinically indicated after evaluation of the initial iron studies, it may be appropriate to perform additional iron studies either on the initial specimen or on a subsequently obtained specimen. After a diagnosis of iron deficiency or iron overload is established, either iron/TIBC (or transferrin) or ferritin may be medically necessary for monitoring, but not both. 6. It would not ordinarily be considered medically necessary to do a ferritin as a preoperative test except in the presence of anemia or recent autologous blood collections prior to the surgery. Lipid Testing Policy 190.23 Indications The medical community recognizes lipid testing as appropriate for evaluating atherosclerotic cardiovascular disease. Conditions in which lipid testing may be indicated include: • Assessment of patients with atherosclerotic cardiovascular disease. • Evaluation of primary dyslipidemia. • Any form of atherosclerotic disease, or any disease leading to the formation of atherosclerotic disease. • Diagnostic evaluation of diseases associated with altered lipid metabolism, such as: nephrotic syndrome, pancreatitis, hepatic disease, and hypo and hyperthyroidism. • Secondary dyslipidemia, including diabetes mellitus, disorders of gastrointestinal absorption, chronic renal failure. • Signs or symptoms of dyslipidemias, such as skin lesions. • As follow-up to the initial screen for coronary heart disease (total cholesterol + HDL cholesterol) when total cholesterol is determined to be high (>240 mg/dL), or borderline-high (200240 mg/dL) plus two or more coronary heart disease risk factors, PeaceHealth Laboratories | Indications and Limitations xxi Indications and Limitations Test Name Lipid Testing Policy 190.23 Indications/Limitations or an HDL cholesterol, <35 mg/dl. To monitor the progress of patients on anti-lipid dietary management and pharmacologic therapy for the treatment of elevated blood lipid disorders, total cholesterol, HDL cholesterol and LDL cholesterol may be used. Triglycerides may be obtained if this lipid fraction is also elevated or if the patient is put on drugs (for example, thiazide diuretics, beta blockers, estrogens, glucocorticoids, and tamoxifen) which may raise the triglyceride level. When monitoring long term anti-lipid dietary or pharmacologic therapy and when following patients with borderline high total or LDL cholesterol levels, it may be reasonable to perform the lipid panel annually. A lipid panel at a yearly interval will usually be adequate while measurement of the serum total cholesterol or a measured LDL should suffice for interim visits if the patient does not have hypertriglyceridemia. Any one component of the panel or a measured LDL may be reasonable and necessary up to six times the first year for monitoring dietary or pharmacologic therapy. More frequent total cholesterol HDL cholesterol, LDL cholesterol and triglyceride testing may be indicated for marked elevations or for changes to anti-lipid therapy due to inadequate initial patient response to dietary or pharmacologic therapy. The LDL cholesterol or total cholesterol may be measured three times yearly after treatment goals have been achieved. Electrophoretic or other quantitation of lipoproteins may be indicated if the patient has a primary disorder of lipoid metabolism. Effective January 1, 2005, the Medicare law expanded coverage to cardiovascular screening services. Several of the procedures included in this NCD may be covered for screening purposes subject to specified frequencies. See 42 CFR 410.17 and section 100, chapter 18, of the Claims Processing Manual, for a full description of this benefit. Limitations Lipid panel and hepatic panel testing may be used for patients with severe psoriasis which has not responded to conventional therapy and for which the retinoid etretinate has been prescribed and who have developed hyperlipidemia or hepatic toxicity. Specific examples include erythrodermia and generalized pustular type and psoriasis associated with arthritis. PeaceHealth Laboratories | Indications and Limitations xxii Indications and Limitations Test Name Indications/Limitations Lipid Testing Policy 190.23 Routine screening and prophylactic testing for lipid disorder are not covered by Medicare. While lipid screening may be medically appropriate, Medicare by statute does not pay for it. Lipid testing in asymptomatic individuals is considered to be screening regardless of the presence of other risk factors such as family history, tobacco use, etc. Once a diagnosis is established, one or several specific tests are usually adequate for monitoring the course of the disease. Less specific diagnoses (for example, other chest pain) alone do not support medical necessity of these tests. When monitoring long term anti-lipid dietary or pharmacologic therapy and when following patients with borderline high total or LDL cholesterol levels, it is reasonable to perform the lipid panel annually. A lipid panel at a yearly interval will usually be adequate while measurement of the serum total cholesterol or a measured LDL should suffice for interim visits if the patient does not have hypertriglyceridemia. Any one component of the panel or a measured LDL may be medically necessary up to six times the first year for monitoring dietary or pharmacologic therapy. More frequent total cholesterol HDL cholesterol, LDL cholesterol and triglyceride testing may be indicated for marked elevations or for changes to anti-lipid therapy due to inadequate initial patient response to dietary or pharmacologic therapy. The LDL cholesterol or total cholesterol may be measured three times yearly after treatment goals have been achieved. If no dietary or pharmacological therapy is advised, monitoring is not necessary. When evaluating non-specific chronic abnormalities of the liver (for example, elevations of transaminase, alkaline phosphatase, abnormal imaging studies, etc.), a lipid panel would generally not be indicated more than twice per year. Occult Blood, Fecal Policy 190.34 Indications 1. To evaluate known or suspected alimentary tract conditions that might cause bleeding into the intestinal tract. 2. To evaluate unexpected anemia. 3. To evaluate abnormal signs, symptoms, or complaints that might be associated with loss of blood. 4. To evaluate patient complaints of black or red-tinged stools. PeaceHealth Laboratories | Indications and Limitations xxiii Indications and Limitations Test Name Indications/Limitations Occult Blood, Fecal Policy 190.34 Limitations 1. The FOBT is reported once for the testing of up to three separate specimens (comprising either one or two tests per specimen). 2. In patients who are taking non-steroidal anti-inflammatory drugs and have a history of gastrointestinal bleeding but no other signs, symptoms, or complaints associated with gastrointestinal blood loss, testing for occult blood may generally be appropriate no more than once every three months. 3. When testing is done for the purpose of screening for colorectal cancer in the absence of signs, symptoms, conditions, or complaints associated with gastrointestinal blood loss, report the HCPCS code for colorectal cancer screening; fecal-occult blood test, 1-3 simultaneous determinations should be used. Partial Thromboplastin Time (PTT) Policy 190.16 Indications 1. The PTT is most commonly used to quantitate the effect of therapeutic unfractionated heparin and to regulate its dosing. Except during transitions between heparin and warfarin therapy, in general both the PTT and PT are not necessary together to assess the effect of anticoagulation therapy. PT and PTT must be justified separately. 2. A PTT may be used to assess patients with signs or symptoms of hemorrhage or thrombosis. For example: abnormal bleeding, hemorrhage or hematoma petechiae or other signs of thrombocytopenia that could be due to disseminated intravascular coagulation; swollen extremity with or without prior trauma. 3. A PTT may be useful in evaluating patients who have a history of a condition known to be associated with the risk of hemorrhage or thrombosis that is related to the intrinsic coagulation pathway. Such abnormalities may be genetic or acquired. For example: dysfibrinogenemia; afibrinogenemia (complete); acute or chronic liver dysfunction or failure, including Wilson's disease; hemophilia; liver disease and failure; infectious processes; bleeding disorders; disseminated intravascular coagulation; lupus erythematosus or other conditions associated with circulating inhibitors, e.g., Factor VIII Inhibitor, lupus-like anticoagulant, etc.; sepsis; von Willebrand's disease; arterial and venous thrombosis, including the evaluation of hypercoagulable states; clinical conditions associated with nephrosis or renal failure; other acquired and congenital coagulopathies as well as thrombotic states. PeaceHealth Laboratories | Indications and Limitations xxiv Indications and Limitations Test Name Indications/Limitations Partial Thromboplastin Time (PTT) Policy 190.16 4. A PTT may be used to assess the risk of thrombosis or hemorrhage in patients who are going to have a medical intervention known to be associated with increased risk of bleeding or thrombosis. An example is as follows: evaluation prior to invasive procedures or operations of patients with personal or family history of bleeding or who are on heparin therapy. Limitations 1. The PTT is not useful in monitoring the effects of warfarin on a patient's coagulation routinely. However, a PTT may be ordered on a patient being treated with warfarin as heparin therapy is being discontinued. A PTT may also be indicated when the PT is markedly prolonged due to warfarin toxicity. 2. The need to repeat this test is determined by changes in the underlying medical condition and/or the dosing of heparin. 3. Testing prior to any medical intervention associated with a risk of bleeding and thrombosis (other than thrombolytic therapy) will generally be considered medically necessary only where there are signs or symptoms of a bleeding or thrombotic abnormality or a personal history of bleeding, thrombosis or a condition associated with a coagulopathy. Hospital/clinic-specific policies, protocols, etc., in and of themselves, cannot alone justify coverage. Prostate Specific Antigen (PSA) Policy 190.31 Indications PSA is of proven value in differentiating benign from malignant disease in men with lower urinary tract signs and symptoms (e.g., hematuria, slow urine stream, hesitancy, urgency, frequency, nocturia and incontinence) as well as with patients with palpably abnormal prostate glands on physician exam, and in patients with other laboratory or imaging studies that suggest the possibility of a malignant prostate disorder. PSA is also a marker used to follow the progress of prostate cancer once a diagnosis has been established, such as in detecting metastatic or persistent disease in patients who may require additional treatment. PSA testing may also be useful in the differential diagnosis of men presenting with as yet undiagnosed disseminated metastatic disease. Limitations Generally, for patients with lower urinary tract signs or symptoms, the test is performed only once per year unless there is a change in the patient's medical condition. PeaceHealth Laboratories | Indications and Limitations xxv Indications and Limitations Test Name Indications/Limitations Prostate Specific Antigen (PSA) Policy 190.31 Testing with a diagnosis of in situ carcinoma is not reasonably done more frequently than once, unless the result is abnormal, in which case the test may be repeated once. Prothrombin Time Policy 190.17 Indications 1. A PT may be used to assess patients taking warfarin. The prothrombin time is generally not useful in monitoring patients receiving heparin who are not taking warfarin. 2. A PT may be used to assess patients with signs or symptoms of abnormal bleeding or thrombosis. For example: swollen extremity with or without prior trauma; unexplained bruising; abnormal bleeding, hemorrhage or hematoma; petechiae or other signs of thrombocytopenia that could be due to disseminated intravascular coagulation. 3. A PT may be useful in evaluating patients who have a history of a condition known to be associated with the risk of bleeding or thrombosis that is related to the extrinsic coagulation pathway. Such abnormalities may be genetic or acquired. For example: dysfibrinogenemia; afibrinogenemia (complete); acute or chronic liver dysfunction or failure, including Wilson's disease and Hemochromatosis; disseminated intravascular coagulation (DIC); congenital and acquired deficiencies of factors II, V, VII, X; vitamin K deficiency; lupus erythematosus; hypercoagulable state; paraproteinemia; lymphoma; amyloidosis; acute and chronic leukemias; plasma cell dyscrasia; HIV infection; malignant neoplasms; hemorrhagic fever; salicylate poisoning; obstructive jaundice; intestinal fistula; malabsorption syndrome; colitis; chronic diarrhea; presence of peripheral venous or arterial thrombosis or pulmonary emboli or myocardial infarction; patients with bleeding or clotting tendencies; organ transplantation; presence of circulating coagulation inhibitors. 4. A PT may be used to assess the risk of hemorrhage or thrombosis in patients who are going to have a medical intervention known to be associated with increased risk of bleeding or thrombosis. For example: evaluation prior to invasive procedures or operations of patients with personal history of bleeding or a condition associated with coagulopathy prior to the use of thrombolytic medication. PeaceHealth Laboratories | Indications and Limitations xxvi Indications and Limitations Test Name Indications/Limitations Prothrombin Time Policy 190.17 Limitations 1. When an ESRD patient is tested for PT, testing more frequently than weekly requires documentation of medical necessity, e.g., other than chronic renal failure or renal failure, unspecified. 2. The need to repeat this test is determined by changes in the underlying medical condition and/or the dosing of warfarin. In a patient on stable warfarin therapy, it is ordinarily not necessary to repeat testing more than every two to three weeks. When testing is performed to evaluate a patient with signs or symptoms of abnormal bleeding or thrombosis and the initial test result is normal, it is ordinarily not necessary to repeat testing unless there is a change in the patient's medical status. 3. Since the INR is a calculation, it will not be paid in addition to the PT when expressed in seconds, and is considered part of the conventional prothrombin time. 4. Testing prior to any medical intervention associated with a risk of bleeding and thrombosis (other than thrombolytic therapy) will generally be considered medically necessary only where there are signs or symptoms of a bleeding or thrombotic abnormality or a personal history of bleeding, thrombosis or a condition associated with a coagulopathy. Hospital/clinic-specific policies, protocols, etc., in and of themselves, cannot alone justify coverage. PeaceHealth Laboratories | Indications and Limitations xxvii Indications and Limitations Test Name Indications/Limitations Sexually Transmitted Infections (STI’s) Policy 210.10 Indications CMS has determined that the evidence is adequate to conclude that screening for chlamydia, gonorrhea, syphilis, and hepatitis B, as well as HIBC to prevent STIs, consistent with the grade A and B recommendations by the USPSTF, is reasonable and necessary for the early detection or prevention of an illness or disability and is appropriate for individuals entitled to benefits under Part A or enrolled under Part B. Therefore, effective for claims with dates of services on or after November 8, 2011, CMS will cover screening for these USPSTFindicated STIs with the appropriate Food and Drug Administration (FDA)-approved/cleared laboratory tests, used consistent with FDAapproved labeling, and in compliance with the Clinical Laboratory Improvement Act (CLIA) regulations, when ordered by the primary care physician or practitioner, and performed by an eligible Medicare provider for these services. Screening for chlamydia and gonorrhea: • Pregnant women who are 24 years old or younger when the diagnosis of pregnancy is known, and then repeat screening during the third trimester if high-risk sexual behavior has occurred since the initial screening test. • Pregnant women who are at increased risk for STIs when the diagnosis of pregnancy is known, and then repeat screening during the third trimester if high-risk sexual behavior has occurred since the initial screening test. • Women at increased risk for STIs annually. Screening for syphilis: • Pregnant women when the diagnosis of pregnancy is known; and then repeat screening during the third trimester and at delivery if high-risk sexual behavior has occurred since the previous screening test. • Men and women at increased risk for STIs annually. Screening for hepatitis B: • Pregnant women at the first prenatal visit when the diagnosis of pregnancy is known, and then rescreening at time of delivery for those with new or continuing risk factors. In addition, effective for claims with dates of service on or after November 8, 2011, CMS will cover up to two individual 20- to 30minute, face-to-face counseling sessions annually for Medicare beneficiaries for HIBC to prevent STIs, for all sexually active adolescents, and for adults at increased risk for STIs, if referred for PeaceHealth Laboratories | Indications and Limitations xxviii Indications and Limitations Test Name Indications/Limitations Sexually Transmitted Infections (STI’s) Policy 210.10 this service by a primary care physician or practitioner, and provided by a Medicare eligible primary care provider in a primary care setting. Coverage of HIBC to prevent STIs is consistent with the USPSTF recommendation. HIBC is defined as a program intended to promote sexual risk reduction or risk avoidance, which includes each of these broad topics, allowing flexibility for appropriate patient-focused elements: • education • skills training • guidance on how to change sexual behavior The high/increased risk individual sexual behaviors, based on the USPSTF guidelines, include any of the following: • Multiple sex partners • Using barrier protection inconsistently • Having sex under the influence of alcohol or drugs • Having sex in exchange for money or drugs • Age (24 years of age or younger and sexually active for women for chlamydia and gonorrhea) • Having an STI within the past year • IV drug use (for hepatitis B only) • In addition for men – men having sex with men (MSM) and engaged in high risk sexual behavior, but no regard to age In addition to individual risk factors, in concurrence with the USPSTF recommendations, community social factors such as high prevalence of STIs in the community populations should be considered in determining high/increased risk for chlamydia, gonorrhea, syphilis, and for recommending HIBC. High/increased risk sexual behavior for STIs is determined by the primary care provider by assessing the patient’s sexual history which is part of any complete medical history, typically part of an annual wellness visit or prenatal visit and considered in the development of a comprehensive prevention plan. The medical record should be a reflection of the service provided. For the purposes of this NCD, a primary care setting is defined as the provision of integrated, accessible health care services by clinicians who are accountable for addressing a large majority of personal health care needs, developing a sustained partnership with patients, and practicing in the context of family and community. Emergency departments, inpatient hospital settings, ambulatory surgical centers, independent diagnostic testing facilities, skilled nursing PeaceHealth Laboratories | Indications and Limitations xxix Indications and Limitations Test Name Indications/Limitations Sexually Transmitted Infections (STI’s) Policy 210.10 facilities, inpatient rehabilitation facilities, clinics providing a limited focus of health care services, and hospice are examples of settings not considered primary care settings under this definition. Thyroid Testing Policy 190.22 Indications Thyroid function tests are used to define hyper function, euthyroidism, or hypofunction of thyroid disease. Thyroid testing may be reasonable and necessary to: • Distinguish between primary and secondary hypothyroidism; • Confirm or rule out primary hypothyroidism; • Monitor thyroid hormone levels (for example, patients with goiter, thyroid nodules, or thyroid cancer); • Monitor drug therapy in patients with primary hypothyroidism; • Confirm or rule out primary hyperthyroidism; and • Monitor therapy in patients with hyperthyroidism. Thyroid function testing may be medically necessary in patients with disease or neoplasm of the thyroid and other endocrine glands. Thyroid function testing may also be medically necessary in patients with metabolic disorders; malnutrition; hyperlipidemia; certain types of anemia; psychosis and non-psychotic personality disorders; unexplained depression; ophthalmologic disorders; various cardiac arrhythmias; disorders of menstruation; skin conditions; myalgias; and a wide array of signs and symptoms, including alterations in consciousness; malaise; hypothermia; symptoms of the nervous and musculoskeletal system; skin and integumentary system; nutrition and metabolism; cardiovascular; and gastrointestinal system. It may be medically necessary to do follow-up thyroid testing in patients with a personal history of malignant neoplasm of the endocrine system and in patients on long-term thyroid drug therapy. Limitations Testing may be covered up to two times a year in clinically stable patients; more frequent testing may be reasonable and necessary for patients whose thyroid therapy has been altered or in whom symptoms or signs of hyperthyroidism or hypothyroidism are noted. PeaceHealth Laboratories | Indications and Limitations xxx Indications and Limitations Test Name Urinalysis Policy L33034 Indications/Limitations Urinalysis is a commonly used physical, chemical, and/or microscopic examination of the urine used to detect renal or urinary tract disease or systemic disorders manifested by or through the urinary system. In order for Medicare coverage to be provided for urinalysis, the patient must have signs or symptoms of a kidney/urinary tract disorder or a condition, which is known to affect the kidney/urinary tract. The following is a list of conditions in which urinalysis may be considered medically reasonable and necessary: • • • • • • • • • The patient has symptoms suggestive of possible kidney/urinary tract disorder, e.g., dysuria, frequency, hesitancy, nocturia, urgency, flank pain, pelvic pain, abdominal pain, etc. The patient exhibits signs of kidney/urinary tract disorder such as hematuria, discoloration of urine, edema, and malodorous urine. The patient has been recently treated or is under treatment for urinary tract disorder and follow-up urinalysis is necessary to evaluate the patient. The patient has a condition known to affect the kidneys or urinary tract, e.g., hypertension, diabetes mellitus, known renal disease, collagen vascular disease and a urinalysis is necessary to evaluate the patient. The patient is undergoing treatment with medication known to potentially adversely affect the kidneys, e.g., gold therapy. The patient has sustained trauma suggestive of possible kidney/urinary tract injury. The patient has unexplained fever. The patient is pregnant and urinalysis is being done as part of standard prenatal care. The patient is pregnant and urinalysis is being done to screen for pre-eclampsia. Urinalysis can be covered as part of the evaluation of a dehydrated patient. PeaceHealth Laboratories | Indications and Limitations xxxi Indications and Limitations Test Name Indications/Limitations Urine Culture, Bacterial/ Sensitivity Studies Policy 190.12 Indications 1. A patient's urinalysis is abnormal suggesting urinary tract infection, for example, abnormal microscopic (hematuria, pyuria, bacteriuria); abnormal biochemical urinalysis (positive leukocyte esterase, nitrite, protein, blood); a Gram's stain positive for microorganisms; positive bacteriuria screen by a non-culture technique; or other significant abnormality of a urinalysis. While it is not essential to evaluate a urine specimen by one of these methods before a urine culture is performed, certain clinical presentations with highly suggestive signs and symptoms may lend themselves to an antecedent urinalysis procedure where follow-up culture depends upon an initial positive or abnormal test result. 2. A patient has clinical signs and symptoms indicative of a possible urinary tract infection (UTI). Acute lower UTI may present with urgency, frequency, nocturia, dysuria, discharge or incontinence. These findings may also be noted in upper UTI with additional systemic symptoms (for example, fever, chills, lethargy); or pain in the costovertebral, abdominal, or pelvic areas. Signs and symptoms may overlap considerably with other inflammatory conditions of the genitourinary tract (for example, prostatitis, urethritis, vaginitis, or cervicitis). Elderly or immunocompromised patients, or patients with neurologic disorders may present atypically (for example, general debility, acute mental status changes, declining functional status). 3. The patient is being evaluated for suspected urosepsis, fever of unknown origin, or other systemic manifestations of infection but without a known source. Signs and symptoms used to define sepsis have been well established. 4. A test-of cure is generally not indicated in an uncomplicated infection. However, it may be indicated if the patient is being evaluated for response to therapy and there is a complicating co-existing urinary abnormality including structural or functional abnormalities, calculi, foreign bodies, or ureteral/renal stents or there is clinical or laboratory evidence of failure to respond as described in Indications 1 and 2. 5. In surgical procedures involving major manipulations of the genitourinary tract, preoperative examination to detect occult infection may be indicated in selected cases (for example, prior to renal transplantation, manipulation or removal of kidney stones, or transurethral surgery of the bladder or prostate). PeaceHealth Laboratories | Indications and Limitations xxxii Indications and Limitations Test Name Indications/Limitations Urine Culture, Bacterial/ Sensitivity Studies Policy 190.12 6. Urine culture may be indicated to detect occult infection in renal transplant recipients on immunosuppressive therapy. Limitations 1. CPT 87086 may be used one time per encounter. 2. Colony count restrictions on coverage of CPT 87088 do not apply as they may be highly variable according to syndrome or other clinical circumstances (for example, antecedent therapy, collection time, degree of hydration). 3. CPT 87088, 87184, and 87186 may be used multiple times in association with or independent of 87086, as urinary tract infections may be polymicrobial. 4. Testing for asymptomatic bacteriuria as part of a prenatal evaluation may be medically appropriate but is considered screening and, therefore, not covered by Medicare. The US Preventive Services Task Force has concluded that screening for asymptomatic bacteriuria outside of the narrow indication for pregnant women is generally not indicated. There are insufficient data to recommend screening in ambulatory elderly patients including those with diabetes. Testing may be clinically indicated on other grounds including likelihood of recurrence or potential adverse effects of antibiotics, but is considered screening in the absence of clinical or laboratory evidence of infection. Vitamin D Assay Policy L32132 Indications: Measurement of 25-OH Vitamin D, CPT 82306, level is indicated for patients with: • • • • • • • • • • • chronic kidney disease stage III or greater cirrhosis hypocalcemia hypercalcemia hypercalciuria hypervitaminosis D parathyroid disorders malabsorption states obstructive jaundice osteomalacia osteoporosis if (continued on next page) i. T score on DEXA scan <-2.5 or ii. History of fragility fractures or PeaceHealth Laboratories | Indications and Limitations xxxiii Indications and Limitations Test Name Indications/Limitations iii. FRAX > 3% 10-year probability of hip fracture or 20% 10-year probability of other major osteoporotic fracture or iv. FRAX > 3% (any fracture) with T-score <-1.5 or v. Initiating bisphosphanate therapy (Vit D level should be determined and managed as necessary before bisphosphonate is initiated) Vitamin D Assay Policy L32132 • • • osteosclerosis/petrosis rickets Vitamin D deficiency on replacement therapy related to a condition listed above; to monitor the efficacy of treatment. Measurement of 1, 25-OH Vitamin D, CPT 82652, level is indicated for patients with: • • • • • unexplained hypercalcemia (suspected granulomatous disease or lymphoma) unexplained hypercalciuria (suspected granulomatous disease or lymphoma) suspected genetic childhood rickets suspected tumor-induced osteomalacia nephrolithiasis or hypercalciuria Limitations: Testing may not be used for routine or other screening. Both assays of vitamin D need not be performed for each of the above conditions. Often, one type is more appropriate for a certain disease state than another. The most common type of vitamin D deficiency is 25-OH vitamin D. A much smaller percentage of 1,25 dihydroxy vitamin D deficiency exists; mostly, in those with renal disease. Documentation must justify the test(s) chosen for a particular disease entity. Various component sources of 25-OH vitamin D, such as stored D or diet-derived D, should not be billed separately. Once a beneficiary has been shown to be vitamin D deficient, further testing may be medically necessary only to ensure adequate replacement has been accomplished. If Vitamin D level is between 20 and 50 ng/dl and patient is clinically stable, repeat testing is often unnecessary; if performed, documentation must clearly indicate the necessity of the test. If level <20 ng/dl or > 60 ng/dl, a subsequent level(s) may be reimbursed until the level is within the normal range. PeaceHealth Laboratories | Indications and Limitations xxxiv Alpha-fetoprotein Policy Type: NCD (National Coverage Decision) CPT CODE(S) 82105 ICD-9 CODES TEST NAME Alpha-fetoprotein; serum ICD-9 DESCRIPTIONS Chronic viral hepatitis B with hepatic coma, with or without mention of hepatitis delta 070.22–070.23 070.32–070.33 070.44 070.54 095.3 121.1 121.3 155.0–155.2 164.2–164.9 183.0 186.0 186.9 197.1 197.7 198.6 198.82 209.20-209.27, 209.29 209.70 209.71 209.72 209.73 209.74 209.75 209.79 211.5 235.3 272.2 273.4 275.01 275.02 275.03 275.09 275.1 277.00 277.03 277.6 285.0 Chronic viral hepatitis B without mention of hepatic coma, with or without mention of hepatitis delta Chronic hepatitis C with hepatic coma Chronic hepatitis C without mention of hepatic coma Syphilis of liver Clonorchiasis Fascioliasis Malignant neoplasm of the liver and intrahepatic bile ducts Malignant neoplasm of the mediastinum Malignant neoplasm, ovary Malignant neoplasm of undescended testis Malignant neoplasm, other and unspecific testis Secondary malignant neoplasm of mediastinum Secondary malignant neoplasm of liver Secondary malignant neoplasm of ovary Secondary malignant neoplasm, genital organs Malignant carcinoid tumors of other and unspecified sites Secondary neuroendocrine tumor, unspecified site Secondary neuroendocrine tumor of distant lymph nodes Secondary neuroendocrine tumor of liver Secondary neuroendocrine tumor of bone Secondary neuroendocrine tumor of peritoneum Secondary Merkel cell carcinoma Secondary neuroendocrine tumor of other sites Benign neoplasm of liver and biliary passages Neoplasm of uncertain behavior of liver and biliary passages Mixed hyperlipidemia Alpha-1-antitrypsin deficiency Hereditary hemochromatosis Hemochromatosis due to repeated red blood cell transfusions Other hemochromatosis Other disorders of iron metabolism Disorder of copper metabolism Cystic Fibrosis without mention of meconium ileus Cystic fibrosis with gastrointestinal manifestations Other deficiencies of circulating enzymes Sideroblastic Anemia PeaceHealth Laboratories | Medicare Coverage Policies 1 Alpha-fetoprotein….con’t 82105 338.3 Neoplasm related to pain (acute) (chronic) 414.4 Coronary atherosclerosis due to calcified coronary lesion 444.01 Saddle embolus of abdominal aorta 444.09 Other arterial embolism and thrombosis of abdominal aorta 571.2 Alcoholic cirrhosis of liver 571.40 Chronic hepatitis, unspecified 571.41 Chronic persistent hepatitis 571.42 Autoimmune hepatitis 571.49 Other chronic hepatitis 571.5 Cirrhosis of liver without mention of alcohol 573.5 Hepatopulmonary syndrome 608.89 Other specified disorders of male genital organs 793.11 Solitary pulmonary nodule 793.19 Other nonspecific abnormal finding of lung field 793.2 Non-specific abnormal findings of other intrathoracic organs 793.3 Non-specific abnormal findings of biliary tract 793.6 Non-specific abnormal findings of abdominal area, including retro peritoneum 795.89 Other abnormal tumor markers V10.07 Personal history of malignant neoplasm, liver V10.43 Personal history of malignant neoplasm, ovary V10.47 Personal history of malignant neoplasm, testis V86.0 Estrogen receptor positive status [ER+] V86.1 Estrogen receptor negative status [ER-] PeaceHealth Laboratories | Medicare Coverage Policies 2 B-type Natriuretic Peptide (BNP) Policy # L31568 Policy Type: LCD (Local Coverage Decision) CPT CODE(S) 83880 ICD-9 CODES 402.01 402.11 402.91 404.01 404.03 404.11 404.13 404.91 404.93 410.62 410.72 410.82 410.92 423.2 425.4 428.0 428.1 428.20 428.21 428.22 428.23 428.30 428.31 428.32 428.33 428.40 428.41 428.42 428.43 428.9 491.21 491.22 493.22 493.92 519.11 TEST NAME Natriuretic peptide ICD-9 DESCRIPTIONS Malignant hypertensive heart disease with heart failure Benign hypertensive heart disease with heart failure Unspecified hypertensive heart disease with heart failure Hypertensive heart and chronic kidney disease, malignant, with heart failure and with chronic kidney disease Stage I through Stage IV, or unspecified Hypertensive heart and chronic kidney disease, malignant, with heart failure and with chronic kidney disease Stage V or end stage renal disease Hypertensive heart and chronic kidney disease, benign, with heart failure and with chronic kidney disease Stage I through Stage IV, or unspecified Hypertensive heart and chronic kidney disease, benign, with heart failure and chronic kidney disease Stage V or end stage renal disease Hypertensive heart and chronic kidney disease, unspecified, with heart failure and with chronic kidney disease Stage I through Stage IV, or unspecified Hypertensive heart and chronic kidney disease, unspecified, with heart failure and chronic kidney disease Stage V or end stage renal disease True posterior wall infarction subsequent episode of care Subendocardial infarction subsequent episode of care Acute myocardial infarction of other specified sites subsequent episode of care Acute myocardial infarction of unspecified site subsequent episode of care Constructive pericarditis Other primary cardiomyopathies Congestive heart failure unspecified Left heart failure Unspecified systolic heart failure Acute systolic heart failure Chronic systolic heart failure Acute on chronic systolic heart failure Unspecified diastolic heart failure Acute diastolic heart failure Chronic diastolic heart failure Acute on chronic diastolic heart failure Unspecified combined systolic and diastolic heart failure Acute combined systolic and diastolic heart failure Chronic combined systolic and diastolic heart failure Acute on chronic combined systolic and diastolic heart failure Heart failure unspecified Obstructive chronic bronchitis with (acute) exacerbation Obstructive chronic bronchitis with acute bronchitis Chronic obstructive asthma with (acute) exacerbation Asthma unspecified with (acute) exacerbation Acute bronchospasm PeaceHealth Laboratories | Medicare Coverage Policies 3 B-type Natuiuretic Peptide (BNP)…(con’t) 786.00 786.02 786.05 786.06 786.07 786.09 83880 Respiratory abnormality unspecified Orthopnea Shortness of breath Tachypnea Wheezing Respiratory abnormality other PeaceHealth Laboratories | Medicare Coverage Policies 4 ICD-9 codes listed are NON-COVERED codes Blood Counts Policy Type: NCD (National Coverage Decision) CPT CODE(S) 85004 TEST NAME Automated differential WBC count Blood smear, microscopic examination with manual differential WBC count Blood smear, microscopic examination without manual differential parameters Spun microhematocrit Hematocrit (Hct) Hemoglobin CBC, automated (Hgb, Hct, RBC, WBC and platelet count) and automated differential WBC count CBC, automated (Hgb, Hct, RBC, WBC and platelet count) Manual cell count (erythrocyte, leukocyte, or platelet) Leukocyte (WBC), automated Platelet, automated 85007 85008 85013 85014 85018 85025 85027 85032 85048 85049 ICD–9–CM Codes COVERED by Medicare Program: Any code NOT listed in either of the ICD–9 sections below. NON-COVERED ICD-9 CODES 078.10–078.19 210.0–210.9 214.0 216.0–216.9 217 222.0–222.9 224.0 230.0 232.0–232.9 300.00–300.09 301.0–301.9 302.0–302.9 307.0 307.20–307.23 307.3 307.80–307.89 312.00–312.9 313.0–313.9 314.00–314.9 338.0 338.11 ICD-9 DESCRIPTIONS Viral warts Benign neoplasm of lip, oral cavity, and pharynx Lipoma, skin and subcutaneous tissue of face Benign neoplasm of skin Benign neoplasm of breast Benign neoplasm of male genital organs Benign neoplasm of eye Carcinoma in situ of lip, oral cavity and pharynx Carcinoma in situ of skin Neurotic disorders Personality disorders Sexual deviations and disorders Stammering and stuttering Tics Stereotyped repetitive movements Psychalgia Disturbance of conduct, not elsewhere classified Disturbance of emotions specific to childhood and adolescence Hyperkinetic syndrome of childhood Central pain syndrome Acute pain due to trauma PeaceHealth Laboratories | Medicare Coverage Policies 5 Blood Counts…….con’t 85004, 85007, 85008, 85013, 85014, 85018 NON-COVERED ICD-9 CODES 338.12 338.18 338.19 338.21 338.22 338.28 338.29 338.4 363.30–363.35 363.40–363.43 363.50–363.57 363.70–363.9 366.00–366.9 367.0–367.9 371.00–371.9 373.00–373.9 375.00–375.9 376.21–376.22 376.40-376.47 376.50-376.52 376.6 376.81-376.82 376.89 376.9 377.10–377.16 377.21–377.24 384.20–384.25 384.81–384.82 385.00–385.9 387.0–387.9 388.00–388.32 388.40-388.45 388.5 389.00–389.06, 389.08 389.10-389.18 389.20-389.22 389.7 389.8, 389.9 440.0–440.1 443.81–443.9 448.1 457.0 470 471.0–471.9 478.0 85025, 85027, 85032, 85048, 85049 Acute post-thoracotomy pain Other acute postoperative pain Other acute pain Chronic pain due to trauma Chronic post-thoracotomy pain Other chronic postoperative pain Other chronic pain Chronic pain syndrome Chorioretinal scars Choroidal degeneration Hereditary choroidal dystrophies Choroidal detachment Cataract Disorders of refraction and accommodation Corneal opacity and other disorders of cornea Inflammation of eyelids Disorders of lacrimal system Endocrine exophthalmos Deformity of orbit Enophthalmos Retained (old)foreign body following penetrating wound of orbit Orbital cysts; myopathy of extraocular muscles Other orbital disorders Unspecified disorder of orbit Optic atrophy Other disorders of optic disc Perforation of tympanic membrane Other specified disorders of tympanic membrane Other disorders of middle ear and mastoid Otosclerosis Degenerative and vascular disorders of ear; noise effects on inner ear; sudden hearing loss, unspecified; and tinnitus Other abnormal auditory perception Disorders of acoustic nerve Conductive hearing loss Sensorineural hearing loss Mixed hearing loss Deaf, non-speaking, not elsewhere classifiable Hearing loss Atherosclerosis of aorta and renal artery Peripheral vascular disease Capillary nevus, non neoplastic Postmastectomy lymphedema syndrome Deviated nasal septum Nasal polyps Hypertrophy of nasal turbinates PeaceHealth Laboratories | Medicare Coverage Policies 6 Blood Counts…….con’t 85004, 85007, 85008, 85013, 85014, 85018 NON-COVERED ICD-9 CODES 478.11 478.19 478.4 520.0–520.9 521.00–521.15, 521.20521.25, 521.30-521.35, 521.40-521.42, 521.49, 521.5-521.7, 521.81, 521.89, 521.9 524.00–524.9 525.0, 525.10-525.13, 525.19, 525.20-525.26, 525.3, 525.40-525.44, 525.50-525.54, 525.60525.67, 525.69 525.71 525.72 525.73 525.8 525.9 526.0–526.3 526.61 526.62 526.63 526.69 527.6–527.9 575.6 600.00-600.91 603.0 603.8 603.9 605 606.0-606.1 608.1 608.20 608.21 608.22 608.23 608.24 608.3 610.0–610.9 611.1–611.6 611.9 616.2 85025, 85027, 85032, 85048, 85049 Nasal mucositis (ulcerative) Other disease of nasal cavity and sinuses Polyp of vocal cord or larynx Disorders of tooth development and eruption Diseases of hard tissues of teeth Dentofacial anomalies, including malocclusion Other diseases and conditions of teeth and supporting structures Osseointegration failure of dental implant Post-osseointegration biological failure of dental implant Post-osseointegration mechanic failure of dental implant Other specified disorders of the teeth and supporting structures Unspecified disorder of the teeth and supporting structures Diseases of the jaws Perforation of root canal space Endodontic overfill Endodontic underfill Other periadicular pathology associated with previous endodontic treatment Diseases of the salivary glands Cholesterolosis of gallbladder Hyperplasia of prostate Encysted hydrocele Other specified types of hydrocele Hydrocele, unspecified Redundant prepuce and phimosis Infertility, male azoospermia and oligospermia Spermatocele Torsion of testis, unspecified Extravaginal torsion of spermatic cord Intravaginal torsion of spermatic cord Torsion of appendix testis Torsion of appendix epididymis Atrophy of testis Benign mammary dysplasia Other disorders of breast Unspecified breast disorder Cyst of Bartholin’s gland PeaceHealth Laboratories | Medicare Coverage Policies 7 Blood Counts……con’t 85004, 85007, 85008, 85013, 85014, 85018 NON-COVERED ICD-9 CODES 618.00–618.05, 618.09, 618.1-618.7, 618.81618.83, 618.84, 618.89, 618.9 620.0–620.3 621.6–621.7 627.2–627.9 628.0–628.9 676.00–676.94 691.0–691.8 692.0–692.9 700 701.0–701.9 702.0–702.8 703.9 706.0–706.9 709.00–709.4 715.00–715.98 716.00–716.99 718.00–718.99 726.0–726.91 727.00–727.9 728.10–728.85 732.0–732.9 733.00–733.09 734 735.0–735.9 736.00–736.9 737.0–737.9 738.0–738.9 739.0–739.9 799.81 830.0–832.19 832.2 833.00-833.19 834.00-834.12 835.00-835.13 836.0-836.69 837.0-837.1 838.00-838.19 839.00-839.9 840.0–848.9 905.0–909.9 910.0–919.9 930.0–932 955.0–957.9 85025, 85027, 85032, 85048, 85049 Genital prolapse Non-inflammatory disorders of ovary, fallopian tube, and broad ligament Malposition or inversion of uterus Menopausal and postmenopausal disorders Infertility, female Other disorders of breast associated with childbirth and disorders of lactation Atopic dermatitis and related disorders Contact dermatitis and other eczema Corns and callosities Other hypertrophic and atrophic conditions of skin Other dermatoses Unspecified disease of nail Diseases of sebaceous glands Other disorders of skin and subcutaneous tissue Osteoarthrosis Other and unspecified arthropathies Other derangement of joint Peripheral esthesiopathies and allied syndromes Other disorders of synovium, tendon, and bursa Disorders of muscle ligament and fascia Osteochondropathies Osteoporosis Flat foot Acquired deformities of toe Other acquired deformities of limb Curvature of spine Other acquired deformity Nonallopathic lesions, not elsewhere classified Decreased libido Dislocation of jaw, shoulder, and elbow Nursemaid’s elbow Dislocation of wrist Dislocation of finger Dislocation of hip Dislocation of knee Dislocation of ankle Dislocation of foot Other, multiple and ill-defined dislocations Sprains and strains Late effects of musculoskeletal and connective tissue injuries Superficial injuries Foreign body on external eye, in ear, in nose Injury to peripheral nerve PeaceHealth Laboratories | Medicare Coverage Policies 8 Blood Counts…….con’t 85004, 85007, 85008, 85013, 85014, 85018 NON-COVERED ICD-9 CODES V03.0–V06.9 V11.0–V11.3 V11.4 V11.8-V11.9 V14.0–V14.8 V16.0 V16.3 V21.0–V21.9 V25.01–V25.04, V25.09 V25.11 V25.12 V25.13 V25.2-V25.3, V25.40V25.43, V25.49, V25.5, V25.8, V25.9 V26.0–V26.39 V26.41 V26.42 V26.49 V26.51 V26.52 V26.81 V26.82 V26.89-V26.9 V40.0–V40.9 V41.0–V41.9 V43.0–V43.1 V44.0–V44.9 V45.00–V45.02, V45.09 V45.11 V45.12 V45.2-V45.4, V45.51, V45.52, V45.59, V45.61, V45.69, V45.71-V45.79, V45.81-V45.85, V45.86, V45.89 V48.0–V48.9 V49.0–V49.85 V49.86 V49.87 V49.89-V49.9 V51.0 V51.8 V52.0–V52.9 V53.01–V53.09 85025, 85027, 85032, 85048, 85049 Need for prophylactic vaccination Personal history of mental disorder, schizophrenia, affective disorders, neurosis, and alcoholism Personal history of combat and operational stress reaction Personal history of other and unspecified mental disorders Personal history of allergy to medicinal agents Family history of malignant neoplasm, gastrointestinal tract Family history of malignant neoplasm, breast Constitutional states in development Encounter for contraceptive management; general counseling and advice Encounter for insertion of intrauterine contraceptive device Encounter for removal of intrauterine contraceptive device Encounter for removal and reinsertion of intrauterine contraceptive device Encounter for sterilization; menstrual extraction; surveillance of previously prescribed contraceptive methods; and insertion of implantable subdermal contraceptive; other specified and unspecified contraceptive management Procreative management Other procreative counseling and advice using natural family planning Encounter for fertility preservation counseling Other procreative management, counseling and advice Tubal ligation status Vascectomy status Encounter for assisted reproductive fertility procedure cycle Encounter for fertility preservation procedure Other specified and unspecified procreative management Mental and behavioral problems Problems with special senses and other special functions Organ or tissue replaced by other means, eye globe or lens Artificial opening status Other post-surgical states Renal dialysis status Non-compliance with renal dialysis Other post-surgical states Problems with head, neck, and trunk Other conditions influencing health status Do not resuscitate status Physical restraints status Other specified and unspecified conditions influencing health status Encounter for breast reconstruction following mastectomy Other aftercare involving the use of plastic surgery Fitting and adjustment of prosthetic device and implant Fitting and adjustment of devices related to nervous system and special senses PeaceHealth Laboratories | Medicare Coverage Policies 9 Blood Counts…….con’t 85004, 85007, 85008, 85013, 85014, 85018 NON-COVERED ICD-9 CODES V53.1 V53.31–V53.39 V53.4 V53.50 V53.51 V53.59 V53.6 V53.7 V53.8 V53.90-V53.99 V54.01–V54.9 V55.0–V55.9 V57.0–V57.2 V57.3 V57.4-V57.9 V58.5 V59.01–V59.9 V61.01 V61.02 V61.03 V61.04 V61.05 V61.06 V61.07 V61.08 V61.09 V61.10 V61.11 V61.12 V61.20 V61.21 V61.22 V61.23 V61.24 V61.25 V61.29 V61.3 V61.41 V61.42 V61.49, V61.5-V61.9 V62.21 V62.22 V62.29 V62.3-V62.84 85025, 85027, 85032, 85048, 85049 Fitting and adjustment of spectacles and contact lenses Fitting and adjustment of cardiac device Fitting and adjustment of orthodontic devices Fitting and adjustment of other intestinal appliance and device Fitting and adjustment of gastric lap band Fitting and adjustment of other gastrointestinal appliance and device Fitting and adjustment of urinary devices Fitting and adjustment of orthopedic devices Fitting and adjustment of wheelchair Fitting and adjustment of other and unspecified device Other orthopedic aftercare Attention to artificial openings Care involving use of rehabilitation procedures Care involving speech-language therapy Orthopedic training, other specified, and unspecified rehabilitation procedure Orthodontics Donors Family disruption due to family member on military deployment Family disruption due to return of family member from military deployment Family disruption due to divorce or legal separation Family disruption due to parent-child estrangement Family disruption due to child in welfare custody Family disruption due to child in foster care or in care of non-parental family member Family disruption due to death of family member Family disruption due to other extended absence of family member Other family disruption Counseling for marital or partner problems, unspecified Counseling for victim of spousal and partner abuse Counseling for perpetrator of spousal and partner abuse Counseling for parent-child problem Counseling for victim of child abuse Counseling for perpetrator of parental child abuse Counseling for parent-biological child problem Counseling for parent-adopted child problem Counseling for parent (guardian)-foster child problem Other parent-child problems Problems with aged parents or in-laws Alcoholism in family Substance abuse in family Other specified and unspecified family problems Personal current military deployment status Personal history of return from military deployment Other occupational circumstances or maladjustment Educational circumstances; other psychological or physical stress, not elsewhere classified; suicidal ideation PeaceHealth Laboratories | Medicare Coverage Policies 10 Blood Counts…….con’t 85004, 85007, 85008, 85013, 85014, 85018 NON-COVERED ICD-9 CODES V62.85 V62.89-V62.9 V65.2 V65.3 V65.40–V65.49 V65.5 V65.8 V65.9 V66.0–V66.9 V67.3 V67.4 V69.3 V71.01–V71.09 V72.0 V72.11-V72.12; V72.19 V72.2 V72.40, V72.41, V72.42 V72.5 V72.60 V72.61 V72.62 V72.63 V72.69 V72.7 V72.9 V76.10–V76.19 V76.2 V76.44 V76.51 V77.1 V81.0-V81.2 85025, 85027, 85032, 85048, 85049 Homicidal ideation Other psychological or physical stress, not elsewhere classified; and unspecified psychosocial circumstances Person feigning illness Dietary surveillance and counseling Other counseling, not elsewhere classified Person with feared complaint in whom no diagnosis was made Other reasons for seeking consultation Unspecified reason for consultation Convalescence and palliative care Follow-up examination following psychotherapy Follow-up examination following treatment of healed fracture Problems related to lifestyle, gambling and betting Observation and evaluation for suspected conditions not found, mental Examination of eyes and vision Encounter for hearing conservation and treatment; other examination of ears and hearing Dental examination Pregnancy examination or test; pregnancy unconfirmed; negative result; positive result Radiological examination, not elsewhere classified Laboratory examination, unspecified Antibody response examination Laboratory examination ordered as part of a routine general medical examination Pre-procedural laboratory examination Other laboratory examination Diagnostic skin and sensitization tests Unspecified examination Special screening for malignant neoplasms, breast Special screening for malignant neoplasms, cervix Special screening for malignant neoplasms, other sites, prostate Special screening for malignant neoplasms, Intestine, colon Special screening for diabetes mellitus Special screening for cardiovascular diseases PeaceHealth Laboratories | Medicare Coverage Policies 11 CA 125 Policy Type: NCD (National Coverage Decision) CPT CODE(S) 86304 ICD-9 CODES 158.8 158.9 180.0 182.0 183.0 183.2 183.8 184.8 198.6 198.82 236.0–236.3 338.3 789.39 795.82 795.89 V10.41 V10.42 V10.43-V10.44 TEST NAME Immunoassay for tumor antigen, quantitative, CA 125 ICD-9 DESCRIPTIONS Malignant neoplasms, specific parts of peritoneum Malignant neoplasms, peritoneum, unspecified Malignant neoplasm, endocervix Malignant neoplasm of corpus uteri, except isthmus Malignant neoplasm, ovary Malignant neoplasm, fallopian tube Malignant neoplasm, other specified sites of uterine adnexa Malignant neoplasm, other specified sites of female genital organs Secondary malignant neoplasm, ovary Secondary malignancy of genital organs Neoplasm of uncertain behavior of female genital organs Neoplasm related pain (acute) (chronic) Abdominal or pelvic swelling, mass or lump of other specified site Elevated cancer antigen 125 [CA 125] Other abnormal tumor markers Personal history of malignant neoplasm, cervix uteri Personal history of malignant neoplasm, other parts of the uterus Personal history of malignant neoplasm of female genital organs PeaceHealth Laboratories | Medicare Coverage Policies 12 CA 15-3 (27.29) Policy Type: NCD (National Coverage Decision) CPT CODE(S) 86300 ICD-9 CODES 174.0–174.9 175.0–175.9 198.2 198.81 338.3 795.89 V10.3 TEST NAME Immunoassay for tumor antigen, quantitative; CA 15–3 (27.29) ICD-9 DESCRIPTIONS Breast, primary (female)—malignant neoplasm of female breast Breast, primary (male)—malignant neoplasm of male breast Secondary malignant neoplasm (male breast) Secondary malignant neoplasm (female breast) Neoplasm related pain (acute) (chronic) Other abnormal tumor markers Personal history of malignant neoplasm, breast PeaceHealth Laboratories | Medicare Coverage Policies 13 CA 19-9 Policy Type: NCD (National Coverage Decision) CPT CODE(S) 86301 ICD-9 CODES 155.1 156.0 156.1 156.2 156.8 156.9 157.0–157.9 197.8 235.3 235.5 338.3 795.89 V10.09 TEST NAME Immunoassay for tumor antigen, quantitative; CA 19–9 ICD-9 DESCRIPTIONS Malignant neoplasm, intrahepatic bile ducts Malignant neoplasm of the gallbladder Malignant neoplasm, extrahepatic bile ducts Malignant neoplasm of the Ampulla of Vater Malignant neoplasm, other specified sites of gallbladder and extrahepatic bile ducts Malignant neoplasm, unspecified part of biliary tract Malignant neoplasm, pancreas Secondary malignant neoplasm, other digestive organs and spleen Neoplasm of uncertain behavior, liver and biliary passages Neoplasm of uncertain behavior, other and unspecified digestive organs Neoplasm related pain (acute) (chronic) Other abnormal tumor markers Other personal history of cancer PeaceHealth Laboratories | Medicare Coverage Policies 14 Carcinoembryonic Antigen (CEA) Policy Type: NCD (National Coverage Decision) CPT CODE(S) 82378 ICD-9 CODES 150.0–150.9 151.0–151.9 152.0–154.8 157.0–157.9 159.0 162.0–162.9 174.0–174.9 175.0–175.9 183.0 197.0 197.4 197.5 209.00-209.03 209.10-209.17 209.20-209.27, 209.29 209.70 209.71 209.72 209.73 209.74 209.75 209.79 230.3 230.4 230.7 230.9 235.2 338.3 790.99 795.81 795.89 V10.00 V10.05 V10.06 V10.11 V10.3 V10.43 V67.2 TEST NAME Carcinoembryonic antigen (CEA) ICD-9 DESCRIPTIONS Malignant neoplasm of the esophagus Malignant neoplasm of stomach Malignant neoplasm of small intestine, including duodenum, rectum, rectosigmoid junction and anus Primary malignancy of pancreas Malignant neoplasm of intestinal tract, part unspecified Malignant neoplasm of trachea, bronchus, lung Malignant neoplasm of female breast Malignant neoplasm of male breast Malignant neoplasm of ovary Secondary malignant neoplasm of neoplasm of lung Secondary malignant neoplasm of small intestine Secondary malignant neoplasm of large intestine and rectum Malignant carcinoid tumors of the small intestine Malignant carcinoid tumors of the appendix, large intestine, and rectum Malignant carcinoid tumors of other and unspecified sites Secondary neuroendocrine tumor, unspecified site Secondary neuroendocrine tumor of distant lymph nodes Secondary neuroendocrine tumor of liver Secondary neuroendocrine tumor of bone Secondary neuroendocrine tumor of peritoneum Secondary Merkel cell carcinoma Secondary neuroendocrine tumor of other sites Carcinoma in situ of colon Carcinoma in situ of rectum Carcinoma in situ of other/unspecified parts of intestine Carcinoma in situ other and unspecified digestive organs Neoplasm of uncertain behavior of stomach, intestines, rectum Neoplasm related pain (acute) (chronic) Other nonspecific findings on examination of blood Elevated carcinoembryonic antigen (CEA) Other abnormal tumor markers Personal history of malignant neoplasm of gastro-intestinal tract, unspecified Personal history of malignant neoplasm, large intestine Personal history of malignant neoplasm, rectum, rectosigmoid junction, anus Personal history of malignant neoplasm, bronchus, and lung Personal history of malignant neoplasm, breast Personal history of malignant neoplasm, ovary Follow-up examination following chemotherapy PeaceHealth Laboratories | Medicare Coverage Policies 15 Collagen cross links Policy Type: NCD (National Coverage Decision) CPT CODE(S) 82523 ICD-9 CODES 242.00–242.91 245.2 246.9 252.00-252.02, 252.08 256.2 256.31-256.39 256.8 256.9 268.9 269.3 627.0 627.1 627.2 627.4 627.8 627.9 731.0 733.00–733.09 733.10–733.19 733.90 805.8 V58.65 V58.69 TEST NAME Collagen cross links, any method ICD-9 DESCRIPTIONS Thyrotoxicosis Chronic lymphocytic thyroiditis (only if thyrotoxic) Unspecified disorder of thyroid Hyperparathyroidism Postablative ovarian failure Other ovarian failure Other ovarian dysfunction Unspecified ovarian dysfunction Unspecified vitamin D deficiency Mineral deficiency, not elsewhere classified Premenopausal menorrhagia Postmenopausal bleeding Symptomatic menopausal or female climacteric states Symptomatic states associated with artificial menopause Other specified menopausal and postmenopausal disorders Unspecified menopausal & postmenopausal disorder Osteitis deformans without mention of bone tumor (Paget’s disease of bone) Osteoporosis Pathological fracture Disorder of bone and cartilage, unspecified Fracture of vertebral column without mention of spiral cord injury, unspecified, closed Long-term (current) use of steroids Long-term (current) use of other medications PeaceHealth Laboratories | Medicare Coverage Policies 16 Cytogenetics Testing Policy Number: L24295 Policy Type: LCD (Local Coverage Decision) CPT CODE(S) 88120 88121 88230 88233 88235 88237 88239 88240 88241 88245 88248 88249 88261 88262 88263 88264 88267 88269 88271 88272 88273 88274 88275 88280 88283 88285 88289 88291 88299 TEST NAME Cytp urine 3-5 probes ea spec Cytp urine 3-5 probes cmptr Tissue culture lymphocyte Tissue culture skin/biopsy Tissue culture placenta Tissue culture bone marrow Tissue culture tumor Cell cryopreserve/storage Frozen cell preparation Chromosome analysis 20-25 Chromosome analysis 50-100 Chromosome analysis 100 Chromosome analysis 5 Chromosome analysis 15-20 Chromosome analysis 45 Chromosome analysis 20-25 Chromosome analys placenta Chromosome analys amniotic Cytogenetics DNA probe Cytogenetics 3-5 Cytogenetics 10-30 Cytogenetics 25-99 Cytogenetics 100-300 Chromosome karyotype study Chromosome banding study Chromosome count additional Chromosome study additional Cyto/molecular report Cytogenetic study PeaceHealth Laboratories | Medicare Coverage Policies 17 ICD-9 CODES 171.9* 188.0 188.1 188.2 188.3 188.4 188.5 188.6 188.7 188.8 189.0 200.00-200.08 200.10-200.18 200.20-200.28 200.80-200.88 201.00-201.08 201.10-201.18 201.20-201.28 201.40-201.48 201.50-201.58 201.60-201.68 201.70-201.78 201.90-201.98 202.00-202.08 202.80-202.88 202.90-202.98 203.00-203.02 203.10-203.12 203.82 204.00-204.02 204.10 204.12 204.22 204.80-204.82 205.00-205.91 206.00-206.02 206.82 206.90-206.91 207.20-207.22 207.82 208.00-208.02 225.2 238.4 238.6 238.71 ICD-9 DESCRIPTIONS Malignant neoplasm of connective and other soft tissue, site unspecified Malignant neoplasm of trigone of urinary bladder Malignant neoplasm of dome of urinary bladder Malignant neoplasm of lateral wall of urinary bladder Malignant neoplasm of anterior wall of urinary bladder Malignant neoplasm of posterior wall of urinary bladder Malignant neoplasm of bladder neck Malignant neoplasm of ureteric orifice Malignant neoplasm of urachus Malignant neoplasm of other specified sites of bladder Malignant neoplasm of kidney except pelvis Reticulosarcoma Lymphosarcoma Burkitt's tumor or lymphoma Other named variants Hodgkin's paragranuloma Hodgkin's granuloma Hodgkin's sarcoma Lymphocytic-histiocytic predominance Nodular sclerosis Mixed cellularity Lymphocytic depletion Hodgkin's disease, unspecified Other malignant neoplasms of lymphoid and histiocytic tissue Other malignant neoplasms of lymphoid and histiocytic tissue Other and unspecified malignant neoplasms of lymphoid and histiocytic tissue Multiple myeloma Plasma cell leukemia Other immunoproliferative neoplasms, in relapse Lymphoid leukemia Chronic lymphoid leukemia, without mention of having achieved remission Chronic lymphoid leukemia, in relapse Subacute lymphoid leukemia, in relapse Other lymphoid leukemia Myeloid leukemia Acute monocytic leukemia Other monocytic leukemia, in relapse Unspecified monocytic leukemia Megakaryocytic leukemia Other specified leukemia, in relapse Leukemia of unspecified cell type Benign neoplasm of cerebral meninges Polycythemia vera Neoplasm of uncertain behavior of plasma cells Essential thrombocythemia PeaceHealth Laboratories | Medicare Coverage Policies 18 Cytogenetics…….cont’d 238.72 238.73 238.74 238.75 238.77 238.79 259.0 273.1 273.3 284.01 284.09 284.19 284.2 284.81 284.89 284.9 285.0 285.1 285.21 285.22 285.29 285.8 285.9 287.30-287.39 287.41 287.49 288.01* 288.02 288.1 288.2 288.3 288.4 288.61 288.63 288.64 288.65 288.8 289.6 289.7 289.81-289.89 334.8 388.5 389.10 629.9 88120, 88121, 88230, 88233, 88235, 88237, 88239, 88240, 88241, 88245, 88248, 88249, 88261, 88262, 88263, 88264, 88267, 88269, 88271, 88272, 88273, 88274, 88275, 88280, 88283, 88285, 88289, 88291, 88299 Low grade myelodysplastic syndrome lesions High grade myelodysplastic syndrome lesions Myelodysplastic syndrome with 5q deletion Myelodysplastic syndrome, unspecified Post-transplant lymphoproliferative disorder (PTLD) Other lymphatic and hematopoietic tissues Delay in sexual development and puberty, not elsewhere classified Monoclonal paraproteinemia Macroglobulinemia Constitutional red blood cell aplasia Other constitutional aplastic anemia Other pancytopenia Myelophthisis Red cell aplasia (acquired) (adult) (with thymoma) Other specified anemias Anemia unspecified Sideroblastic anemia Acute posthemorrhagic anemia Anemia in chronic kidney disease Anemia in neoplastic disease Anemia of other chronic disease Other specified anemias Anemia unspecified Purpura and other hemorrhagic conditions Posttransfusion purpura Other secondary thrombocytopenia Congenital neutropenia Cyclic neutropenia Functional disorders of polymorphonuclear neutrophils Genetic anomalies of leukocytes Eosinophilia Hemophagocytic syndromes Lymphocytosis (symptomatic) Monocytosis (symptomatic) Plasmacytosis Basophilia Other specified disease of white blood cells Familial polycythemia Methemoglobinemia Other specified diseases of blood and blood-forming organs Other spinocerebellar diseases Disorders of acoustic nerve Sensorineural hearing loss unspecified Unspecified disorder of female genital organs PeaceHealth Laboratories | Medicare Coverage Policies 19 Cytogenetics…….cont’d 630 631.0 632 646.33 655.00-655.23 656.40-656.43 656.50-656.53 656.60-656.63 657.00-657.03 658.00-658.03 659.50-659.53 659.60-659.63 740.0-740.2 742.0-742.8 743.00-743.9 744.00-744.9 745.0-745.9 746.00-746.9 747.0-747.9 748.0-748.9 749.00-749.25 750.0-750.9 751.0-751.9 752.0-752.9 753.0-753.9 754.0-754.89 755.00-755.9 756.0-756.89 757.0 757.1 757.2 757.31-757.39 758.0-758.9 759.83 783.22 783.40 783.41 783.42 783.43 796.5 796.6 V13.61-V13.69 V18.4 88120, 88121, 88230, 88233, 88235, 88237, 88239, 88240, 88241, 88245, 88248, 88249, 88261, 88262, 88263, 88264, 88267, 88269, 88271, 88272, 88273, 88274, 88275, 88280, 88283, 88285, 88289, 88291, 88299 Hydatidiform mole Inappropriate change in quantitative human chorionic gonadotropin (hcg) in early pregnancy Missed abortion Habitual aborter antepartum condition or complication Known or suspected fetal abnormaility affecting management of mother Intrauterine death Poor fetal growth Excessive fetal growth Polyhydramnios Oligohydramnios Elderly primigravida Elderly multigravida Anencephalus and similar anomalies Other congenital anomalies of nervous system Congenital anomalies of eye Congenital anomalies of ear, face, and neck Bulbus cordis anomalies and anomalies of cardiac septal closure Other congenital anomalies of heart Other congenital anomalies of circulatory system Congenital anomalies of respiratory system Cleft palate and cleft lip Other congenital anomalies of upper alimentary tract Other congenital anomalies of digestive system Congenital anomalies of genital organs Congenital anomalies of urinary system Certain congenital musculoskeletal deformities Other congenital anomalies of limbs Other congenital musculoskeletal anomalies Hereditary edema of legs Ichthyosis congenita Dermatoglyphic anomalies Other specified anomalies of skin Chromosomal anomalies Fragile X syndrome Underweight Unspecified lack of normal physiological development Failure to thrive Delayed milestones Short stature Abnormal finding on antenatal screening Nonspecific abnormal findings on neonatal screening Personal history of congenital malformations Family history of mental retardation PeaceHealth Laboratories | Medicare Coverage Policies 20 Cytogenetics…….cont’d V19.5 V49.89* 88120, 88121, 88230, 88233, 88235, 88237, 88239, 88240, 88241, 88245, 88248, 88249, 88261, 88262, 88263, 88264, 88267, 88269, 88271, 88272, 88273, 88274, 88275, 88280, 88283, 88285, 88289, 88291, 88299 Family history of congenital anomalies Other specified conditions influencing health status Special Coding: **171.9 *288.01 *V49.89 Medical record must contain documentation of either alveolar soft part sarcoma, alveolar rhabdomyosarcoma, clear cell sarcoma, desmoplastic small sound cell tumor, Ewing sarcoma, myxoid liposarcoma, low grade fibromyxoid sarcoma, extra skeletal myxoid chondrosarcoma, inflammatory myofibroblastic tumor, or synovial sarcoma in order to use these diagnosis codes. Limited to infantile genetic agranulocytosis only To be used only when repeat testing is believed to be medically reasonable and necessary. PeaceHealth Laboratories | Medicare Coverage Policies 21 Digoxin Policy Type: NCD (National Coverage Decision) CPT CODE(S) 80162 ICD-9 CODES 242.00–242.91 243 244.0–244.9 245.0–245.9 275.2 275.40–275.49 275.5 276.0 276.1 276.2 276.3 276.4 276.50-276.52 276.61 276.69 276.7 276.8 276.9 293.0 293.1 307.47 339.3 368.16 368.8 368.9 397.9 398.0 398.91 402.01 402.11 402.91 403.00–403.91 404.00–404.93 410.00–410.92 411.0–411.89 413.0–413.9 414.4 422.0–422.99 425.0, 425.11, 425.18 425.2-425.9 TEST NAME Digoxin (Therapeutic Drug Assay) ICD-9 DESCRIPTIONS Thyrotoxicosis with or without goiter Congenital hypothyroidism Acquired hypothyroidism Thyroiditis Disorders of magnesium metabolism Disorders of calcium metabolism Hungry bone syndrome Hyperosmolality Hyposmolality Acidosis Alkalosis Mixed acid-base balance disorder Volume depletion Transfusion associated circulatory overload Other fluid overload Hyperpotassemia Hypopotassemia Electrolyte and fluid Disorder (not elsewhere classified) Acute delirium Subacute delirium Other dysfunctions of sleep stages or arousal from sleep Drug induced headache, not elsewhere classified Psychophysical visual disturbances Other specified visual disturbances Unspecified visual disturbances Rheumatic diseases of endocardium Rheumatic Myocarditis Rheumatic Heart Failure Hypertensive heart disease, malignant with heart failure Hypertensive heart disease, benign with heart failure Hypertensive heart disease, unspecified with heart failure Hypertensive kidney disease Hypertensive heart & kidney disease Acute myocardial infarction Other acute & subacute forms of ischemic heart disease Angina pectoris Coronary atherosclerosis due to calcified coronary lesion Acute myocarditis Cardiomyopathy PeaceHealth Laboratories | Medicare Coverage Policies 22 Digoxin……con’t 426.0–426.9 427.0–427.9 428.0–428.9 429.2 429.4 429.5 429.6 429.71 444.01 444.09 514 573.5 579.9 584.5–584.9 585.1-585.9 586 587 588.0 588.1 588.81 588.89 588.9 780.01 780.02 780.09 780.1 780.2 780.4 780.71–780.79 783.0 784.0 787.01–787.03 787.04 787.91 794.31 799.21 799.22 799.23 799.24 799.25 799.29 972.0 972.1 995.20 995.21 995.24 80162 Conduction disorders Cardiac dysrhythmias Heart failure Cardiovascular disease, unspecified Heart Disturbances Postcardiac Surgery Rupture chordae tendinae Rupture papillary muscle Acquired cardiac septal defect Saddle embolus of abdominal aorta Other arterial embolism and thrombosis of abdominal aorta Pulmonary congestion & hypostasis Hepatopulmonary syndrome Unspecified Intestinal malabsorption Acute kidney failure Chronic kidney disease Renal Failure, unspecified Renal sclerosis, unspecified Renal osteodystrophy Nephrogenic Diabetes Insipidus Secondary hyperparathyroidism (of renal origin) Other specified disorders resulting from impaired renal function Unspecified disorder resulting from impaired renal function Coma Transient alteration of awareness Other ill-defined general symptoms (drowsiness, semicoma, somnolence, stupor, unconsciousness) Hallucinations Syncope & collapse Dizziness and giddiness Malaise & fatigue Anorexia Headache Nausea & vomiting Bilious emesis Diarrhea Abnormal electrocardiogram Nervousness Irritability Impulsiveness Emotional lability Demoralization and apathy Other signs and symptoms involving emotional state Poisoning by cardiac rhythm regulators Poisoning by cardiotonic glycosides & drugs of similar action Unspecified adverse effect of drug, medicinal and biological substance Arthus phenomenon Failed moderate sedation during procedure PeaceHealth Laboratories | Medicare Coverage Policies 23 Digoxin……con’t 995.27 995.29 *E942.1 V58.69 Special Coding: *E942.1 80162 Other drug allergy Unspecified adverse effect of other drug, medicinal and biologic substance Adverse effect of cardiotonic glycosides and drugs of similar action Encounter long term—Medication Use (not elsewhere classified) Code may not be reported as a stand-alone or first-listed code on the claim PeaceHealth Laboratories | Medicare Coverage Policies 24 Gamma Glutamyl Transferase (GGT) Policy Type: NCD (National Coverage Decision) CPT CODE(S) 82977 ICD-9 CODES 003.1 006.0–006.9 014.00–014.86 017.90–017.96 018.90–018.96 020.0–020.9 022.3 027.0 027.1 030.1 032.83 036.1 036.2 038.0, 038.10038.19, 038.2, 038.3, 038.40038.49, 038.8, 038.9 038.12 039.2 040.0 042 054.0 054.5 060.0–060.1 070.0–070.9 072.71 073.0 074.8 075 078.5 079.99 082.0–082.9 084.9 086.1 088.81 091.62 095.3 100.0 TEST NAME Glutamyltransferase, gamma (GGT) ICD-9 DESCRIPTIONS Salmonella septicemia Amebiasis Tuberculosis of intestines, peritoneum, and mesenteric glands Tuberculosis of other specified organs Miliary tuberculosis, unspecified Plague Anthrax septicemia Listeriosis Erysipelothrix infection Tuberculoid leprosy [Type T] Diphtheritic peritonitis Meningococcal encephalitis Meningococcemia Septicemia Methicillin resistant Staphylococcus aureus septicemia Actinomycotic infections, abdominal Gas gangrene Human immunodeficiency virus (HIV) disease Eczema herpeticum Herpetic septicemia Yellow fever Viral hepatitis Mumps hepatitis Ornithosis, with pneumonia Other specified diseases due to Coxsackie virus Infectious mononucleosis Cytomegaloviral disease Unspecified viral infection Tick-borne rickettsioses, stet Other pernicious complications of malaria Chagas disease with organ involvement other than heart Lyme disease Secondary syphilitic hepatitis Syphilis of liver Leptospirosis icterohemorrhagica PeaceHealth Laboratories | Medicare Coverage Policies 25 GGT……con’t 112.5 115.00 120.9 121.1 121.3 122.0 122.5 122.8 122.9 130.5 135 150.0–159.9 160.0–165.9 170.0–176.9 179–189.9 200.00–208.92 209.20-209.27, 209.29 209.70 209.71 209.72 209.73 209.74 209.75 209.79 211.5 211.6 211.7 228.04 230.7 230.8 230.9 235.0–238.9 239.0 250.00–250.93 252.00-252.02, 252.08 263.1 263.9 268.0 268.2 269.0 270.2 270.9 271.0 272.0 272.1 82977 Candidiasis, disseminated Infection by Histoplasma capsulatum without mention of manifestation Schistosomiasis, unspecified Clonorchiasis Fascioliasis Echinococcus granulosus infection of liver Echinococcus multilocularis infection of liver Echinococcosis, unspecified, of liver Echinococcus, other and unspecified Hepatitis due to toxoplasmosis Sarcoidosis Malignant neoplasm of digestive organs and peritoneum Malignant neoplasm of respiratory and intrathoracic organs Malignant neoplasm of bone, connective tissue, skin, and breast Malignant neoplasm of genitourinary organs Malignant neoplasm of lymphatic and hematopoietic tissue Malignant carcinoid tumors of other and unspecified sites Secondary neuroendocrine tumor, unspecified site Secondary neuroendocrine tumor of distant lymph nodes Secondary neuroendocrine tumor of liver Secondary neuroendocrine tumor of bone Secondary neuroendocrine tumor of peritoneum Secondary Merkel cell carcinoma Secondary neuroendocrine tumor of other sites Benign neoplasm of liver and biliary passages Benign neoplasm of pancreas, except islets of Langerhans Benign neoplasm of islets of Langerhans Hemangioma of intra-abdominal structures Carcinoma in situ of other and unspecified parts of intestine Carcinoma in situ of liver and biliary system Carcinoma in situ other and unspecified digestive organs Neoplasms of uncertain behavior Neoplasm of unspecified nature of digestive system Diabetes mellitus Hyperparathyroidism Malnutrition of mild degree Unspecified protein-calorie malnutrition Rickets, active Osteomalacia, unspecified Deficiency of vitamin K Other disturbances of aromatic amino acid metabolism Unspecified disorder of amino acid metabolism Glycogenosis Pure hypercholesterolemia Pure hyperglyceridemia PeaceHealth Laboratories | Medicare Coverage Policies 26 GGT……con’t 272.2 272.4 272.7 272.9 273.4 275.01-275.09 275.1 275.2 275.3 275.40–275.49 275.5 277.1 277.30-277.39 277.4 277.6 282.60–282.69 286.6 286.7 289.4 289.52 291.0–291.9 303.00–303.03 303.90–303.93 304.00–304.93 305.00–305.93 357.5 359.21-359.29 452 453.0–453.9 456.0–456.21 555.0–555.9 556.0–556.9 557.0 558.1–558.3, 558.41-558.42, 558.9 560.0–560.2 560.30 560.31 560.32 560.39 560.81-560.89, 560.9 562.01 562.03 562.11 562.13 82977 Mixed hyperlipidemia Other and unspecified hyperlipidemia Lipidoses Unspecified disorder of lipoid metabolism Alpha-1-antitrypsin deficiency Disorders of iron metabolism Disorders of copper metabolism Disorders of magnesium metabolism Disorders of phosphorus metabolism Disorders of calcium metabolism Hungry bone syndrome Disorders of porphyrin metabolism Amyloidosis Disorders of bilirubin excretion Other deficiencies of circulating enzymes Sickle cell anemia Defibrination syndrome Acquired coagulation factor deficiency Hypersplenism Splenic sequestration Alcoholic psychoses Acute alcoholic intoxication Other and unspecified alcohol dependence Drug dependence Non-dependent abuse of drugs Alcoholic polyneuropathy Myotonic disorders Portal vein thrombosis Other vein embolism and thrombosis Esophageal varices Regional enteritis Ulcerative colitis Acute vascular insufficiency of intestine Other noninfectious gastroenteritis and colitis Intestinal obstruction: intussusceptions, paralytic ileus, volvulus Impaction of intestine, unspecified Gallstone ileus Fecal impaction Other impaction of intestine Other and unspecified intestinal obstruction Diverticulitis of small intestine (without mention of hemorrhage) Diverticulitis of small intestine with hemorrhage Diverticulitis of colon (without mention of hemorrhage) Diverticulitis of colon with hemorrhage PeaceHealth Laboratories | Medicare Coverage Policies 27 GGT……con’t 567.0–567.29, 567.38-567.9 569.83 569.87 570 571.0–571.9 572.0–572.8 573.0–573.9 574.00–574.91 575.0–575.9 576.0–576.9 581.0–581.9 582.0–582.9 583.0–583.9 584.5–584.9 585.6 586 587 588.0–588.9 590.00–590.9 642.50-642.54 646.70, 646.71, 646.73 782.4 789.1 790.4 790.5 960.0–979.9 980.0–989.89 V42.7 V58.61–V58.64, V58.69 V67.1 V67.2 V67.51 82977 Peritonitis Perforation of intestine Vomiting of fecal matter Acute and subacute necrosis of liver Chronic liver disease and cirrhosis Liver abscess and sequelae of chronic liver disease Other disorders of liver Cholelithiasis Other disorders of gallbladder Other disorders of biliary tract Nephrotic syndrome Chronic glomerulonephritis Nephritis and nephropathy not specified as acute or chronic Acute renal failure End stage renal disease Renal failure, unspecified Renal sclerosis, unspecified Disorders resulting from impaired renal function Infections of kidney Severe pre-eclampsia Liver disorders in pregnancy Jaundice, unspecified, not of newborn Hepatomegaly Nonspecific elevation of levels of transaminase or lactic acid dehydrgenase Other nonspecific abnormal serum enzyme levels Poisoning by drugs, medicinal, and biological substances Toxic effects of substances chiefly nonmedical as to source Organ replaced by transplant, liver Long term (current) drug use Follow-up examination, radiotherapy Follow-up examination, chemotherapy Follow-up examination after completed treatment with high-risk medications, not elsewhere classified PeaceHealth Laboratories | Medicare Coverage Policies 28 General Health Panel CPT 80050 Includes the following: 1) 85022/85025 Hemogram/CBC 2) 84443 Thyroid Stimulating Hormone 3) 80053 Comprehensive Metabolic Panel Documentation supporting the medical necessity of all procedures, such as ICD-9 code(s), must be submitted with each claim. Claims submitted without such evidence will be denied as not medically necessary. Policy Type: LCD (Local Coverage Policy) PeaceHealth Laboratories | Medicare Coverage Policies 29 Genetic Testing - New CPT’s as of 01/01/13 Policy Number: L24308 Policy Type: LCD (Local Coverage Decision) CPT CODE(S) 81201 81202 81203 81211 81212 81213 81214 81215 81216 81217 81270 81275 81292 81293 81294 81295 TEST NAME APC (Adenomatous polyposis coli) (EG, Familial Adenomatosis Polyposis [FAP], Attenuated FAP) gene analysis; full gene sequence APC (Adenomatous polyposis coli) (EG, Familial Adenomatosis Polyposis [FAP], Attenuated FAP) gene analysis; known familial variants APC (Adenomatous polyposis coli) (EG, Familial Adenomatosis Polyposis [FAP], Attenuated FAP) gene analysis; duplication/deletion variants BRCA1, BRCA2 (Breast cancer 1 & 2) ( EG, hereditary breast & ovarian cancer) gene analysis; full sequence analysis and common duplication/deletion variants in BRCA1 (IE, EXON 13 DEL 3.835KB, EXON 13 DUP 6KB, EXON 14-20 DEL 26KB, EXON 22 DEL 510BP, EXON 8-9 DEL 7.1KB) BRCA1, BRCA2 (Breast cancer 1 & 2) (EG, hereditary breast & ovarian cancer) gene analysis; 185DELAG, 5385INSC, 6174DELT variants BRCA1, BRCA2 (Breast cancer 1 & 2) (EG, hereditary breast & ovarian cancer) gene analysis; uncommon duplication/deletion variants BRCA1 (Breast cancer 1) (EG, hereditary breast & ovarian cancer) gene analysis; full sequence analysis & common duplication/deletion variants (IE, EXON 13 DEL 3.835KB, EXON 13 DUP 6KB, EXON 14-20 DEL 26KB, EXON 22 DEL 510BP, EXON 8-9 DEL 7.1KB) BRCA1 (Breast cancer 1) (EG, hereditary breast & ovarian cancer) gene analysis; known familial variant BRCA2 (Breast cancer 2) (EG, hereditary breast & ovarian cancer) gene analysis; full sequence analysis BRCA2 (Breast cancer 2) (EG, hereditary breast & ovarian cancer) gene analysis; known familial variant JAK2 (Janus Kinase 2) (EG, Myeloproliferative Disorder) gene analysis, P.VAL617PHE (V617F) variant KRAS (V-KI-RAS2 Kirsten Rat Sarcoma Viral Oncogene) (EG, Carcinoma) gene analysis; variants in Codons 12 & 13 MLH1 (MUTL Homolog 1, colon cancer, non-polyposis type 2) (EG, hereditary non-polyposis colorectal cancer, lynch syndrome) gene analysis; full sequence analysis MLH1 (MUTL Homolog 1, colon cancer, non-polyposis type 2) (EG, hereditary non-polyposis colorectal cancer, lynch syndrome) gene analysis; known familial variants MLH1 (MUTL Homolog 1, colon cancer, non-polyposis type 2) (EG, hereditary non-polyposis colorectal cancer, lynch syndrome) gene analysis; duplication/deletion variants MSH2 (MUTS Homolog 2, colon cancer, non-polyposis type 1) (EG, hereditary non-polyposis colorectal cancer, lynch syndrome) gene analysis; full sequence analysis PeaceHealth Laboratories | Medicare Coverage Policies 30 Genetic Testing - New CPT’s as of 01/01/13 (con’t) CPT CODE(S) 81296 81297 81298 81299 81300 81317 81318 81319 81381 81401 81403 81405 81406 88363 Policy Number: L24308 Policy Type: LCD (Local Coverage Decision) TEST NAME MSH2 (MUTS Homolog 2, colon cancer, non-polyposis type 1) (EG, hereditary non-polyposis colorectal cancer, lynch syndrome) gene analysis; known familial variants MSH2 (MUTS Homolog 2, colon cancer, non-polyposis type 1) (EG, hereditary non-polyposis colorectal cancer, lynch syndrome) gene analysis; duplication/deletion variants MSH6 (MUTS Homolog 6 [E.COLI]) (EG, hereditary non-polyposis colorectal cancer, lynch syndrome) gene analysis; full sequence analysis MSH6 (MUTS Homolog 6 [E.COLI]) (EG, hereditary non-polyposis colorectal cancer, lynch syndrome) gene analysis; known familial variants MSH6 (MUTS Homolog 6 [E.COLI]) (EG, hereditary non-polyposis colorectal cancer, lynch syndrome) gene analysis; duplication/deletion variants PMS2 (Postmeiotic segregation increased 2 [S. Cerevisiae]) (EG, hereditary non-polyposis colorectal cancer, lynch syndrome) gene analysis; full sequence analysis PMS2 (Postmeiotic segregation increased 2 [S. Cerevisiae]) (EG, hereditary non-polyposis colorectal cancer, lynch syndrome) gene analysis; known familial variants PMS2 (Postmeiotic segregation increased 2 [S. Cerevisiae]) (EG, hereditary non-polyposis colorectal cancer, lynch syndrome) gene analysis; duplication/deletion variants HLA class I typing, high resolution (IE, Alleles or Allele groups); one Allele or Allele group (EG, B*57:01P), each Molecular pathology procedure, level 2 (EG, 2-10 SNPS, 1 methylated variant, or 1 somatic variant [typically using non-sequencing target variant analysis], or detection of a dynamic mutation disorder/triplet repeat) Molecular pathology procedure, level 4 (EG, analysis of single exon by DNA sequence analysis, analysis of >10 amplicons using multiplex PCR in 2 or more independent reactions, mutation scanning or duplication/deletion variants of 2-5 exons) Molecular pathology procedure, level 6 (EG, analysis of 6-10 exons by DNA sequence analysis, mutation scanning or duplication/deletion variants of 1125 exons) Molecular pathology procedure, level 7 (EG, analysis of 11-25 exons by DNA sequence analysis, mutation scanning or duplication/deletion variants of 2650 exons, cytogenomic array analysis for neoplasia) Examination and selection of retrieved archival (IE, previously diagnosed) tissue(s) for molecular analysis (EG, KRAS mutational analysis) PeaceHealth Laboratories | Medicare Coverage Policies 31 Genetic Testing - Retired CPT’s as of 12/31/12 Policy Number: L24308 Policy Type: LCD (Local Coverage Decision) CPT CODE(S) 83890 TEST NAME Molecular diagnostics; molecular isolation or extraction 83891 Molecular diagnostics; isolation or extraction of highly purified nucleic acid 83892 83893 Molecular diagnostics; enzymatic digestion Molecular diagnostics; dot/slot blot production Molecular diagnostics; separation by gel electrophoresis (eg, agarose, polyacrylamide) Molecular diagnostics; nucleic acid probe, each Molecular diagnostics; amplification, target, each nucleic acid sequence Molecular diagnostics; amplification, target, multiplex, first 2 nucleic acid sequences Molecular diagnostics; mutation identification by sequencing, single segment, each segment Molecular diagnostics; separation and identification by high resolution technique (eg, capillary electrophoresis), each nucleic acid preparation Molecular diagnostics; interpretation and report Examination and selection of retrieved archival (i.e. previously diagnosed) tissue(s) for molecular analysis (e.g. Kras Mutational Analysis) 83894 83896 83898 83900 83904 83909 83912 88363 The following diagnosis codes billed with CPT codes 81211, 81212, 81213, 81214, 81215, 81216, and 81217 meet coverage criteria for BRCA1 and BRCA2 gene mutation testing: ICD-9 CODES 158.0 158.8 174.0 174.1 174.2 174.3 174.4 174.5 174.6 174.8 174.9 175.0 175.9 183.0 183.2 233.0 V10.3 V10.43 ICD-9 DESCRIPTIONS Malignant neoplasm of retroperitoneum Malignant neoplasm of specified parts of peritoneum Malignant neoplasm of nipple and areola of female breast Malignant neoplasm of central portion of female breast Malignant neoplasm of upper-inner quadrant of female breast Malignant neoplasm of lower-inner quadrant of female breast Malignant neoplasm of upper-outer quadrant of female breast Malignant neoplasm of lower-outer quadrant of female breast Malignant neoplasm of axillary tail of female breast Malignant neoplasm of other specified sites of female breast Malignant neoplasm of breast (female) unspecified site Malignant neoplasm of nipple and areola of male breast Malignant neoplasm of other and unspecified sites of male breast Malignant neoplasm of ovary Malignant neoplasm of fallopian tube Carcinoma in situ of breast Personal history of malignant neoplasm of breast Personal history of malignant neoplasm of ovary PeaceHealth Laboratories | Medicare Coverage Policies 32 The following diagnosis codes billed with CPT codes 81201, 81202, 81203, 81275, 81292, 81293, 81294, 81295, 81296, 81297, 81298, 81299, 81300, 81317, 81318, 81319, 81401, 81403, 81405, 81406, and 88363 meet coverage criteria for hereditary colorectal cancer (HNPCC) including endometrial and/or ovarian cancer when the latter two are reasonably considered part of the Lynch syndrome, Familial Adenomatous Polyposis (FAP) testing as well as for KRAS testing, when such testing is used to determine suitability of the use of either Erbitux or Panitumumab within the limitations noted above: ICD-9 CODES 153.0 153.1 153.2 153.3 153.4 153.5 153.6 153.7 153.8 153.9 154.0 154.1 154.2 154.3 154.8 179 182.8 183.0 183.2 197.5 V10.05 V10.06 V10.42 V12.72* ICD-9 DESCRIPTIONS Malignant neoplasm of hepatic flexure Malignant neoplasm of transverse colon Malignant neoplasm of descending colon Malignant neoplasm of sigmoid colon Malignant neoplasm of cecum Malignant neoplasm of appendix vermiformis Malignant neoplasm of ascending colon Malignant neoplasm of splenic flexure Malignant neoplasm of other specified sites of large intestine Malignant neoplasm of colon unspecified site Malignant neoplasm of rectosigmoid junction Malignant neoplasm of rectum Malignant neoplasm of anal canal Malignant neoplasm of anus unspecified site Malignant neoplasm of other sites of rectum rectosigmoid junction and anus Malignant neoplasm of uterus-part uns Malignant neoplasm of other specified sites of body of uterus Malignant neoplasm of ovary Malignant neoplasm of fallopian tube Secondary malignant neoplasm of large intestine and rectum Personal history of malignant neoplasm of large intestine Personal history of malignant neoplasm of rectum, rectosigmoid junction & anus Personal history of malignant neoplasm of other parts of uterus Personal history of colonic polyps *V12.72 should be used to denote any of the polyposis conditions as described under the Indications and Limitations above. PeaceHealth Laboratories | Medicare Coverage Policies 33 The following diagnosis codes when billed with CPT codes 81270 and 81403 meet coverage criteria for JAK2 testing: ICD-9 CODES 204.00 204.10 204.11 204.12 205.00 205.10 238.4 238.71 238.75 238.76 238.79 287.5 288.50 288.51 288.59 288.61 288.69 288.8 453.0 789.2 ICD-9 DESCRIPTIONS Acute lymphoid leukemia, without mention of having achieved remission Chronic lymphoid leukemia, without mention of having achieved remission Lymphoid leukemia, chronic, in remission Chronic lymphoid leukemia, in relapse Acute myeloid leukemia, without mention of having achieved remission Chronic myeloid leukemia, without mention of having achieved remission Polycythemia vera Essential thrombocythemia Myelodysplastic syndrome, unspecified Myelofibrosis with myeloid metaplasia Other lymphatic and hematopoietic tissues Thrombocytopenia unspecified Leukocytopenia, unspecified Lymphocytopenia Other decreased white blood cell count Lymphocytosis (symptomatic) Other elevated white blood cell count Other specified disease of white blood cells Budd-Chiari Syndrome Splenomegaly Multiple CPT codes exist for the various molecular tests for lymphoma. The appropriate code should be selected from the most current CPT manual. The following diagnosis codes meet coverage criteria as indications for molecular testing of lymphoma, so long as documentation of medical necessity for the specific test in question is present in the medical record, as noted elsewhere in this LCD: ICD-9 CODES 200.40 ICD-9 DESCRIPTIONS Mantle cell lymphoma, unspecified site, extranodal and solid organ sites 200.41 Mantle cell lymphoma, lymph nodes of head, face, and neck 200.42 Mantle cell lymphoma, intrathoracic lymph nodes 200.43 Mantle cell lymphoma, intra-abdominal lymph nodes 200.44 Mantle cell lymphoma, lymph nodes of axilla and upper limb 200.45 Mantle cell lymphoma, lymph nodes of inguinal region and lower limb 200.46 Mantle cell lymphoma, intrapelvic lymph nodes 200.47 Mantle cell lymphoma, spleen 200.48 Mantle cell lymphoma, lymph nodes of multiple sites 200.70 Large cell lymphoma, unspecified site, extranodal and solid organ sites 200.71 Large cell lymphoma, lymph nodes of head, face, and neck 200.72 Large cell lymphoma, intrathoracic lymph nodes PeaceHealth Laboratories | Medicare Coverage Policies 34 ICD-9 CODES 200.73 ICD-9 DESCRIPTIONS Large cell lymphoma, intra-abdominal lymph nodes 200.74 Large cell lymphoma, lymph nodes of axilla and upper limb 200.75 Large cell lymphoma, lymph nodes of inguinal region and lower limb 200.76 Large cell lymphoma, intrapelvic lymph nodes 200.77 Large cell lymphoma, spleen 200.78 Large cell lymphoma, lymph nodes of multiple sites 202.00 Nodular lymphoma unspecified site 202.01 Nodular lymphoma involving lymph nodes of head face and neck 202.02 Nodular lymphoma involving intrathoracic lymph nodes 202.03 Nodular lymphoma involving intra-abdominal lymph nodes 202.04 Nodular lymphoma involving lymph nodes of axilla and upper limb 202.05 Nodular lymphoma involving lymph nodes of inguinal region and lower limb 202.06 Nodular lymphoma involving intrapelvic lymph nodes 202.07 Nodular lymphoma involving spleen 202.08 Nodular lymphoma involving lymph nodes of multiple sites The following diagnosis codes when billed with CPT code 81403 meet coverage criteria as indications for testing for BCR/ABL fusion gene so long as documentation of medical necessity for the specific test in question is present in the medical record, as noted elsewhere in this LCD: ICD-9 CODES 204.00 ICD-9 DESCRIPTIONS Acute lymphoid leukemia, without mention of having achieved remission 204.01 Lymphoid leukemia acute in remission 204.02 Acute lymphoid leukemia, in relapse 204.10 Chronic lymphoid leukemia, without mention of having achieved remission 204.11 Lymphoid leukemia chronic in remission 204.12 Chronic lymphoid leukemia, in relapse 204.20 Sub-acute lymphoid leukemia, without mention of having achieved remission 204.21 Lymphoid leukemia sub-acute in remission 204.22 Sub-acute lymphoid leukemia, in relapse 204.80 Other lymphoid leukemia, without mention of having achieved remission 204.81 Other lymphoid leukemia in remission 204.82 Other lymphoid leukemia, in relapse 204.90 Unspecified lymphoid leukemia, without mention of having achieved remission 204.91 Unspecified lymphoid leukemia in remission 204.92 Unspecified lymphoid leukemia, in relapse 205.00 Acute myeloid leukemia, without mention of having achieved remission 205.01 Myeloid leukemia acute in remission 205.02 Acute myeloid leukemia, in relapse PeaceHealth Laboratories | Medicare Coverage Policies 35 ICD-9 CODES 205.10 ICD-9 DESCRIPTIONS Chronic myeloid leukemia, without mention of having achieved remission 205.11 Myeloid leukemia chronic in remission 205.12 Chronic myeloid leukemia, in relapse 205.20 Sub-acute myeloid leukemia, without mention of having achieved remission 205.21 Myeloid leukemia sub-acute in remission 205.22 Sub-acute myeloid leukemia, in relapse 205.30 Myeloid sarcoma, without mention of having achieved remission 205.31 Myeloid sarcoma in remission 205.32 Myeloid sarcoma, in relapse 205.80 Other myeloid leukemia, without mention of having achieved remission 205.81 Other myeloid leukemia in remission 205.82 Other myeloid leukemia, in relapse 205.90 Unspecified myeloid leukemia, without mention of having achieved remission 205.91 Unspecified myeloid leukemia in remission 205.92 Unspecified myeloid leukemia, in relapse 206.00 Acute monocytic leukemia, without mention of having achieved remission 206.01 Monocytic leukemia acute in remission 206.02 Acute monocytic leukemia, in relapse 206.10 Chronic monocytic leukemia, without mention of having achieved remission 206.11 Monocytic leukemia chronic in remission 206.12 Chronic monocytic leukemia, in relapse 206.20 Sub-acute monocytic leukemia, without mention of having achieved remission 206.21 Monocytic leukemia sub-acute in remission 206.22 Sub-acute monocytic leukemia, in relapse 206.80 Other monocytic leukemia, without mention of having achieved remission 206.81 Other monocytic leukemia in remission 206.82 Other monocytic leukemia, in relapse 206.90 Unspecified monocytic leukemia, without mention of having achieved remission 206.91 Unspecified monocytic leukemia in remission 206.92 Unspecified monocytic leukemia, in relapse 208.00 Acute leukemia of unspecified cell type, without mention of having achieved remission 208.01 Leukemia of unspecified cell type acute in remission 208.02 Acute leukemia of unspecified cell type, in relapse 208.10 Chronic leukemia of unspecified cell type, without mention of having achieved remission 208.11 Leukemia of unspecified cell type chronic in remission 208.12 Chronic leukemia of unspecified cell type, in relapse 208.20 Sub-acute leukemia of unspecified cell type, without mention of having achieved remission 208.21 Leukemia of unspecified cell type sub-acute in remission 208.22 Sub-acute leukemia of unspecified cell type, in relapse 208.80 Other leukemia of unspecified cell type, without mention of having achieved remission 208.81 Other leukemia of unspecified cell type in remission PeaceHealth Laboratories | Medicare Coverage Policies 36 ICD-9 CODES 208.82 ICD-9 DESCRIPTIONS Other leukemia of unspecified cell type, in relapse 208.90 Unspecified leukemia, without mention of having achieved remission 208.91 Unspecified leukemia in remission 208.92 Unspecified leukemia, in relapse 288.61 Lymphocytosis (symptomatic) 288.69 Other elevated white blood cell count 288.8 Other specified disease of white blood cells 789.2 Splenomegaly The following diagnosis codes when billed with CPT code 81381 meet coverage criteria as indications for HLA-B*5701 testing prior to initiating abacavir therapy in patients with either Human Immunodeficiency Virus (HIV) disease or Asymptomatic Human Immunodeficiency virus (HIV) infection. ICD-9 CODES 042 ICD-9 DESCRIPTIONS Human immunodeficiency virus (HIV) disease V08 Asymptomatic human immunodeficiency virus (HIV) infection status PeaceHealth Laboratories | Medicare Coverage Policies 37 Glucose Testing Policy Type: NCD (National Coverage Decision) CPT CODE(S) 82947 82948 82962 ICD-9 CODES 011.00–011.96 038.0–038.9 112.1 112.3 118 157.4 158.0 211.7 242.00–242.91 249.00-249.91 250.00–250.93 251.0–251.9 253.0–253.9 255.0 263.0–263.9 271.0–271.9 272.0–272–4 275.01-275.09 276.0–276.9 278.3 293.0 294.9 298.9 300.9 310.1 331.83 337.9 345.10–345.11 348.31 355.9 356.9 357.9 362.10 362.18 362.29 TEST NAME Glucose; quantitative, blood (except reagent strip) Glucose; blood, reagent strip Glucose, blood by glucose monitoring device(s) cleared by the FDA specifically for home use ICD-9 DESCRIPTIONS Tuberculosis Septicemia Recurrent vaginal candidiasis Interdigital candidiasis Opportunistic mycoses Malignant neoplasm of Islets of Langerhans Malignant neoplasm of retroperitoneum Benign neoplasm of Islets of Langerhans Thyrotoxicosis Secondary diabetes mellitus Diabetes mellitus Disorders of pancreatic internal secretion Disorders of the pituitary gland Cushing syndrome Malnutrition Disorders of carbohydrate transport and metabolism Disorders of lipoid metabolism Hemochromotosis Disorders of fluid, electrolyte and acid-base balance Hypercarotinemia Acute delirium Unspecified organic brain syndrome Unspecified psychosis Unspecified neurotic disorder Organic personality syndrome Mild cognitive impairment, so stated Autonomic nervous system neuropathy Generalized convulsive epilepsy Metabolic encephalopathy Neuropathy, not otherwise specified Unspecified hereditary and idiopathic peripheral neuropathy Unspecified inflammatory and toxic neuropathy Background retinopathy Retinal vasculitis Nondiabetic proliferative retinopathy PeaceHealth Laboratories | Medicare Coverage Policies 38 Glucose Testing…cont’d 362.50–362.57 362.60–362.66 362.81–362.89 362.9 365.04 365.32 366.00–366.09 366.10–366.19 367.1 368.8 373.00 377.24 377.9 378.50–378.55 379.45 410.00–410.92 414.00–414.19 414.3 414.4 425.9 440.23 440.24 440.9 458.0 462 466.0 480.0–486 490 491.0–491.9 527.7 528.00 528.09 535.50–535.51 536.8 571.8 572.0–572.8 574.50–574.51 575.0–575.12 576.1 577.0 577.1 577.8 590.00–590.9 595.9 596.4 596.53 82947, 82948, 82962 Degeneration of macular posterior pole Peripherial retinal degeneration Other retinal disorders Unspecified retinal disorders Borderline glaucoma, ocular hypertension Corticosteriod-induced glaucoma residual Presenile cataract Senile cataract Acute myopia Other specified visual disturbance Blepharitis Pseudopapilledema Autonomic nervous system neuropathy Paralytic strabiamus Argyll-Robertson pupils Acute myocardial infarctions Coronary atherosclerosis and aneurysm of heart Coronary atherosclerosis due to lipid rich plaque Coronary atherosclerosis due to calcified coronary lesion Secondary cardiomyopathy, unspecified Arteriosclerosis of extremities with ulceration Arteriosclerosis of extremities with gangrene Arteriosclerosis, not otherwise specified Postural hypotension Acute pharyngitis Acute bronchitis Pneumonia Recurrent bronchitis, not specified as acute or chronic Chronic bronchitis Disturbance of salivory secretion (drymouth) Stomatitis & mucositis, unspecified Other stomatitis & mucositis (ulcerative) Gastritis Dyspepsia Other chronic nonalcoholic liver disease Liver abscess and sequelae of chronic liver disease Choledocholitiasis Cholecystitis Cholangitis Acute pancreatitis Chronic pancreatitis Pancreatic multiple calculi Infections of the kidney Recurrent cystitis Bladder atony Bladder paresis PeaceHealth Laboratories | Medicare Coverage Policies 39 Glucose Testing…cont’d 599.0 607.84 608.89 616.10 626.0 626.4 628.9 648.00 82947, 82948, 82962 Urinary tract infection, recurrent Impotence of organic origin Other disorders male genital organs Vulvovaginitis Amenorrhea Irregular menses Infertility—female Diabetes mellitus complicating pregnancy, Childbirth or the puerperium, unspecified as to episode of care or not applicable 648.03 Diabetes mellitus complicating pregnancy, Childbirth or the puerperium, antipartum condition or complication 648.04 Diabetes mellitus complicating pregnancy, Childbirth or the puerperium, postpartum condition or complication 648.80 Abnormal glucose tolerance complicating pregnancy, childbirth or the puerperium, unspecified as to episode of care or not applicable 648.83 Abnormal glucose tolerance complicating pregnancy, childbirth or the puerperium, antipartum condition or complication 648.84 649.20-649.24 656.60–656.63 657.00–657.03 680.0–680.9 686.00–686.9 698.0 698.1 704.1 705.0 707.00–707.9 709.3 729.1 730.07 730.17 730.27 780.01 780.02 780.09 780.2 780.31 780.32 780.33 780.39 780.4 780.71–780.79 780.8 781.0 782.0 Abnormal glucose tolerance complicating pregnancy, childbirth or the puerperium, postpartum condition or complication Bariatric surgery status complicating pregnancy Fetal problems affecting management of mother—large for-date of fetus Polyhydramnios Carbuncle and furuncle Infections of skin and subcutaneous tissue Pruritis ani Pruritis of genital organs Hirsutism Anhidrosis Chronic ulcer of skin Degenerative skin disorders Myalgia Acute osteomyelitis of ankle and foot Chronic osteomyelitis of ankle and foot Unspecified osteomyelitis of ankle and foot Coma Transient alteration of awareness Alteration of consciousness, other Syncope and collapse Febrile convulsions Complex febrile convulsions Post traumatic seizures Seizures, not otherwise specified Dizziness and giddiness Malaise and fatigue Hyperhidrosis Abnormal involuntary movements Loss of vibratory sensation PeaceHealth Laboratories | Medicare Coverage Policies 40 Glucose Testing…cont’d 783.1 783.21 783.5 783.6 785.0 785.4 786.01 786.09 786.50 787.60-787.63 787.91 788.41–788.43 789.1 790.21 790.22 790.29 790.6 791.0 791.5 796.1 799.4 V23.0–V23.9 V58.63 V58.64 V58.65 V58.67 V58.69 V67.2 V67.51 V77.1 Covered for procedure code 82947 only 82947, 82948, 82962 Abnormal weight gain Abnormal loss of weight Polydipsia Polyphagia Tachycardia Gangrene Hyperventilation Dyspnea, Chest pain, unspecified Fecal incontinence Diarrhea Frequency of urination and polyuria Hepatomegaly Impaired fasting glucose Impaired glucose tolerance test (oral) Other abnormal glucose Other abnormal blood chemistry (hyperglycemia) Proteinuria Glycosuria Abnormal reflex Cachexia Supervision of high risk pregnancy Long-term (current) use of antiplatelets/antithrombotics Long-term (current) use of non-steroidal anti-inflammatories (NSAID) Long-term (current) use of steroids Long-term (current) use of insulin Long term current use of other medication Follow-up examination, following chemotherapy Follow up examination with high-risk medication not elsewhere classified Screening for diabetes mellitus PeaceHealth Laboratories | Medicare Coverage Policies 41 Glycated Protein/Glycohemoglobin Policy Type: NCD (National Coverage Decision) CPT CODE(S) 82985 83036 ICD-9 CODES 211.7 249.00-249.01 249.10-249.11 249.20-249.21 249.30-249.31 249.40-249.41 249.50-249.51 249.60-249.61 249.70-249.71 249.80-249.81 249.90-249.91 250.00–250.93 251.0 251.1 251.2 251.3 251.4 251.8 251.9 258.0–258.9 271.4 275.01-275.09 577.1 579.3 648.00 TEST NAME Glycated protein Hemoglobin; glycated ICD-9 DESCRIPTIONS Benign neoplasm of islets of Langerhans Secondary diabetes mellitus without mention of complication Secondary diabetes mellitus with ketoacidosis Secondary diabetes mellitus with hyperosmolarity Secondary diabetes mellitus with other coma Secondary diabetes mellitus with renal manifestations Secondary diabetes mellitus with ophthalmic manifestations Secondary diabetes mellitus with neurological manifestations Secondary diabetes mellitus with peripheral circulatory disorders Secondary diabetes mellitus with other specified manifestations Secondary diabetes mellitus with unspecified complication Diabetes mellitus & various related codes Hypoglycemic coma Other specified hypoglycemia Hypoglycemia unspecified Post-surgical hypoinsulinemia Abnormality of secretion of glucagon Other specified disorders of pancreatic internal secretion Unspecified disorder of pancreatic internal secretion Polyglandular dysfunction Renal glycosuria Hemochromatosis Chronic pancreatitis Other and unspecified postsurgical nonabsorption Diabetes mellitus complicating pregnancy, Childbirth or the puerperium, unspecified as to episode of care or not applicable 648.03 Diabetes mellitus complicating pregnancy, Childbirth or the puerperium, antepartum condition or complication 648.04 Diabetes mellitus complicating pregnancy, Childbirth or the puerperium, postpartum condition or complication 648.80 Abnormal glucose tolerance complicating pregnancy, childbirth or the puerperium, unspecified as to episode of care or not applicable 648.83 Abnormal glucose tolerance complicating pregnancy, childbirth or the puerperium, antepartum condition or complication 648.84 790.21 Abnormal glucose tolerance complicating pregnancy, childbirth or the puerperium, postpartum condition or complication Impaired fasting glucose PeaceHealth Laboratories | Medicare Coverage Policies 42 Glycated Protein/Glycohemoglobin………con’t 790.22 790.29 790.6 962.3 V12.21 V12.29 V58.67 V58.69 82985, 83036 Impaired glucose tolerance test (oral) Other abnormal glucose Other abnormal blood chemistry (hyperglycemia) Poisoning by insulin and antidiabetic agents Personal history of gestational diabetes Personal history of other endocrine, metabolic, and immunity disorders Long-term (current) use of insulin Long-term use of other medication PeaceHealth Laboratories | Medicare Coverage Policies 43 Gonadotropin (hCG) Policy Type: NCD (National Coverage Decision) CPT CODE(S) 84702 ICD-9 CODES 158.0 158.8 164.2 164.3 164.8 164.9 181 183.0 183.8 186.0 186.9 194.4 197.1 197.6 198.6 198.82 236.1 338.3 623.8 625.9 630 631.0 631.8 632 633.90-633.91 634.00–634.02 640.00–640.03 642.30–642.34 642.40–642.74 642.90–642.94 795.89 V10.09 V10.29 V10.43 TEST NAME Gonodotropin, chorionic (hCG); quantitative ICD-9 DESCRIPTIONS Malignant neoplasm of retroperitoneum Malignant neoplasm of specified parts of peritoneum Malignant neoplasm of anterior mediastinum Malignant neoplasm of posterior mediastinum Malignant neoplasm, other (includes malignant neoplasm of contiguous overlapping sites of thymus, heart, and mediastinum whose point of origin cannot be determined Malignant neoplasm of mediastinum, part unspecified Malignant neoplasm of placenta Malignant neoplasm of ovary Other specified sites of uterine adnexas Malignant neoplasm of undescended testes Malignant neoplasm of other and unspecified testis Malignant neoplasm of pineal gland Secondary malignant neoplasm of mediastinum Secondary malignant neoplasm of retroperitoneum and peritoneum Secondary malignant neoplasm of ovary Secondary malignant neoplasm of other genital organs Neoplasm of uncertain behavior, placenta Neoplasm related pain (acute) (chronic) Vaginal bleeding Pelvic pain Hydatidiform mole Inappropriate change in quantitative human chorionic gonadotropin (hCG) in early pregnancy Other abnormal products of conception Missed abortion Ectopic pregnancy Spontaneous abortion, complicated by genital tract and pelvic infection Threatened abortion Transient hypertension of pregnancy Pre-eclampsia or eclampsia Unspecified hypertension complicating pregnancy, childbirth, or the proerperium Other abnormal tumor markers Personal history of malignant neoplasm, other gastrointestinal sites Personal history of malignant neoplasm of other respiratory and intrathoracic organs Personal history of malignant neoplasm, ovary PeaceHealth Laboratories | Medicare Coverage Policies 44 ICD-9 CODES V10.47 V22.0–V22.1 ICD-9 DESCRIPTIONS Personal history of malignant neoplasm, testis Pregnancy PeaceHealth Laboratories | Medicare Coverage Policies 45 Hepatitis Panel Policy Type: NCD (National Coverage Decision) CPT CODE(S) 80074 ICD-9 CODES 070.0–070.9 456.0–456.21 570 571.5 572.0–572.8 573.3 573.5 780.31 780.32 780.33 780.71 780.72 780.79 782.4 783.0–783.6 787.01–787.03 787.04 789.00–789.09 789.1 789.61 789.7 790.4 794.8 996.82 V72.85 TEST NAME Acute Hepatitis Panel ICD-9 DESCRIPTIONS Viral hepatitis Esophageal varices with or without mention of bleeding Acute and subacute necrosis of liver Cirrhosis of liver without mention of alcohol Liver abscess and sequelae of chronic liver disease Hepatitis, unspecified Hepatopulmonary syndrome Febrile convulsions Complex febrile convulsions Post traumatic seizures Chronic fatigue syndrome Functional quadiplegia Other malaise and fatigue Jaundice, unspecified, not of newborn Symptoms concerning nutrition, metabolism, and development Nausea and vomiting Bilious emesis Abdominal pain Hepatomegaly Localized abdominal tenderness (RUQ) Colic Nonspecific elevation of levels of transaminase or lactic acid dehydrogenase (LDH) Nonspecific abnormal results of function Complications of transplanted organ, liver Liver transplant recipient evaluation PeaceHealth Laboratories | Medicare Coverage Policies 46 HIV testing: diagnosis Policy Type: NCD (National Coverage Decision) CPT CODE(S) 86689 86701 86702 86703 87390 87391 87534 87535 87537 87538 ICD-9 CODES 003.1 007.2 007.4 007.8 010.00–010.96 011.00–011.96 012.00–012.86 013.00–013.96 014.00–014.86 015.00–015.96 016.00–016.96 017.00–017.96 018.00–018.96 027.0 031.0–031.9 038.2 038.43 039.0–039.9 041.7 042 046.3 049.0–049.9 052.0–052.8 TEST NAME Qualitative or semi-quantitative immunoassays performed by multiple step methods; HTLV or HIV antibody, confirmatory test (for example, Western Blot) Antibody; HIV–1 Antibody; HIV–2 Antibody; HIV-1 and HIV-2, single assay Infectious agent antigen detection by enzyme immunoassay technique, qualitative or semi-quantitative, multiple step; HIV--1 Infectious agent antigen detection by enzyme immunoassay technique, qualitative or semi-quantitative, multiple step: HIV--2 Infectious agent detection by nucleic acid (DNA or RNA); HIV–1, direct probe technique Infectious agent detection by nucleic acid (DNA or RNA); HIV–1, direct probe technique HIV–1, amplified probe technique Infectious agent detection by nucleic acid (DNA or RNA); HIV–2, direct probe technique Infectious agent detection by nucleic acid (DNA or RNA); HIV–2, amplified probe technique ICD-9 DESCRIPTIONS Salmonella septicemia Coccidiosis (Isoporiasis) Cryptosporidiosis Other specified protozoal intestinal diseases Primary tuberculous infection Pulmonary tuberculosis Other respiratory tuberculosis Tuberculosis of meninges and central nervous system Tuberculosis of intestines, peritoneum and mesenteric glands Tuberculosis of bones and joints Tuberculosis of genitourinary system Tuberculosis of other organs Miliary tuberculosis Listeriosis Diseases due to other mycobacteria Pneumococcal septicemia Septicemia (Pseudomonas) Actinomycotic infections (includes Nocardia) Pseudomonas infection HIV disease (Acute retroviral syndrome, AIDS-related complex) Progressive multifocal leukoencephalopathy Other non-arthropod-borne viral diseases of central nervous system Chickenpox (with complication) PeaceHealth Laboratories | Medicare Coverage Policies 47 HIV Testing: diagnosis….con’t 053.0–053.9 054.0–054.9 055.0–055.8 070.20–070.23 070.30–070.33 070.41 070.42 070.44 070.49 070.51 070.52 070.54 070.59 070.6 070.70 070.71 070.9 078.0 078.10–078.19 078.3 078.5 078.88 079.50 079.51 079.52 079.53 079.59 079.83 079.88 079.98 085.0–085.9 088.0 090.0–090.9 091.0–091.9 092.0–092.9 093.0–093.9 094.0–094.9 095.0–095.9 096 097.0–097.9 098.0–098.89 099.0 099.1 099.2 099.3 099.40–099.49 86689, 86701, 86702, 86703, 87390, 87391, 87534, 87535, 87537, 87538 Herpes zoster Herpes simplex Measles (with complication) Viral hepatitis B with hepatic coma Viral hepatitis B without mention of hepatic coma Acute or unspecified hepatitis C with hepatic coma Hepatitis delta without mention of active hepatitis B disease with hepatic coma Chronic hepatitis C with hepatic coma Other specified viral hepatitis with hepatic coma Acute or unspecified hepatitis C without hepatic coma Hepatitis delta without mention of active hepatitis B disease without hepatic coma Chronic hepatitis C without hepatic coma Other specified viral hepatitis without hepatic coma Unspecified viral hepatitis with hepatic coma Unspecified viral hepatitis C without hepatic coma Unspecified viral hepatitis C with hepatic coma Unspecified viral hepatitis without hepatic coma Molluscum contagiosum Viral warts Cat-scratch disease Cytomegaloviral disease Other specified diseases due to Chlamydiae Retrovirus unspecified HTLV–I HTLV–II HTLV–III Other specified Retrovirus Parvovirus B19 Other specified chlamydial infection Unspecified chlamydial infection Leishmaniasis Bartonellosis Congenital syphilis Early syphilis symptomatic Early syphilis, latent Cardiovascular syphilis Neurosyphilis Other forms of late syphilis, with symptoms Late syphilis, latent Other and unspecified syphilis Gonococcal infections Chancroid Lymphogranuloma venereum Granuloma inguinale Reiter’s disease Other nongonococcal urethritis PeaceHealth Laboratories | Medicare Coverage Policies 48 86689, 86701, 86702, 86703, 87390, 87391, 87534, 87535, 87537, 87538 Other venereal diseases due to Chlamydia trachomatis Other specified venereal disease Venereal disease unspecified Dermatophytosis of nail Pityriasis versicolor Candidiasis Coccidioidomycosis Histoplasmosis Blastomycotic infection Aspergillosis Cryptococcosis Opportunistic mycoses Strongyloidiasis Toxoplasmosis Trichomonal vulvovaginitis Phthirus pubis Scabies Specific infections by free living amebae Pneumocystosis Other specified infectious and parasitic disease (for example, microsporidiosis) Kaposi’s sarcoma Malignant neoplasm of cervix uteri Burkitt’s tumor or lymphoma Lymphosarcoma, other named variants Hodgkin’s disease Malnutrition of moderate degree Malnutrition of mild degree Unspecified protein-calorie malnutrition Iron deficiency anemias Anemia, unspecified Primary thrombocytopenia Neutropenia Hemophagocytic syndromes Decreased white blood cell count Increased white blood cell count Other specified disease of white blood cells Neutropenic splenomegaly Other specified organic brain syndromes (chronic) Organic personality syndrome Chronic meningitis Other frontotemporal dementia Mild cognitive impairment, so stated Unspecified disease of spinal cord Encephalopathy, unspecified Other encephalopathy Mononeuritis of upper limbs and mononeuritis multiplex HIV Testing: diagnosis….con’t 099.50–099.59 099.8 099.9 110.1 111.0 112.0–112.9 114.0–114.9 115.00–115.99 116.0–116.2 117.3 117.5 118 127.2 130.0–130.9 131.01 132.2 133.0 136.21-136.29 136.3 136.8 176.0–176.9 180.0–180.9 200.20–200.28 200.80–200.88 201.00–201.98 263.0 263.1 263.9 280.0–280.9 285.9 287.30-287.39 288.00-288.09 288.4 288.50-288.59 288.60-288.69 288.8 289.53 294.8 310.1 322.2 331.19 331.83 336.9 348.30 348.39 354.0–354.9 PeaceHealth Laboratories | Medicare Coverage Policies 49 86689, 86701, 86702, 86703, 87390, 87391, 87534, 87535, 87537, 87538 Other specified idiopathic peripheral neuropathy Chorioretinitis, unspecified Other primary cardiomyopathies Chronic sinusitis Pneumococcal pneumonia Pneumonia in cytomegalic inclusion disease Pneumonia, organism unspecified Primary spontaneous pneumothorax Secondary spontaneous pneumothorax Chronic pneumothorax Other specified alveolar and parietoalveolar pneumonopathies Oral aphthae Leukoplakia of oral mucosa Ulcer of esophagus without bleeding Ulcer of esophagus with bleeding Barrett’s esophagus Nephropathy with unspecified pathological lesion in kidney Secondary hyperparathyroidism (of renal origin) Other specified disorders resulting from impaired renal function Other viral diseases complicating pregnancy (use for HIV I and II) Other cellulitis and abscess Seborrheic dermatitis Other psoriasis Lichenification and lichen simplex chronicus Other specified diseases of hair and hair follicles Diseases of sebaceous glands Fever, unspecified Fever presenting with conditions classified elsewhere Postprocedural fever Postvaccination fever Chills (without fever) Hypothermia not associated with low environmental temperature Febrile nonhemolytic transfusion reaction Other malaise and fatigue Abnormal loss of weight Lack of expected normal physiological development Enlargement of lymph nodes Respiratory abnormality, unspecified Shortness of breath Cough Hemoptysis Abnormal sputum Diarrhea Nonspecific serologic evidence of human immunodefiency virus Wasting disease Contact or exposure to varicella HIV Testing: diagnosis….con’t 356.8 363.20 425.4 473.0–473.9 481–482.9 484.1 486 512.81 512.82 512.83 516.8 528.2 528.6 530.20 530.21 530.85 583.9 588.81 588.89 647.60–647.64 682.0–682.9 690.10–690.18 696.1 698.3 704.8 706.0–706.9 780.60 780.61 780.62 780.63 780.64 780.65 780.66 780.79 783.21 783.40 785.6 786.00 786.05 786.2 786.30-786.39 786.4 787.91 795.71 799.4 V01.71 PeaceHealth Laboratories | Medicare Coverage Policies 50 86689, 86701, 86702, 86703, 87390, 87391, 87534, 87535, 87537, 87538 Contact or exposure to other viral diseases Rape HIV Testing: diagnosis….con’t V01.79 V71.5 PeaceHealth Laboratories | Medicare Coverage Policies 51 HIV testing: prognosis, including monitoring Policy Type: NCD (National Coverage Decision) CPT CODE(S) 87536 87539 ICD-9 CODES 042 079.53 647.60–647.64 795.71 V08 TEST NAME Infectious agent detection by nucleic acid (DNA or RNA); HIV–1, quantification Infectious agent detection by nucleic acid (DNA or RNA); HIV–2, quantification ICD-9 DESCRIPTIONS Human immunodeficiency virus [HIV] disease Human immunodeficiency virus, type 2 [HIV–2] Other viral diseases complicating pregnancy (including HIV–I and II) Nonspecific serologic evidence of human immunodeficiency virus [HIV] Asymptomatic human immunodeficiency virus [HIV] infection status PeaceHealth Laboratories | Medicare Coverage Policies 52 Iron Studies Policy Type: NCD (National Coverage Decision) CPT CODE(S) 82728 83540 83550 84466 ICD-9 CODES 002.0–002.9 003.0–003.9 006.0–006.9 007.0–007.9 008.00–008.8 009.0–009.3 011.50–011.56 014.00–014.86 015.00–015.96 016.00–016.06 016.10–016.16 016.20–016.26 016.30–016.36 042 070.0–070.9 140.0–149.9 150.0–159.9 160.0–165.9 170.0–176.9 179–189.9 190.0–199.2 200.00–208.92 209.00-209.03 209.10-209.17 209.20-209.27, 209.29 209.30-209.36 209.40-209.43 209.50-209.57 209.60-209.67, 209.69 209.70-209.79 210.0–229.9 230.0–234.9 235.0–238.9 239.0–239.9 TEST NAME Ferritin Iron Iron Binding capacity Transferrin ICD-9 DESCRIPTIONS Typhoid and paratyphoid fevers Other salmonella infections Amebiasis Other protozoal intestinal diseases Intestinal infections due to other organisms Ill-defined intestinal infections Tuberculous bronchiectasis Tuberculosis of intestines, peritoneum, and mesenteric glands Tuberculosis of bones and joints Tuberculosis of kidney Tuberculosis of bladder Tuberculosis of ureter Tuberculosis of other urinary organs Human Immunodeficiency virus (HIV) disease Viral hepatitis Malignant neoplasm of lip oral cavity and pharynx Malignant neoplasm of digestive organs and peritoneum Malignant neoplasm of respiratory and intrathoracic organs Malignant neoplasm of bone, connective tissue, skin and breast Malignant neoplasm of genitourinary organs Malignant neoplasm of other and unspecified sites Malignant neoplasm of lymphatic and hematopoietic tissue Malignant carcinoid tumors of the small intestine Malignant carcinoid tumors of the appendix, large intestine, and rectum Malignant carcinoid tumors of other and unspecified sites Merkel cell carcinoma Benign carcinoid tumors of the small intestine Benign carcinoid tumors of the appendix, large intestine, and rectum Benign carcinoid tumor of other and unspecified sites Secondary neuroendocrine tumor Benign neoplasms Carcinoma in situ Neoplasms of uncertain behavior Neoplasms of unspecified nature PeaceHealth Laboratories | Medicare Coverage Policies 53 Iron Studies……con’t 249.00-249.91 250.00–250.93 253.2 253.7 253.8 256.31-256.39 257.2 260 261 262 263.0–263.9 275.01-275.09 277.1 280.0–280.9 281.0–281.9 282.40-282.49 282.60-282.69 285.0 285.1 285.21 285.22 285.29 285.3 285.9 286.0–286.9 287.0–287.9 289.52 306.4 307.1 307.50–307.59 403.01 403.11 403.91 404.02 404.03 404.12 404.13 404.92 82728, 83540, 83550, 84466 Secondary diabetes mellitus Diabetes mellitus Panhypopituitarism Iatrogenic pituitary disorders Other disorders of the pituitary and other syndromes of diencephalohypophyseal origin Other ovarian failure Other testicular hypofunction Kwashiorkor Nutritional marasmus Other severe protein-calorie malnutrition Other and unspecified protein-calorie malnutrition Disorders of iron metabolism Disorders of porphyrin metabolism Iron deficiency anemias Other deficiency anemias Thalassemias Sickle-cell anemia Sideroblastic anemia (includes hemochromatosis with refractory anemia) Acute post-hemorrhagic anemia Anemia in chronic kidney disease Anemia in neoplastic disease Anemia of other chronic disease Antineoplastic chemotherapy induced anemia Anemia, unspecified Coagulation defects (congenital factor disorders) Purpura and other hemorrhagic conditions Splenic sequestration Physiological malfunction arising from mental factors, gastrointestinal Anexoria nervosa Other and unspecified disorders of eating Hypertensive kidney disease, malignant, with chronic kidney disease Hypertensive kidney disease, benign, with chronic kidney disease Hypertensive kidney disease, unspecified, with chronic kidney disease Hypertensive heart and kidney disease, malignant, with chronic kidney disease Hypertensive heart and kidney disease, malignant, with heart failure and chronic kidney disease Hypertensive heart and kidney disease, benign, with chronic kidney disease Hypertensive heart and kidney disease, benign, with heart failure and chronic kidney disease Hypertensive heart and kidney disease, unspecified, with chronic kidney disease PeaceHealth Laboratories | Medicare Coverage Policies 54 Iron Studies……con’t 404.93 425.4 425.5 425.7 425.8 425.9 426.0–426.9 427.0–427.9 428.0–428.9 530.7 530.82 531.00–531.91 532.00–532.91 533.00–533.91 534.00–534.91 535.00–535.71 536.0–536.9 537.83 537.84 555.0–555.9 556.0–556.9 557.0 557.1 562.02 562.03 562.12 562.13 569.3 569.85 569.86 569.87 570 571.0–571.9 572.0–572.8 573.0–573.9 578.0–578.9 579.0–579.3 579.8–579.9 581.0–581.9 585.4 585.5 585.6 585.9 586 608.3 82728, 83540, 83550, 84466 Hypertensive heart and kidney disease, unspecified, with heart failure and chronic kidney disease Other primary cardiomyopathies Alcoholic cardiomyopathy Nutritional and metabolic cardiomyopathy Cardiomyopathy in other diseases classified elsewhere Secondary cardiomyopathy, unspecified Conduction disorders Cardiac dysrhythmias Heart Failure Gastroesophageal laceration-hemorrhage syndrome Esophageal hemorrhage Gastric ulcer Duodenal ulcer Peptic ulcer, site unspecified Gastrojejunal ulcer Gastritis and duodenitis Disorders of function of stomach Angiodysplasia of stomach and duodenum with hemorrhage Dieulafoy lesion (hemorrhagic) of stomach and duodenum Regional enteritis Ulcerative colitis Acute vascular insufficiency of intestine Chronic vascular insufficiency of intestine Diverticulosis of small intestine with hemorrhage Diverticulitis of small intestine with hemorrhage Diverticulosis of colon with hemorrhage Diverticulitis of colon with hemorrhage Hemorrhage of rectum and anus Angiodysplasia of intestine with hemorrhage Dieulafoy lesion (hemorrhagic) of intestine Vomiting of fecal matter Acute and subacute necrosis of liver Chronic liver disease and cirrhosis Liver abscess and sequelae of chronic liver disease Other disorders of liver Gastrointestinal hemorrhage Intestinal malabsorption Other specified and unspecified intestinal malabsorption Nephrotic syndrome Chronic kidney disease, Stage IV (severe) Chronic kidney disease, Stage V End stage renal disease Chronic kidney disease, unspecified Renal failure, unspecified Atrophy of testis PeaceHealth Laboratories | Medicare Coverage Policies 55 Iron Studies……con’t 626.0–626.9 627.0 627.1 648.20–648.24 698.0–698.9 704.00–704.09 709.00–709.09 713.0 716.40–716.99 719.40–719.49 773.2 773.3 773.4 773.5 783.9 790.01-790.09 790.4 790.5 790.6 799.4 964.0 984.0–984.9 996.85 999.80 999.83 999.84 999.85 999.89 V08 V12.1 V12.3 V15.1 V15.21 V15.22 V15.29 V43.21 V43.22 V43.3 V43.4 V43.60 V56.0 V56.8 82728, 83540, 83550, 84466 Disorders of menstruation and other abnormal bleeding from female genital tract Premenopausal menorrhagia Postmenopausal bleeding Other current conditions in the mother classifiable elsewhere, but complicating pregnancy, childbirth, or the puerperium: Anemia Pruritis and related conditions Alopecia Dyschromia Arthropathy associated with other endocrine and matabolic disorders Other and unspecified arthropathies Pain in joint Hemolytic disease due to other and unspecified isoimmunization Hydrops fetalis due to isoimmunization Kernicterus due to isoimmunization Late anemia due to isoimmunization Other symptoms concerning nutrition, metabolism and development Abnormality of red blood cells Nonspecific elevation of levels of transaminase or lactic acid dehydrogenase [LDH] Other nonspecific abnormal serum enzyme levels Other abnormal blood chemistry Cachexia Poisoning by agents primarily affecting blood constituents, iron compounds Toxic effect of lead and its compounds (including fumes) Complications of transplanted organ, bone marrow Transfusion reaction, unspecified Hemolytic transfusion reaction, incompatibility unspecified Acute hemolytic transfusion reaction, incompatibility unspecified Delayed hemolytic transfusion reaction, incompatibility unspecified Other transfusion reactions Asymptomatic HIV infection Personal history of nutritional deficiency Personal history of diseases of blood and blood forming organs Personal history of surgery to heart and great vessels Personal history of undergoing in utero procedure during pregnancy Personal history of undergoing in utero procedure while a fetus Surgery to other organs Heart assist device Fully implantable artificial heart Heart valve replaced by other means Blood vessel replaced by other means Unspecified joint replaced by other means Extracorporeal dialysis Other dialysis PeaceHealth Laboratories | Medicare Coverage Policies 56 Lipids Testing Policy Type: NCD (National Coverage Decision) The lipid NCD is being subdivided into two parts in order to implement the new cardiovascular and diabetes screening benefits that were added to Medicare by the MMA. CPT CODE(S) 80061 82465 83718 84478 ICD-9 CODES 242.00–245.9 249.00-249.01 249.10-249.11 249.20-249.21 249.30-249.31 249.40-249.41 249.50-249.51 249.60-249.61 249.70-249.71 249.80-249.81 249.90-249.91 250.00–250.93 255.0 260 261 262 263.0 263.1 263.8 263.9 270.0 271.1 272.0 272.1 272.2 272.3 272.4 272.5 272.6 272.7 272.8 TEST NAME Lipid panel Cholesterol, serum or whole blood, total Lipoprotein, direct measurement; high density cholesterol (HDL cholesterol) Triglycerides ICD-9 DESCRIPTIONS Disorders of the thyroid gland with hormonal dysfunction Secondary diabetes mellitus without mention of complication Secondary diabetes mellitus with ketoacidosis Secondary diabetes mellitus with hyperosmolarity Secondary diabetes mellitus with other coma Secondary diabetes mellitus with renal manifestations Secondary diabetes mellitus with ophthalmic manifestations Secondary diabetes mellitus with neurological manifestations Secondary diabetes mellitus with peripheral circulatory disorders Secondary diabetes mellitus with other specified manifestations Secondary diabetes mellitus with unspecified complication Diabetes mellitus Cushing’s syndrome Kwashiorkor Nutritional marasmus Other severe, protein-calorie malnutrition Malnutrition of moderate degree Malnutrition of mild degree Other protein-calorie malnutrition Unspecified protein-calorie malnutrition Disturbances of amino-acid transport Galactosemia Pure hypercholesterolemia Hyperglyceridemia Mixed hyperlipidemia (tuberous xanthoma) Hyperchylomicronemia Other and unspecified hyperlipidemia (unspecified xanthoma) Lipoprotein deficiencies Lipodystrophy Lipidoses Other disorders of lipoid metabolism PeaceHealth Laboratories | Medicare Coverage Policies 57 Lipids Testing……con’t 80061, 82465, 83718, 84478 272.9 Unspecified disorders of lipoid metabolism 277.30-277.39 Amyloidosis 278.00 Obesity 278.01 Morbid obesity 278.02 Overweight 278.03 Obesity hypoventilation syndrome 303.90–303.92 Alcoholism 362.10–362.16 Other background retinopathy and retinal vascular change 362.30–362.34 Retinal vascular occlusion 362.82 Retinal exudates and deposits 371.41 Corneal arcus, juvenile 374.51 Xanthelasma 379.22 Crystalline deposits in vitreous 388.00 Degenerative & vascular disorder of ear, unspecified 388.02 Transient ischemic deafness 401.0, 401.1, 401.9 Essential hypertension 402.00–402.91 Hypertensive heart disease 403.00–403.91 Hypertensive kidney disease 404.00–404.93 Hypertensive heart and kidney disease 405.01–405.99 Secondary hypertension 410.00–410.92 Acute myocardial infarction 411.0–411.1 Other acute & subacute forms of ischemic heart disease 411.81 Coronary occlusion without myocardial infarction 411.89 Other acute and subacute ischemic heart disease 412 Old myocardial infarction 413.0–413.1 Angina pectoris 413.9 Other and unspecified angina pectoris 414.00–414.03 Coronary atherosclerosis 414.04 Coronary athrscl-artery bypass graft 414.05 Coronary athrscl-unspec graft 414.06 Coronary athrscl-of coronary artery of transplanted heart 414.07 Coronary atherosclerosis of bypass graft (artery) (vein) of transplanted heart 414.10 Aneurysm of heart (wall) 414.11 Coronary vessel aneurysm 414.12 Dissection of coronary artery 414.19 Other aneurysm of heart 414.3 Coronary atherosclerosis due to lipid rich plaque 414.4 Coronary atherosclerosis due to calcified coronary lesion 414.8 Other specified forms of chronic ischemic heart disease 414.9 Chronic ischemic heart disease, unspecified 428.0–428.9 Heart failure 429.2 Arteriosclerotic cardiovascular disease 429.9 Heart disease NOS 431 Intracerebral hemorrhage 433.00–433.91 Occlusion & stenosis of precerebral arteries 434.00–434.91 Occlusion of cerebral arteries 435.0–435.9 Transient cerebral ischemia PeaceHealth Laboratories | Medicare Coverage Policies 58 Lipids Testing……con’t 80061, 82465, 83718, 84478 437.0 Other & ill-defined cerebrovascular disease 437.1 Other generalized ischemic cerebrovascular disease 437.5 Moyamoya disease 438.0, 438.10438.14, 438.19, 438.20-438.22, 438.30-438.32, Late effects of cerebrovascular disease 438.40-438.42, 438.50-438.53, 438.6, 438.7, 438.81438.85, 438.89, 438.9 440.0-440.32 Arteriosclerosis of aorta; of other arteries; of bypass grafts 440.4 Chronic total occlusion of the artery of the extremities Atherosclerosis of other specified arteries; generalized and unspecified 440.8-440.9 atherosclerosis 441.00–441.9 Aortic aneurysms 442.0 Upper extremity aneurysm 442.1 Renal artery aneurysm 442.2 Iliac artery aneurysm 444.01, 444.09, Arterial embolism & thrombosis 444.1-444.9 557.1 Chronic vascular insufficiency of intestine 571.8 Other chronic non-alcoholic liver disease 571.9 Unspecified chronic liver disease without mention of alcohol 573.5 Hepatopulmonary syndrome 573.8 Other specified disorders of liver 573.9 Unspecified disorders of liver 577.0–577.9 Pancreatic disease 579.3 Other & unspecified postsurgical nonabsorption 579.8 Other specified intestinal malabsorption 581.0–581.9 Nephrotic syndrome 584.5 Acute renal failure with lesion of tubular necrosis 585.4 Chronic kidney disease, Stage IV (severe) 585.5 Chronic kidney disease, Stage V 585.6 End stage renal disease 585.9 Chronic kidney disease, unspecified 588.0 Renal osteodystrophy 588.1 Nephrogenic diabetes insipidus 588.81 Secondary hyperparathyroidism (of renal origin) 588.89 Other specified disorders resulting from impaired renal function 588.9 Unspecified disorder resulting from impaired renal function 607.84 Impotence of organic origin, penis disorder 646.70–646.71 Liver disorders in pregnancy 646.73 Liver disorder antepartum 648.10–648.14 Thyroid disfunction in pregnancy and the puerperium 696.0 Psoriatic arthropathy 696.1 Other psoriasis PeaceHealth Laboratories | Medicare Coverage Policies 59 Lipids Testing……con’t 80061, 82465, 83718, 84478 751.61 Biliary atresia 764.10–764.19 ‘‘Light for dates’’ with signs of fetal malnutrition 786.50 Chest pain, unspecified 786.51 Precordial pain 786.59 Chest pain, other 789.1 Hepatomegaly 790.4 Abnormal transaminase 790.5 Abnormal alkaline phosphatase 790.6 Other abnormal blood chemistry Nonspecific (abnormal) findings on radiological and other examination of 793.4 gastrointestinal tract 987.9 Toxic effect of unspecified gas or vapor 996.81 Complication of transplanted organ, kidney V42.0 Transplanted organ, kidney V42.7 Organ replacement by transplant, liver V58.63-V58.64 Long-term (current) drug use V58.69 Long term (current) use of other medications The following are screening codes that Medicare will cover only once every 5 years. Please advise your patient that Medicare may deem this test patient responsibility based on this frequency limitation. V81.0 V81.1 V81.2 Screening for ischemic heart disease Screening for hypertension Screening for other unspecified cardiovascular conditions PeaceHealth Laboratories | Medicare Coverage Policies 60 Lipids Testing Policy Type: NCD (National Coverage Decision) The lipid NCD is being subdivided into two parts in order to implement the new cardiovascular and diabetes screening benefits that were added to Medicare by the MMA. CPT CODE(S) 83700 83701 TEST NAME Lipoprotein, blood; electrophoretic separation and quantitation Lipoprotein, blood; high resolution fractionation and quantitation of lipoproteins including lipoprotein subclasses when performed 83704 Lipoprotein, blood; quantitation of lipoprotein particle numbers and lipoprotein particle subclasses (e.g., by nuclear magnetic resonance spectroscopy) 83721 Lipoprotein, direct measurement, LDL cholesterol ICD-9 CODES 242.00–245.9 249.00-249.01 249.10-249.11 249.20-249.21 249.30-249.31 249.40-249.41 249.50-249.51 249.60-249.61 249.70-249.71 249.80-249.81 249.90-249.91 250.00–250.93 255.0 260 261 262 263.0 263.1 263.8 263.9 270.0 271.1 272.0 272.1 272.2 272.3 272.4 272.5 272.6 272.7 ICD-9 DESCRIPTIONS Disorders of the thyroid gland with hormonal dysfunction Secondary diabetes mellitus without mention of complication Secondary diabetes mellitus with ketoacidosis Secondary diabetes mellitus with hyperosmolarity Secondary diabetes mellitus with other coma Secondary diabetes mellitus with renal manifestations Secondary diabetes mellitus with ophthalmic manifestations Secondary diabetes mellitus with neurological manifestations Secondary diabetes mellitus with peripheral circulatory disorders Secondary diabetes mellitus with other specified manifestations Secondary diabetes mellitus with unspecified complication Diabetes mellitus Cushing’s syndrome Kwashiorkor Nutritional marasmus Other severe, protein-calorie malnutrition Malnutrition of moderate degree Malnutrition of mild degree Other protein-calorie malnutrition Unspecified protein-calorie malnutrition Disturbances of amino-acid transport Galactosemia Pure hypercholesterolemia Hyperglyceridemia Mixed hyperlipidemia (tuberous xanthoma) Hyperchylomicronemia Other and unspecified hyperlipidemia (unspecified xanthoma) Lipoprotein deficiencies Lipodystrophy Lipidoses PeaceHealth Laboratories | Medicare Coverage Policies 61 Lipids Testing……con’t 272.8 272.9 277.30-277.39 278.00 278.01 278.02 278.03 303.90–303.92 362.10–362.16 362.30–362.34 362.82 371.41 374.51 379.22 388.00 388.02 401.0, 401.1, 401.9 402.00–402.91 403.00–403.91 404.00–404.93 405.01–405.99 410.00–410.92 411.0–411.1 411.81 411.89 412 413.0–413.1 413.9 414.00–414.03 414.04 414.05 414.06 414.07 414.10 414.11 414.12 414.19 414.3 414.4 414.8 414.9 428.0–428.9 429.2 429.9 431 433.00–433.91 83700, 83701, 83704,83721 Other disorders of lipoid metabolism Unspecified disorders of lipoid metabolism Amyloidosis Obesity Morbid obesity Overweight Obesity hypoventilation syndrome Alcoholism Other background retinopathy and retinal vascular change Retinal vascular occlusion Retinal exudates and deposits Corneal arcus, juvenile Xanthelasma Crystalline deposits in vitreous Degenerative & vascular disorder of ear, unspecified Transient ischemic deafness Essential hypertension Hypertensive heart disease Hypertensive renal disease Hypertensive heart and renal disease Secondary hypertension Acute myocardial infarction Other acute & subacute forms of ischemic heart disease Coronary occlusion without myocardial infarction Other acute and subacute ischemic heart disease Old myocardial infarction Angina pectoris Other and unspecified angina pectoris Coronary atherosclerosis Coronary athrscl-artery bypass graft Coronary athrscl-unspec graft Coronary athrscl-of coronary artery of transplanted heart Coronary atherosclerosis of bypass graft (artery) (vein) of transplanted heart Aneurysm of heart (wall) Coronary vessel aneurysm Dissection of coronary artery Other aneurysm of heart Coronary atherosclerosis due to lipid rich plaque Coronary atherosclerosis due to calcified coronary lesion Other specified forms of chronic ischemic heart disease Chronic ischemic heart disease, unspecified Heart failure Arteriosclerotic cardiovascular disease Heart disease NOS Intracerebral hemorrhage Occlusion & stenosis of precerebral arteries PeaceHealth Laboratories | Medicare Coverage Policies 62 Lipids Testing……con’t 434.00–434.91 435.0–435.9 437.0 437.1 437.5 438.0, 438.10-438.14, 438.19, 438.20-438.22, 438.30-438.32, 438.40438.42,438.50-438.53, 438.6, 438.7, 438.81438.85, 438.89, 438.9 440.0–440.32 440.4 440.8-440.9 441.00–441.9 442.0 442.1 442.2 444.01, 444.09, 444.1444.9 557.1 571.8 571.9 573.5 573.8 573.9 577.0–577.9 579.3 579.8 581.0–581.9 584.5 585.4 585.5 585.6 585.9 588.0 588.1 588.81 588.89 588.9 607.84 646.70–646.71 646.73 648.10–648.14 83700, 83701, 83704, 83721 Occlusion of cerebral arteries Transient cerebral ischemia Other & ill-defined cerebrovascular disease Other generalized ischemic cerebrovascular disease Moyamoya disease Late effects of cerebrovascular disease Atherosclerosis of aorta; of other arteries; of bypass grafts Chronic total occlusion of the artery of the extremities Atherosclerosis of other specified arteries; generalized and unspecified atherosclerosis Aortic aneurysms Upper extremity aneurysm Renal artery aneurysm Iliac artery aneurysm Arterial embolism & thrombosis Chronic vascular insufficiency of intestine Other chronic non-alcoholic liver disease Unspecified chronic liver disease without mention of alcohol Hepatopulmonary syndrome Other specified disorders of liver Unspecified disorders of liver Pancreatic disease Other & unspecified postsurgical nonabsorption Other specified intestinal malabsorption Nephrotic syndrome Acute renal failure with lesion of tubular necrosis Chronic kidney disease, Stage IV (severe) Chronic kidney disease, Stage V End stage renal disease Chronic kidney disease, unspecified Renal osteodystrophy Nephrogenic diabetes insipidus Secondary hyperparathyroidism (of renal origin) Other specified disorders resulting from impaired renal function Unspecified disorder resulting from impaired renal function Impotence of organic origin, penis disorder Liver disorders in pregnancy Liver and biliary tract disorders in pregnancy, antepartum condition or complication Thyroid dysfunction in pregnancy and the puerperium PeaceHealth Laboratories | Medicare Coverage Policies 63 Lipids Testing……con’t 696.0 696.1 751.61 764.10–764.19 786.50 786.51 786.59 789.1 790.4 790.5 790.6 793.4 987.9 996.81 V42.0 V42.7 V58.63 V58.64 V58.69 83700, 83701, 83704, 83721 Psoriatic arthropathy Other psoriasis Biliary atresia ‘‘Light for dates’’ with signs of fetal malnutrition Chest pain, unspecified Precordial pain Chest pain, other Hepatomegaly Abnormal transaminase Abnormal alkaline phosphatase Other abnormal blood chemistry Abnormal imaging study Toxic effect of unspecified gas or vapor Complication of transplanted organ, kidney Transplanted organ, kidney Organ replacement by transplant, liver Long-term (current) use of antiplatelets/antithrombotics Long-term (current) use of non-steroidal anti-inflammatories (NSAID) Long term (current) use of other medications PeaceHealth Laboratories | Medicare Coverage Policies 64 Occult Blood, Diagnostic CPT CODE(S) 82272 ICD-9 CODES 003.0 003.1 004.0–004.9 005.0–005.9 006.0–006.9 007.0–007.9 008.41–008.49 009.0–009.3 014.00–014.86 040.2 095.2 095.3 098.0 098.7 098.84 123.0–123.9 124 127.0–127.9 139.8 150.0–157.9 159.0—159.9 176.3 197.4–197.5 197.8 199.0 204.00–204.92 205.00–208.92 209.00–209.03 209.10–209.17 209.40–209.43 209.50–209.57 209.70–209.74 209.75 209.79 211.0–211.9 Policy Type: NCD (National Coverage Decision) TEST NAME Blood, occult, by peroxidase activity (e.g. guaiac), qualitative, feces, 1-3 simultaneous determinations, performed for other than colorectal neoplasm screening ICD-9 DESCRIPTIONS Salmonella gastroenteritis Salmonella septicemia Shigellosis Other food poisoning (bacterial) Amebiasis Other protozoal intestinal diseases Intestinal infections due to other specified bacteria Ill-defined intestinal infections Tuberculosis of intestines, peritoneum, and mesenteric glands Whipple’s disease Syphilitic peritonitis Syphilis of liver Gonococcal infections, acute, lower enitourinary tract Gonococcal infection anus and rectum Gonococcal endocaritis Other cestode infection Trichinosis Other intestinal helminthiases Late effects of other and unspecified infectious and parasitic diseases Malignant neoplasm of digestive organisms Malignant neoplasm of other and ill-defined sites within the digestive organs and peritoneum Kaposi’s sarcoma, gastrointestinal sites Secondary malignant neoplasm of intestines Secondary malignant neoplasm of other digestive organs and spleen Disseminated malignant neoplasm Lymphoid leukemia Leukemia Malignant carcinoid tumors of the small intestine Malignant carcinoid tumors of the appendix, large intestine, and rectum Benign carcinoid tumors of the small intestine Benign carcinoid tumors of the appendix, large intestine, and rectum Secondary neuroendocrine tumor Secondary Merkel cell carcinoma Secondary neuroendocrine tumor of other sites Benign neoplasm of other parts of digestive system PeaceHealth Laboratories | Medicare Coverage Policies 65 Occult Blood……con’t 228.04 230.2–230.9 235.2 235.5 239.0 280.0–280.9 284.2 285.0–285.9 286.0–286.9 287.0–287.9 338.3 448.0 455.0–455.8 456.0–456.21 530.10-530.21, 530.3530.7, 530.81-530.89, 530.9 531.00-535.61 535.70–535.71 536.2 536.8–536.9 537.0–537.4 537.82–537.83 537.84 537.89 555.0–558.3 558.41 558.42 558.9 560.0–560.39 562.10–562.13 564.00–564.9 565.0–565.1 569.0 569.1 569.3 569.41–569.44, 569.49 569.82–569.83 569.84–569.85 569.86 569.87 571.0–571.9 577.0–577.9 578.0–578.9 579.0 82272 Hemangioma of intra-abdominal structures Carcinoma in situ of digestive organs Neoplasm of uncertain behavior of stomach, intestines, and rectum Neoplasm of uncertain behavior of other and unspecified digestive organs Neoplasm of unspecified nature, digestive system Iron deficiency anemias Myelophthisis Other and unspecified anemias Coagulation defects Purpura and other hemorrhagic conditions Neoplasm related pain (acute) (chronic) Hereditary hemorrhagic telangiectasia Hemorrhoids Esophageal varices with or without mention of bleeding Diseases of the esophagus Gastric ulcer; duodenal ulcer; peptic ulcer, site unspecified; gastrojejunal ulcer; and gastritis and duodenitis Eosinophilic gastritis Persistent vomiting Dyspepsia and other specified and unspecified functional disorders of the stomach Other disorders of stomach and duodenum Angiodysplasia of stomach and duodenum Dieulafoy lesion (hemorrhagic) of stomach and duodenum Other specified disorders of stomach and duodenum Non-infectious enteritis and colitis Eosinophilic gastroenteritis Eosinophilic colitis Non-infectious enteritis and colitis Intestinal obstruction/impaction without mention of hernia Diverticulosis/diverticulitis of colon Functional digestive disorders, not elsewhere classified Anal fissure and fistula Anal and rectal polyp Rectal prolapse Hemorrhage of rectum and anus Other specified disorders of rectum and anus Ulceration and perforation of intestine Angiodysplasia of intestine with or without mention of hemorrhage Dieulafoy lesion (hemorrhagic) of intestine Vomiting of fecal matter Chronic liver disease and cirrhosis Diseases of the pancreas Gastrointestinal hemorrhage Celiac disease PeaceHealth Laboratories | Medicare Coverage Policies 66 Occult Blood……con’t 579.8 596.1 617.5 780.71 780.72 780.79 783.0 783.21 787.01–787.03 787.04 787.1 787.20-787.29 787.7 787.91 787.99 789.00–789.09 789.30–789.39 789.40–789.49 789.51 789.59 789.60–789.69 789.7 790.92 792.1 793.6 794.8 863.0–863.90 863.91-863.95, 863.99 864.00–864.09 864.11–864.19 866.00–866.03 866.10–866.13 902.0–902.9 926.11–926.19 926.8 926.9 964.2 995.20 995.24 V10.00–V10.09 V12.00 V12.72 V58.61 V58.63-V58.65 V58.66 V58.69 82272 Other specified intestinal malabsorption Intestinovesical fistula Endometriosis of intestine Chronic fatigue syndrome Functional quadriplegia Other malaise and fatigue Anorexia Abnormal loss of weight Nausea and vomiting Bilious emesis Heartburn Dysphagia Abnormal feces Diarrhea Other symptoms involving digestive system Abdominal pain Abdominal or pelvic swelling, mass, or lump Abdominal rigidity Malignant ascites Other ascites Abdominal tenderness Colic Abnormal coagulation profile Nonspecific abnormal findings in stool contents Nonspecific abnormal findings on radiological and other examination, abdominal area, including retroperitoneum Nonspecific abnormal results of function studies, liver Injury to gastrointestinal tract Injury to gastrointestinal tract Injury to liver without mention of open wound into cavity Injury to liver with open wound into cavity Injury to kidney without mention of open wound into cavity Injury to kidney with open wound into cavity Injury to blood vessels of abdomen and pelvis Crushing injury of trunk, other specified sites Crushing injury of trunk, multiple sites Crushing injury of trunk, unspecified site Poisoning by agents primarily affecting blood constituents, anticoagulants Unspecified adverse effect of drug, medicinal, and biological substance Failed moderate sedation during procedure Personal history of malignant neoplasm, gastrointestinal tract Personal history of unspecified infectious and parasitic disease Personal history of colonic polyps Long term (current) use of anticoagulants Long term (current) drug use Long term (current) use of aspirin Long term (current) use of other medications PeaceHealth Laboratories | Medicare Coverage Policies 67 Occult Blood……con’t V67.51 82272 Following treatment with high risk medication, not elsewhere specified PeaceHealth Laboratories | Medicare Coverage Policies 68 Partial Thromboplastin Time (PTT) Policy Type: NCD (National Coverage Decision) CPT CODE(S) 85730 ICD-9 CODES 002.0–002.9 003.0–003.9 038.9 042 060.0–060.9 065.0–065.9 070.0–070.9 075 078.6 078.7 120.0 121.1 121.3 124 135 155.0–155.2 197.7 238.4 238.71-238.79 239.9 246.3 249.40 249.41 250.40–250.43 269.0 273.0–273.9 275.01–275.9 277.1 277.30-277.39 285.1 286.0 286.1 286.2–286.3 286.4 286.52 286.53 286.59 286.6 TEST NAME Thromboplastin time, partial (PTT); plasma or whole blood ICD-9 DESCRIPTIONS Typhoid and paratyphoid Other Salmonella infections Unspecified Septicemia Human immunodeficiency virus (HIV) disease Yellow fever Arthopod borne hemorrhagic fever Viral Hepatitis Infectious mononucleosis Hemorrhagic nephrosonephritis Arenaviral hemorrhagic fever Schistosomiasis haematobium Clonorchiasis Fascioliasis Trichinosis Sarcoidosis Malignant neoplasm of liver and intrahepatic bile ducts Malignant neoplasm of liver, specified as secondary Polycythemia vera Lymphatic and hemapoietic tissues Neoplasm of unspecified nature, site unspecified Hemorrhage and infarction of thyroid Secondary diabetes mellitus with renal manifestations, not uncontrolled Secondary diabetes mellitus with renal manifestations, uncontrolled Diabetic with renal manifestations Deficiency of Vitamin K Disorders of plasma protein metabolism Disorders of iron metabolism Disorders of porphyrin metabolism Amyloidosis Acute posthemorrhagic anemia Congenital factor VIII disorder—Hemophilia A Congenital factor IX disorder—Hemophilia B Other congenital factor deficiencies von Willebrand’s disease Acquired hemophilia Antiphospholipid antibody with hemorrhagic disorder Other hemorrhagic disorder due to intrinsic circulating anticoagulants, antibodies, or inhibitors Defibrination syndrome PeaceHealth Laboratories | Medicare Coverage Policies 69 PTT……..con’t 286.7 286.9 287.0–287.9 289.0 289.81 325 360.43 362.30–362.37 362.43 362.81 363.61-363.63 363.72 368.9 372.72 374.81 376.32 377.42 379.23 380.31 403.01, 403.11, 403.91 404.02, 404.12, 404.92 410.00–410.92 423.0 427.31 427.9 428.0 429.79 430–432.9 433.00–433.91 434.00–434.91 435.9 444.01–444.9 446.6 447.2 448.0 451.0–451.9 453.0–453.9 456.0 456.1 456.8 459.89 530.7 530.82 531.00–535.71 537.83 85730 Acquired coagulation factor deficiency Other and unspecified coagulation defects Purpura and other hemorrhagic conditions Polycythemia, secondary Primary hypercoagulable state Phlebitis and thrombophlebitis of intracranial ventricles sinuses Hemophthalmos, except current injury Retinal vasclar occlusion Hemorrhagic detachmentof retinal pigment epithelium Retinal hemorrhage Choroidal hemorrhage Choroidal detachment Unspecified Visual Disturbances Conjunctive hemorrhage Hemorrhage of eyelid Orbital hemorrhage Hemorrhage in optic nerve sheaths Vitreous hemorrhage Hematoma of auricle or pinna Hypertensive kidney disease with chronic kidney disease Hypertensive heart and kidney disease with chronic kidney disease Acute myocardial infarction Hemopericardium Atrial fibrillation Cardiac dysrhythmias, unspecified Congestive heart failure, unspecified Mural thrombus Cerebral hemorrhage Occlusion and stenosis of precerebral arteries Occlusion of cerebral arteries Focal neurologic deficit Arterial embolism and thrombosis Thrombotic microangiopathy Rupture of artery Hereditary Hemorrhagic telangiectasia Phlebitis and thrombophlebitis Other Venous emboli and thrombosis Esophageal varices with bleeding Esophageal varices without bleeding Varices of other sites Ecchymosis Gastroesophageal laceration—hemorrhage syndrome Esophgael hemorrhage Gastric-Duodenal ulcer disease Angiodysplasia of stomach and duodenum with hemorrhage PeaceHealth Laboratories | Medicare Coverage Policies 70 PTT……..con’t 537.84 556.0–557.9 562.02–562.03 562.12 562.13 568.81 569.3 570 571.0–573.9 576.0–576.9 577.0 578.0–578.9 579.0–579.9 581.0–581.9 583.9 584.5–584.9 585.4 585.5 585.6 585.9 586 593.81–593.89 596.7 596.81 596.82 596.83 596.89 599.70-599.72 607.82 608.83 611.89 620.7 621.4 622.8 623.6 623.8 624.5 626.6 626.7 627.0 627.1 629.0 632 634.00–634.92 635.10–635.12 636.10–636.12 637.10–637.12 85730 Dieulafoy lesion (hemorrhagic) of stomach and duodenum Hemorrhagic bowel disease Diverticulosis of small intestine with hemorrhage Diverticulosis of colon with hemorrhage Diverticulitis of colon without hemorrhage Hemoperitoneum (nontraumatic) Hemorrhage of rectum and anus Acute and subacute necrosis of liver Liver disease (in place of specific codes listed) Biliary tract disorders Acute pancreatitis Gastrointestinal Hemorrhage Malabsorption Nephrotic Syndrome Nephritis, with unspecified pathological lesion in kidney Acute Renal Failure Chronic kidney disease, Stage IV (severe) Chronic kidney disease, Stage V End stage renal disease Chronic kidney disease, unspecified Renal failure Other disorders of kidney and ureter, with hemorrhage Hemorrhage into bladder wall Infection of cystostomy Mechanical complication of cystostomy Other complication of cystostomy Other specified disorders of bladder Hematuria Penile hemorrhage Vascular disorders of male genital organs Other specified disorders of breast, including hematoma Hemorrhage of broad ligament Hematometra Other specified disorders of cervix, with hemorrhage Vaginal hematoma Other specified diseases of the vagina, with hemorrhage Hematoma of vulva Metrorrhagia Postcoital bleeding Premenopausal bleeding Postmenopausal bleeding Hematocele female not elsewhere classified Missed abortion Spontaneous abortion Legally induced abortion, complicated by delayed or excessive hemorrhage Illegally induced abortion, complicated by delayed or excessive hemorrhage Abortion unspecified, complicated by delayed or excessive hemorrhage PeaceHealth Laboratories | Medicare Coverage Policies 71 PTT……..con’t 638.1 639.1 639.6 640.00–640.93 641.00–641.93 642.00–642.94 646.70–646.73 649.30-649.34 649.50 649.51 649.53 656.00–656.03 658.40–658.43 666.00–666.34 671.20–671.54 673.00–673.84 674.30–674.34 710.0 713.2 713.6 719.10–719.19 729.5 729.81 733.10-733.19 762.1 764.90–764.99 767.0–767.11 767.8 770.3 772.0–772.9 774.0–774.7 776.0–776.9 780.2 782.4 782.7 784.7 784.8 785.4 785.50 786.05 786.30-786.39 85730 Failed attempt abortion, complicated by delayed or excessive hemorrhage Delayed or excessive hemorrhage following abortion and ectopic and molar pregnancies Complications following abortion and ectopic and molar pregnancies, embolism Hemorrhage in early pregnancy Antepartum hemorrhage Hypertension complicating pregnancy, childbirth, and the puerperium Liver disorders in pregnancy Coagulation defects complicating pregnancy, childbirth, or the puerperium Spotting complicating pregnancy, unspecified as to episode of care or not applicable Spotting complicating pregnancy, delivered, with or without mention of antepartum condition Spotting complicating pregnancy, antepartum condition or complication Fetal maternal hemorrhage Infection of amniotic cavity Postpartum hemorrhage Phlebitis in pregnancy Obstetrical pulmonary embolus Other complications of surgical wounds, with hemorrhage Systemic Lupus erythematosus Arthropathy associated with hematologic disorders (note: may not be used without indicating associated condition first) Arthropathy associated with Henoch Schoenlein (note: may not be used without indicating associated condition first) Hemarthrosis Leg pain/calf pain Swelling of limb Pathologic fracture associated with fat embolism Other forms of placental separation with hemorrhage (affecting newborn code do not assign to mother's record) Fetal intrauterine growth retardation Subdural and cerebral hemorrhage Other specified birth trauma, with hemorrhage Fetal and newborn pulmonary hemorrhage Fetal and neonatal hemorrhage Other perinatal jaundice Hemorrhagic disease of the newborn Syncope Jaundice, unspecified, not of newborn Spontaneous ecchymoses Petechiae Epistaxis Hemorrhage from throat Gangrene Shock Shortness of breath Hemoptysis PeaceHealth Laboratories | Medicare Coverage Policies 72 PTT……..con’t 786.50 786.59 789.00–789.09 789.7 790.92 800.00–800.99 801.00–801.99 802.20–802.9 803.00–803.99 804.00–804.99 805.00–806.9 807.00–807.09 807.10–807.19 808.8–808.9 809.0–809.1 810.00–810.13 811.00–811.19 812.00–812.59 813.10–813.18 813.30–813.33 813.50–813.54 813.90–813.93 819.0–819.1 820.00–821.39 823.00–823.92 827.0–829.1 852.00–853.19 860.0–860.5 861.00–861.32 862.0–862.9 863.0–863.99 864.00–864.19 865.00–865.19 866.00–866.13 867.0–867.9 868.00–868.19 869.0–869.1 900.00–900.9 901.0–901.9 902.0–902.9 903.00–903.9 904.0–904.9 920—924.9 925.1–929.9 958.2 959.9 85730 Chest pain, unspecified Chest pain Abdominal pain Colic Abnormal coagulation profile Fracture of vault of skull Fracture of base of skull Fracture of face bones Other fracture, skull Multiple fractures, skull Fracture, vertebral column Fractures of rib(s), closed Fracture of rib(s), open Fracture of pelvis Fracture of trunk Fracture of clavicle Fracture of scapula Fracture of humerus Fracture of radius and ulna, upper end, open Fracture of radius and ulna, shaft, open Fracture of radius and ulna, lower end, open Fracture of radius and ulna, unspecified part, open Multiple fractures Femur Tibia and fibula Other multiple lower limb Subarachnoid subdural, and extradural hemorrhage, following injury, Other and specified intracranial hemorrhage following injury Traumatic pneumothorax and hemothorax Injury to heart and lung Injury to other and unspecified intrathoracic organs Injury to gastrointestinal tract Injury to liver Injury to spleen Injury to kidney Injury to pelvic organs Injury to other intra-abdominal organs Internal injury to unspecified or ill defined organs Injury to blood vessels of head and neck Injury to blood vessels of the thorax Injury to blood vessels of the abdomen and pelvis Injury to blood vessels of upper extremity Injury to blood vessels of lower extremity and unspecified sites Contusion with intact skin surface Crushing injury Secondary and recurrent hemorrhage Injury, unspecified site PeaceHealth Laboratories | Medicare Coverage Policies 73 PTT……..(con’t) 964.2 964.5 964.7 980.0 989.5 995.20 995.21 995.24 995.27 995.29 996.70-996.79 997.02 998.11 998.12 999.2 V12.3 V58.2 V58.61 V58.83 85730 Poisoning by anticoagulants Poisoning by anticoagulant antagonists Poisoning by natural blood and blood products Toxic effects of alcohol Snake venom Unspecified adverse effect of unspecified drug, medicinal and biological substance Arthus phenomenon Failed moderate sedation during procedure Other drug allergy Unspecified adverse effect of other drug, medicinal and biological substance Other complications of internal prosthetic device Iatrogenic cerbrovascular infarction or hemorrhage Hemorrhage or hematoma complicating a procedure Hematoma complicating a procedure Other vascular complications of medical care Personal history of diseases of blood and blood forming organs Admission for Transfusion of blood products Long term (current use) of anticoagulants Encounter for therapeutic drug monitoring PeaceHealth Laboratories | Medicare Coverage Policies 74 Prostate Specific Antigen (PSA), Total Policy Type: NCD (National Coverage Decision) CPT CODE(S) 84153 ICD-9 CODES 185 188.5 196.5 196.6 196.8 198.5 198.82 233.4 236.5 239.5 596.0 599.60 599.69 599.70-599.72 600.00 600.01 600.10 600.11 600.21 601.9 602.9 788.20 788.21 788.30 788.41 788.43 788.62 788.63 788.64 788.65 790.93 793.6/793.7 794.9 V10.46 TEST NAME Prostate Specific Antigen (PSA), total ICD-9 DESCRIPTIONS Malignant neoplasm of prostate Malignant neoplasm of bladder neck Secondary malignant neoplasm, lymph nodes inguinal region and lower limb Secondary malignant neoplasm, intrapelvic lymph nodes Secondary malignant neoplasm, lymph nodes of multiple sites Secondary malignant neoplasm, bone and bone marrow Secondary malignant neoplasm, genital organs Carcinoma in situ, prostate Neoplasm of uncertain behavior of prostate Neoplasm of unspecified nature, other genitourinary organs Bladder neck obstruction Urinary obstruction, unspecified Urinary obstruction, not elsewhere classified Hematuria Hypertrophy (benign) of prostate without urinary obstruction and other lower urinary tract symptoms (LUTS) Benign prostate hypertrophy with urinary obstruction Nodular prostate without urinary obstruction Nodular prostate with urinary obstruction Benign localized hyperplasia of prostate with urinary obstruction and other lower urinary tract symptoms (LUTS) Unspecified prostatitis Unspecified disorder of prostate Retention of urine, unspecified Incomplete bladder emptying Urinary incontinence, unspecified Urinary frequency Nocturia Slowing of urinary stream Urgency of urination Urinary hesitancy Straining on urination Elevated prostate specific antigen Non-specific abnormal result of radiologic examination, evidence of malignancy Bone scan evidence of malignancy Personal history of malignant neoplasm; prostate PeaceHealth Laboratories | Medicare Coverage Policies 75 Prothrombin Time Policy Type: NCD (National Coverage Decision) CPT CODE(S) 85610 ICD-9 CODES 002.0—002.9 003.0—003.9 038.9 042 060.0—060.9 065.0–065.9 070.0–070.9 075 078.6 078.7 084.8 120.0 121.1 121.3 124 134.2 135 152.0–152.9 155.0–155.2 156.0–156.9 157.0–157.9 188.0–189.9 197.7 198.0 198.1 200.00–200.88 202.00–202.98 209.20-209.27, 209.29 209.70 209.71 209.72 209.73 209.74 209.75 209.79 223.0–223.9 238.4 238.5 TEST NAME Prothrombin Time ICD-9 DESCRIPTIONS Typhoid and paratyphoid Other Salmonella infections Unspecified Septicemia Human Immunodeficiency virus (HIV) disease Yellow fever Arthropod-borne hemorrhagic fever Viral hepatitis Infectious mononucleosis Hemorrhagic nephrosonephritis Arenaviral hemorrhagic fever Blackwater fever Schistosomiasis Clonorchiasos Fascioliasis Trichinosis Hirudiniasis Sarcoidosis Malignant neoplasm of small intestine, including duodenum Malignant neoplasm of liver and intrahepatic bile ducts Malignant neoplasm of gallbladder and extrahepatic bile ducts Malignant neoplasm of pancreas Malignant neoplasm of bladder, kidney, and other and unspecified urinary organs Secondary malignant neoplasm, liver Secondary malignant neoplasm, kidney Secondary malignant neoplasm, other urinary organs Lymphosarcoma and reticulosarcoma Nodular and other Lymphomas Malignant carcinoid tumors of other and unspecified sites Secondary neuroendocrine tumor, unspecified site Secondary neuroendocrine tumor of distant lymph nodes Secondary neuroendocrine tumor of liver Secondary neuroendocrine tumor of bone Secondary neuroendocrine tumor of peritoneum Secondary Merkel cell carcinoma Secondary neuroendocrine tumor of other sites Benign neoplasm of kidney and other urinary organs Polycythemia vera Histocytic and mast cells—neoplasm of uncertain behavior PeaceHealth Laboratories | Medicare Coverage Policies 76 PT………..con’t 238.6 238.71-238.79 239.4 239.5 239.9 246.3 249.40 249.41 250.40–250.43 263.0–263.9 269.0 269.2 273.0–273.9 275.01-275.09 277.1 277.30-277.39 280.0 280.9 281.0 281.1 281.9 285.0 285.1 286.0–286.9 287.0–287.9 289.81 290.40–290.43 325 342.90–342.92 360.43 362.18 362.30–362.37 362.43 362.81 363.61–363.72 368.9 372.72 374.81 376.32 377.42 377.53 377.62 377.72 379.23 380.31 386.2 386.50 85610 Plasma cells—neoplasm of uncertain behavior Lymphatic and hematoppoietic tissues Neoplasm of unspecified nature, bladder Neoplasm of unspecified nature, other genitourinary organs Neoplasm of unspecified nature, site unspecified Hemorrhage and infarction of thyroid Secondary diabetes mellitus with renal manifestations, not uncontrolled Secondary diabetes mellitus with renal manifestations, uncontrolled Diabetic with renal manifestations Other and unspecified protein/calorie malnutrition Deficiency of Vitamin K Unspecified vitamin deficiency Disorders of plasma protein metabolism Disorders of iron metabolism Disorders of porphyrin metabolism Amyloidosis Iron deficiency anemia, secondary to blood loss—chronic Iron deficiency anemia, unspecified Pernicious anemia Other Vitamin B12 Deficiency Anemia, NEC Unspecified Deficiency Anemia, NOS Sideroblastic anemia Acute posthemorrhagic anemia Coagulation defects Purpura and other hemorrhagic conditions Primary hypercoagulable state Arteriosclerotic dementia Phlebitis and thrombophlebitis of intracranial venous sinuses Hemiplegia NOS Hemophthalmios, except current injury Retinal vasculitis Retinal vascular occlusion Hemorrhagic detachment of retnal pigment epithelium Retinal hemorrhage Choroidal hemorrhage and rupture, detachment Unspecified Visual Disturbances Conjunctival hemorrhage Hemorrhage of eyelid Orbital hemorrhage Hemorrhage in optic nerve sheaths Disorders of optic chiasm associated with vascular disorders Disorders of visual pathways associated with vascular disorders Disorders of visual cortex associated with vascular disorders Vitreous hemorrhage Hematoma of auricle or pinna Vertigo of central origin Labyrinthine dysfunction, unspecified PeaceHealth Laboratories | Medicare Coverage Policies 77 PT………..con’t 394.0–394.9 395.0 395.2 396.0–396.9 397.0–397.9 398.0–398.99 403.01, 403.11, 403.91 404.02, 404.12, 404.92 410.00–410.92 411.1 411.81 411.89 413.0–413.9 414.00–414.07 414.3 414.4 414.8 414.9 415.0–415.19 416.9 423.0 424.0 424.1 424.90 425.0–425.9 427.0–427.9 428.0–428.9 429.0–429.4 429.79 430 431 432.0–432.9 433.00–433.91 434.00–434.91 435.0–435.9 436 437.0 437.1 437.6 440.0–440.9 441.0–441.9 443.0–443.9 444.01, 444.09, 444.1-444.9 447.1 85610 Diseases of the mitral valve Rheumatic aortic stenosis Rheumatic aortic stenosis with insufficiency Diseases of mitral and aortic valves Diseases of other endocardial structures Other rheumatic heart disease Hypertensive kidney disease with chronic kidney disease Hypertensive heart and kidney disease with chronic kidney disease Acute myocardial infarction Intermediate coronary syndrome Coronary occlusion without myocardial infarction Other acute and subacute forms of ischemic heart disease Angina pectoris Coronary atherosclerosis Coronary atherosclerosis due to lipid rich plaque Coronary atherosclerosis due to calcified coronary lesion Other specified forms of chronic ischemic heart disease Chronic ischemic heart disease, unspecified Acute pulmonary heart disease Chronic pulmonary heart disease, unspecified Hemopericardium Mitral valve disorders Aortic valve disorder Endocarditis, valve unspecified, unspecified cause Cardiomyopathy Cardiac dysrhythmias Heart failure Ill-defined descriptions and complications of heart disease Other certain sequelae of myocardial infarction, not elsewhere classified Subarachnoid hemorrhage Intracerebral hemorrhage Other and unspecified intracranial hemorrhage Occlusion and stenosis of precerebral arteries Occlusion of cerebral arteries Transient cerebral ischemia Acute, but ill-defined cerebrovascular disease Cerebral atherosclerosis Other generalized ischemic cerebrovascular disease Nonpyogenic thrombosis of intracranial venous sinus Atherosclerosis Aortic aneurysm and dissection Other peripheral vascular disease Arterial embolism and thrombosis Stricture of artery PeaceHealth Laboratories | Medicare Coverage Policies 78 PT………..con’t 447.2 447.6 448.0 448.9 451.0–451.9 452 453.0–453.9 455.2 455.5 455.8 456.0–456.1 456.8 459.0 459.10-459.19 459.2 459.81 459.89 511.81-511.89 514 530.7 530.82 530.86 530.87 531.00–535.71 555.0–555.9 556.0–556.9 557.0–557.9 562.02—562.03 562.10 562.11 562.12 562.13 568.81 569.3 571.0–571.9 572.2 572.4 572.8 573.1–573.9 576.0–576.9 577.0 578.0–578.9 579.0–579.9 581.0–581.9 583.9 584.5–584.9 85610 Rupture of artery Arteritis, unspecified Hereditary hemorrhagic telangiectasia Other and unspecified capillary diseases Phlebitis and thrombophlebitis Portal vein thrombosis Other venous embolism and thrombosis Internal hemorrhoids with other complication External hemorrhoids with other complication Unspecified hemorrhoids with other complication Esophageal varices Varices of other sites Hemorrhage, unspecified Postphlebitis syndrome Compression of vein Venous (peripheral) insufficiency, unspecified Other, other specified disorders of circulatory system Other specified forms of effusion, except tuberculosis Pulmonary congestion and hypostasis Gastroesophageal laceration—hemorrhage syndrome Esophageal hemorrhage Infection of esophagostomy Mechanical complication of esophagostomy Gastric ulcer, duodenal ulcer, peptic ulcer, gastrojejunal ulcer, gastritis and duodenitis Regional enteritis Ulcerative colitis Vascular insufficiency of intestine Diverticulosis of small intestine with hemorrhage Diverticulosis of colon w/o hemorrhage Diverticulitis of colon w/o hemorrhage Diverticulosis of colon with hemorrhage Diverticulitis of colon with hemorrhage Hemoperitoneum (nontraumatic) Hemorrhage of rectum and anus Chronic liver disease and cirrhosis Hepatic coma Hepatorenal syndrome Other sequelae of chronic liver disease Hepatitis in viral diseases, other and unspecified disorder of liver Other disorders of Biliary tract Acute pancreatitis Gastrointestinal hemorrhage Intestinal Malabsorption Nephrotic Syndrome Nephritis, with unspecified pathological lesion in kidney Acute Renal Failure PeaceHealth Laboratories | Medicare Coverage Policies 79 PT………..con’t 585.4 585.5 585.6 585.9 586 593.81–593.89 596.7 585.4 585.5 585.6 585.9 586 593.81–593.89 596.7 596.81 596.82 596.83 596.89 599.70-599.72 607.82 608.83 611.89 620.7 621.4 622.8 623.6 623.8 624.5 626.2–626.9 627.0 627.1 629.0 632 634.10–634.12 635.10–635.12 636.10–636.12 637.10–637.12 638.1 639.1 639.6 640.00–640.93 641.00–641.93 642.00–642.94 646.70–646.73 649.30-649.34 85610 Chronic kidney disease, Stage IV (severe) Chronic kidney disease, Stage V End stage renal disease Chronic kidney disease, unspecified Renal failure, unspecified Other specified disorders of kidney and ureter Hemorrhage into bladder wall Chronic kidney disease, Stage IV (severe) Chronic kidney disease, Stage V End stage renal disease Chronic kidney disease, unspecified Renal failure, unspecified Other specified disorders of kidney and ureter Hemorrhage into bladder wall Infection of cystostomy Mechanical complication of cystostomy Other complication of cystostomy Other specified disorders of bladder Hematuria Vascular disorders of penis Vascular disorders of male genital organs Other specified disorders of breast, including hematoma Hemorrhage of broad ligament Hematometra Other specified noninflammatory disorders of cervix Vaginal hematoma Other specified noninflammatory disorders of the vagina Hematoma of vulva Abnormal bleeding from female genital tract Premenopausal menorrhagia Postmenopausal bleeding Hematocele female, not classified elsewhere Missed abortion Spontaneous abortion, complicated by excessive hemorrhage Legally induced abortion, complicated by delayed or excessive hemorrhage Illegally induced abortion, complicated by delayed or excessive hemorrhage Abortion unspecified, complicated by delayed or excessive hemorrhage Failed attempted abortion, complicated by delayed or excessive hemorrhage Delayed or excessive hemorrhage following abortion and ectopic and molar pregnancies Complications following abortion and ectopic and molar pregnancies with embolism Hemorrhage in early pregnancy Antepartum hemorrhage, abruptio placentae, and placenta previa Hypertension complicating pregnancy, childbirth, and the puerperium Liver disorders in pregnancy Coagulation defects complicating pregnancy, childbirth, or the puerperium PeaceHealth Laboratories | Medicare Coverage Policies 80 PT………..con’t 649.50-649.53 656.00–656.03 658.40–658.43 666.00–666.34 671.20–671.94 673.00–673.84 674.30–674.34 713.2 713.6 719.15 719.16 719.19 729.5 729.81 733.10 746.00–746.9 762.1 767.0, 767.11 767.8 770.3 772.0–772.9 774.6 776.0–776.9 780.2 782.3 782.4 782.7 784.7 784.8 785.4 785.50 786.05 786.30-786.39 786.50 786.51 786.59 789.00–789.09 789.1 789.51 789.59 789.7 790.92 790.94 791.2 794.8 800.00–800.99 801.00–801.99 85610 Spotting complicating pregnancy Fetal maternal hemorrhage Infection of amniotic cavity Postpartum hemorrhage Venous complications in pregnancy and the puerperium Obstetrical pulmonary embolism Other complications of obstetrical surgical wounds Arthropathy associated with hematological disorders Arthropathy associated with hypersensitivity reaction Hemarthrosis pelvic region and thigh Lower leg Multiple sites Pain in limb Swelling of limb Patholgic fracture, unspecified site Other Congenital anomalies of heart Other forms of placental separation and hemorrhage Birth trauma, subdural and cerebral hemorrhage and injury to scalp Other specified birth trauma Pulmonary hemorrhage Fetal and neonatal hemorrhage Unspecified fetal and neonatal jaundice Hemorrhagic disease of the newborn Syncope and collapse Edema Jaundice, unspecified, not of newborn Spontaneous ecchymosis Epistaxis Hemorrhage from throat Gangrene Shock without mention of trauma Shortness of breath Hemoptysis Chest pain, no other symptoms Precordial pain Chest pain, other Abdominal pain Hepatomegaly Malignant ascites Other ascites Colic Abnormal coagulation profile Euthyroid sick syndrome Hemoglobinuria Abnormal Liver Function Study Fracture of vault of skull Fracture of base of skull PeaceHealth Laboratories | Medicare Coverage Policies 81 PT………..con’t 802.20–802.9 803.00–803.99 804.00–804.99 805.00–806.9 807.00–807.09 807.10–807.19 808.8–808.9 809.0–809.1 810.00–810.13 811.00–811.19 812.00–812.59 813.10–813.18 813.30–813.33 813.50–813.54 813.90–813.93 819.0–819.1 820.00–821.39 823.00–823.92 827.0–829.1 852.00–853.19 860.0–860.5 861.00–861.32 862.0–862.9 863.0–863.99 864.00–864.19 865.00–865.19 866.00–866.13 867.0–867.9 868.00–868.19 869.0–869.1 900.00–900.9 901.0–901.9 902.0–902.9 903.00–903.9 904.0–904.9 920–924.9 925.1–929.9 958.2 959.9 964.0–964.9 980.0–980.9 981 982.0–982.8 987.0–987.9 989.0–989.9 85610 Fracture of face bones Other and unqualified skull fractures Multiple fractures involving skull or face with other bones Fracture, vertebral column Fractures of rib(s), closed Fracture of rib(s), open Fracture of Pelvis Ill-defined fractures of bones of Trunk Fracture of Clavicle Fracture of Scapula Fracture of Humerus Fracture of radius and ulna, upper end, open Shaft, open Lower end, open Fracture unspecified part, open Multiple fractures involving both upper limbs, closed and open Fracture of neck of femur Fracture of tibia and fibula Other multiple lower limb Subarachnoid, subdural, and extradural hemorrhage, following injury, other and specified intracranial hemorrhage following injury. Traumatic pneumothorax and hemothorax Injury to heart and lung Injury to other and unspecified intrathoracic organs Injury to gastrointestinal tract Injury to liver Injury to spleen Injury to kidney Injury to pelvic organs Injury to other intra-abdominal organs Internal injury to unspecified or ill defined organs Injury to blood vessels of head and neck Injury to blood vessels of the thorax Injury to blood vessels of the abdomen and pelvis Injury to blood vessels of upper extremity Injury to blood vessels of lower extremity and unspecified sites Contusion with intact skin surface Crushing injury Secondary and recurrent hemorrhage Injury, unspecified site Poisoning by agents primarily affecting blood constituents Toxic effect of alcohol Toxic effect of petroleum products Toxic effects of solvents other than petroleum-based Toxic effect of other gases, fumes or vapors Toxic effect of other substances chiefly non-medicinal as to source PeaceHealth Laboratories | Medicare Coverage Policies 82 PT………..con’t 995.20 995.21 995.24 995.27 995.29 996.82 997.02 997.41 997.49 998.11–998.12 999.2 999.80 999.83 999.84 999.85 999.89 V08 V12.1 V12.3 V12.50–V12.55, V12.59 V15.1 V15.21-V15.29 V42.0 V42.1 V42.2 V42.6 V42.7 V42.81-V42.89 V43.21 V43.22 V43.3 V43.4 V58.2 V58.61 V58.83 85610 Unspecified adverse effect of unspecified drug, medicinal and biological substance Arthus phenomenon Failed moderate sedation during procedure Other drug allergy Unspecified adverse effect of other drug, medicinal and biological substance Complication of transplanted liver Iatrogenic cerbrovascular infarction or hemorrhage Retained cholelithiasis following cholecystectomy Other digestive system complications Hemorrhage or hematoma complicating a procedure Other vascular complications Transfusion reaction, unspecified Hemolytic transfusion reaction, incompatibility unspecified Acute hemolytic transfusion reaction, incompatibility unspecified Delayed hemolytic transfusion reaction, incompatibility unspecified Other transfusion reaction Asymptomatic HIV infection History of nutritional deficiency Personal history of diseases of blood and blood-forming organs Personal history of transient ischemic attack, cerebral infarction, or pulmonary embolism without residual deficits Personal history of surgery to heart and great vessels Personal history of surgery of other major organs Kidney replaced by transplant Heart replaced by transplant Heart valve replaced by transplant Lung replaced by transplant Liver replaced by transplant Other specified organ or tissue replaced by transplant Heart assist device Fully implantable artificial heart Heart valve replaced by other means Blood vessel replaced by other means Transfusion of blood products Long-term (current) use of anticoagulants Encounter for therapeutic drug monitoring PeaceHealth Laboratories | Medicare Coverage Policies 83 Sexually Transmitted Infections (STI’s) Includes the following: 1) 86631, 86332, 87110, 87270, 87320, 87490, 87491, 87810, 87800* Chlamydia 2) 87590, 87591, 87850, 87800* Gonorrhea 3) 86592, 86593, 86780 Syphilis 4) 87340, 87341 Hepatitis B (Hepatitis B surface antigen) *87800 Used for combined Chlamydia & Gonorrhea testing Policy Type: NCD (National Coverage Decision) Item/Service Description Sexually transmitted infections (STIs) are infections that are passed from one person to another through sexual contact. STIs remain an important cause of morbidity in the United States and have both health and economic consequences. Many of the complications of STIs are borne by women and children Often, STIs do not present any symptoms so can go untreated for long periods of time The presence of an STI during pregnancy may result in significant health complications for the woman and infant. In fact, any person who has an STI may develop health complications. Screening tests for the STIs in this national coverage determination (NCD) are laboratory tests. Under §1861(ddd) of the Social Security Act (the Act), the Centers for Medicare & Medicaid Services (CMS) has the authority to add coverage of additional preventive services if certain statutory requirements are met. The regulations provide: 410.64 Additional preventative services (a) Medicare Part B pays for additional preventive services not described in paragraph (1) or (3) of the definition of “preventive services” under §410.2, that identify medical conditions or risk factors for individuals if the Secretary determines through the national coverage determination process (as defined in section 1869(f)(1)(B) of the Act) that these services are all of the following: (1) reasonable and necessary for the prevention or early detection of illness or disability.(2) recommended with a grade of A or B by the United States Preventive Services Task Force, (3) appropriate for individuals entitled to benefits under Part A or enrolled under Part B. (b) In making determinations under paragraph (a) of this section regarding the coverage of a new preventive service, the Secretary may conduct an assessment of the relation between predicted outcomes and the expenditures for such services and may take into account the results of such an assessment in making such national coverage determinations. PeaceHealth Laboratories | Medicare Coverage Policies 84 STI’s……con’t The scope of the national coverage analysis for this NCD evaluated the evidence for the following STIs and high intensity behavioral counseling (HIBC) to prevent STIs for which the United States Preventive Services Task Force (USPSTF) has issued either an A or B recommendation: • Screening for chlamydial infection for all sexually active non-pregnant young women aged 24 and younger and for older non-pregnant women who are at increased risk, • Screening for chlamydial infection for all pregnant women aged 24 and younger and for older pregnant women who are at increased risk, • Screening for gonorrhea infection in all sexually active women, including those who are pregnant, if they are at increased risk, • Screening for syphilis infection for all pregnant women and for all persons at increased risk, • • Screening for hepatitis B viris (HBV) infection in pregnant women at their first prenatal visit. HIBC for the prevention of STI’s for all sexually active adolescents, and for adults at increased risk for STI’s. PeaceHealth Laboratories | Medicare Coverage Policies 85 Pursuant to Section 1861(ddd) of the Social Security Act, CMS may add coverage of “additional preventive services” through the National Coverage Determination (NCD) process. The preventive services must be: 1. Reasonable and necessary for the prevention or early detection of illness or disability; 2. Recommended with a grade of A or B by the United States Preventive Services Task Force (USPSTF); and 3. Appropriate for individuals entitled to benefits under Part A or enrolled under Part B. CMS reviewed the USPSTF recommendations and supporting evidence for screening for STIs and HIBC to prevent STIs and determined that the criteria listed above were met, enabling CMS to cover these preventive services. Therefore, effective November 8, 2011, CMS will cover screening for the indicated STIs and HIBC to prevent STIs. The covered screening lab tests must be ordered by the primary care provider. The HIBC must be provided by primary care providers in primary care settings such as by the beneficiary’s family practice physician, internal medicine physician, or nurse practitioner (NP) in the doctor’s office. A new Healthcare Common Procedure Coding System (HCPCS) code, G0445 (high-intensity behavioral counseling to prevent sexually transmitted infections, face-to-face, individual, includes: education, skills training, and guidance on how to change sexual behavior, performed semi-annually, 30 minutes), has been created for use when reporting HIBC to prevent STIs, effective November 8, 2011. This code is included in the January 2012 Medicare Physician Fee Schedule Database (MPFSDB) and Integrated Outpatient Code Editor (IOCE) updates. This code may be paid on the same date of service as an annual wellness visit (AWV), evaluation and management (E&M) code, or during the global billing period for obstetrical care, but only one G0445 may be paid on any one date of service. If billed on the same date of service with an E&M code, the E&M code should have a distinct diagnosis code other than the diagnosis code used to indicate high/increased risk for STIs for the G0445 service. An E&M code should not be billed when the sole reason for the visit is HIBC to prevent STIs. The use of the correct diagnosis code(s) on the claims is imperative to identify these services as preventive services and to show that the services were provided within the guidelines for coverage as preventive services. The patient’s medical record must clearly support the diagnosis of high/increased risk for STIs and clearly reflect the components of the HIBC service provided – education, skills training, and guidance on how to change sexual behavior - as required for coverage. The appropriate screening diagnosis code (ICD-9-CM V74.5 (screening bacterial – sexually transmitted) or V73.89 (screening, disease or disorder, viral, specified type NEC)), when used with the screening lab tests identified by Change Request (CR) 7610, will indicate that the test is a screening test covered by Medicare. Diagnosis code V69.8 (other problems related to life style) is used to indicate that the beneficiary is at high/increased risk for STIs. Providers should also use V69.8 for sexually active adolescents when billing G0445 counseling services. Diagnosis codes V22.0 (supervision of normal first pregnancy), V22.1 (supervision of other normal pregnancy), or V23.9 (supervision of unspecified high-risk pregnancy) are also to be used when appropriate. For services provided on an annual basis, this is defined as a 12-month period. PeaceHealth Laboratories | Medicare Coverage Policies 86 STI’s……con’t CMS will cover screening for Chlamydia (86631, 86632, 87110, 87270, 87320, 87490, 87491, 87810, 87800 (used for combined Chlamydia and gonorrhea testing), gonorrhea (87590, 87591, 87850, 87800 (used for combined Chlamydia and gonorrhea testing), syphilis (86592, 86593, 86780), and hepatitis B (hepatitis B surface antigen) 87340, 87341)) with the appropriate FDA approved/cleared laboratory tests, used consistent with FDA-approved labeling and in compliance with the CLIA regulations, when ordered by the primary care provider, and performed by an eligible Medicare provider for these services. As per the requirements, the presence of V74.5 or V73.89 and V69.8, denoting STI screening and high-risk behavior, respectively, and/or V22.0, V22.1, or V23.9, denoting pregnancy as appropriate, must also be present on the claim for STI services along with one of the procedure codes above. Coverage for HIBC CMS will also cover up to two, individual, 20- to 30-minute, face-to-face counseling sessions annually for Medicare beneficiaries for HIBC to prevent STIs (G0445) for all sexually active adolescents and for adults at increased risk for STIs (V69.8), if referred for this service by a primary care provider and provided by a Medicare eligible primary care provider in a primary care setting. HIBC is defined as a program intended to promote sexual risk reduction or risk avoidance which includes each of these broad topics, allowing flexibility for appropriate patient-focused elements: • Education; • Skills training; and, • Guidance on how to change sexual behavior. The high/increased risk individual sexual behaviors, based on the USPSTF guidelines, include any of the following: • Multiple sex partners; • Using barrier protection inconsistently; • Having sex under the influence of alcohol or drugs; • Having sex in exchange for money or drugs; • Age (24 years of age or younger and sexually active for women for chlamydia and gonorrhea); • Having an STI within the past year; • IV drug use (hepatitis B only); and, • In addition, for men – men having sex with men (MSM) and engaged in high-risk sexual behavior, but no regard to age. Community social factors such as high prevalence of STIs in the community populations should also be considered in determining high/increased risk for chlamydia, gonorrhea, syphilis, and in recommending HIBC. High/increased risk sexual behavior for STIs is determined by the primary care provider by assessing the patient’s sexual history which is part of any complete medical history, typically part of an AWV or prenatal visit and considered in the development of a comprehensive prevention plan. The medical record should be a reflection of the service provided. For the purposes of this NCD, a primary care setting is defined as the provision of integrated, accessible health care services by clinicians who are accountable for addressing a large majority of sonal health care needs, developing a sustained partnership with patients, and practicing in the context of family and community. Emergency departments, inpatient hospital settings, ambulatory surgical centers (ASCs), independent diagnostic testing facilities, skilled nursing facilities (SNFs), inpatient rehabilitation facilities, clinics providing a limited focus of health care services, and hospice are PeaceHealth Laboratories | Medicare Coverage Policies 87 STI’s……con’t Con’t… examples of settings not considered primary care settings under this definition. Billing Reminders • Institutional providers should note that coverage requires services be performed in a primary care setting. Consequently, if STI services are billed on Types of Bill (TOB) other than 13X, 14X and 85X (when the revenue code on the 85X is not 096X, 097X, or 098X), OR, if G0445 is submitted on a TOB other than 13X, 71X, 77X, or 85X, payment for the services will be denied using the following: • Claim Adjustment Reason Code (CARC) 170 – “Payment is denied when performed/billed by this type of provider. Note: Refer to the 835 Healthcare Policy Identification Segment (loop 2110 Service Payment Information REF), if present.” • Remittance Advice Remark Code (RARC) N428 – “This service was denied because Medicare only covers this service in certain settings.” • When applying frequency limitations to HIBC services, contractors will allow both a claim for the professional service and a claim for the facility fee. Institutional claims may be identified as facility Coverage fee claims for screening services if they contain G0445, and TOB 13X or TOB 85X (when the revenue code is not 096X, 097X, or 098X). All other claims should be identified as professional service claims for HIBC services (professional claims, and institutional claims with TOB 71X or 77X, or 85X when the revenue code is 096X, 097X, or 098X. • Contractors will allow institutional claims, TOBs 71X and 77X, to submit additional revenue lines on claims with G0445. Also, HCPCS G0445 will not pay separately with another encounter/visit on the same day for TOBs 71X and 77X with the exception of: initial preventive physical claims, claims containing modifier 59, and 77X claims containing diabetes self-management training and medical nutrition therapy services. If HCPCS G0445 is present on revenue lines along with an encounter/visit with the same line-item date of service, contractors will assign group code CO and reason code 97 – “The benefit for this service is included in the payment/allowance for another service/procedure that has already been adjudicated. Note: Refer to the 835 Healthcare Policy Identification Segment (loop 2110 Services Payment Information REF), if present.” • G0445 on institutional claims in hospital outpatient departments (TOB 13X) are paid based on OPPS, in critical access hospitals (TOB 85X, not equal to 096X, 097X, or 098X) based on reasonable cost. HCPCS G0445 with revenue codes 096X, 097X, or 098X, when billed on TOB 85X Method II is paid based on 115 percent of the lesser of the MPFS amount or submitted charge. • Medicare will enforce the frequency requirement for STI services, as mentioned above. Medicare will deny line items that exceed the coverage frequency requirements using the following: • CARC 119 – “Benefit maximum for this period or occurrence has been reached.” • RARC N362 – “The number of days or units of service exceeds our acceptable maximum.” • Medicare will deny line items on claims submitted for screening for STIs if the claim lacks the appropriate ICD-9-CM code as mentioned earlier. Such services will be denied payment using: • CARC 50 – “These are non-covered services because this is not deemed a “medical necessity” by the payer. Note: Refer to the 835 Healthcare Policy Identification Segment (loop 2110 Service Payment Information REF), if present.” PeaceHealth Laboratories | Medicare Coverage Policies 88 STI’s……con’t •RARC N386 – “This decision was based on a National Coverage Determination (NCD), An NCD provides a coverage determination as to whether a specific item or service is covered. A copy of this policy is available at http://www.cms.gov/mcd/search.asp. If you do not have web access, you may contact the contractor to request a copy of the NCD.” • The presence of ICD-9 code V74.5 or V73.89 identifies STI laboratory tests as screening lab tests payable under CR7610 rather than as diagnostic tests. • Screening for STI’s must be ordered by a primary care setting, with one of the following specialty codes: • 01 – General Practice • 08 – Family Practice • 11 – Internal Medicine • 16 – Obstetrics/Gynecology • 37 – Pediatric Medicine • 38 – Geriatric Medicine • 42 – Certified Nurse Midwife • 50 – Nurse Practitioner • 89 – Certified Clinical Nurse Specialist • 97 – Physician Assistant • STI screenings ordered by other than the above types of providers will be denied payment when submitted on professional claims using: Coverage • CARC 184 – “The prescribing/ordering provider is not eligible to prescribe/order the service billed. Note: Refer to the 835 Healthcare Policy Identification Segment (loop 2110 Service Payment Information REF), if present.” • Medicare will deny line items for G0445 if performed by other than the above types of providers when submitted on professional claims using: o CARC 185 – “The rendering provider is not eligible to perform the service billed. Note: Refer to the 835 Healthcare Policy Identification Segment (loop 2110 Service Payment Information REF), if present.” • RARC N95 – “This provider type/provider specialty may not bill this service.” • Claims for G0445 must be for services performed in the following Places of Service (POS): • 11 – Physician Office; • 22 – Outpatient Hospital; • 49 – Independent Clinic; or • 71 – State or local public health clinic. • Medicare will deny line items for G0445 if the POS code is other than 11, 22, 49, or 71, using the following: • CARC 58 – “Treatment was deemed by the payer to have been rendered in an inappropriate or invalid place of service. Note: Refer to the 835 Healthcare Policy Identification Segment (loop 2110 Service Payment Information REF), if present.” • RARC N428 – “Not covered when performed in this Place of Service.” • Upon full implementation in Medicare systems on July 2, 2012, providers may submit eligibility inquiries in order to identify the next eligible date that beneficiaries may receive these services. • Until systems are implemented, contractors will hold institutional claims received before July 2, 2012, with TOBs 13X, 71X, 77X, and 85X reporting HCPCS G0445, or TOBs 13X, 14X, and 85X, when the revenue code is not 096X, 097X, or 098X, for STI services. • Effective for dates of service on or after November 8, 2011, contractors will not apply deductible or coinsurance to claim lines containing HCPCS G0445, HIBC services. • Contractors will load HCPCS G0445 to their HCPCS file with an effective date of November 8, 2011. PeaceHealth Laboratories | Medicare Coverage Policies 89 Thyroid Testing Policy Type: NCD (National Coverage Decision) CPT CODE(S) 84436 84439 84443 84479 TEST NAME Thyroxine; total Thyroxine; free Thyroid stimulating hormone (TSH) Thyroid hormone (T3 or T4) uptake or thyroid hormone binding ratio (THBR) ICD-9 CODES ICD-9 DESCRIPTIONS 017.50–017.56 183.0 193 194.8 198.89 220 226 227.3 234.8 237.4 239.7 240.0–240.9 241.0–241.9 242.00–242.91 243 244.0–244.9 245.0–245.9 246.0–246.9 249.00-249.01 249.10-249.11 249.20-249.21 249.30-249.31 249.40-249.41 249.50-249.51 249.60-249.61 249.70-249.71 249.80-249.81 249.90-249.91 250.00–250.93 252.1 253.1 253.2 253.3 253.4 253.7 255.2 Tuberculosis of the thyroid gland Malignant neoplasm of ovary Malignant neoplasm of thyroid gland Malignant neoplasm of other endocrine glands and related structures, other Secondary malignant neoplasm of the thyroid Benign neoplasm of ovary Benign neoplasm of thyroid gland Benign neoplasm of pituitary gland and craniopharyngeal duct Carcinoma in situ of other and unspecified sites Neoplasm of uncertain behavior of other and unspecified endocrine glands Neoplasm of unspecified nature, thyroid gland Goiter specified and unspecified Nontoxic nodular goiter Thyrotoxicosis with or without goiter Congenital hypothyroidism Acquired hypothyroidism Thyroiditis Other disorders of thyroid Secondary diabetes mellitus without mention of complication Secondary diabetes mellitus with ketoacidosis Secondary diabetes mellitus with hyperosmolarity Secondary diabetes mellitus with other coma Secondary diabetes mellitus with renal manifestations Secondary diabetes mellitus with ophthalmic manifestations Secondary diabetes mellitus with neurological manifestations Secondary diabetes mellitus with peripheral circulatory disorders Secondary diabetes mellitus with other specified manifestations Secondary diabetes mellitus with unspecified complication Diabetes mellitus Hypoparathyroidism Other and unspecified anterior pituitary hyper function Panhypopituitarism Pituitary dwarfism Other anterior pituitary disorders Iatrogenic pituitary disorders Adrenogenital disorders PeaceHealth Laboratories | Medicare Coverage Policies 90 Thyroid Testing……con’t 84436, 84439, 84443, 84479 255.41 Glucocorticoid deficiency 255.42 Mineralocorticoid deficiency 256.31-256.39 Ovarian failure 257.2 Testicular hypofunction 258.01–258.9 Polyglandular dysfunction 262 Malnutrition, severe 263.0–263.9 Malnutrition, other and unspecified 266.0 Ariboflavinosis 272.0 Pure hypercholesterolemia 272.2 Mixed hyperlipidemia 272.4 Other and unspecified hyperlipidemia 275.40–275.49 Calcium disorders 275.5 Hungry bone syndrome 276.0 Hyposmolality and/or hypernatremia 276.1 Hyposmolality and/or hyponatremia 278.3 Hypercarotinemia 279.41 Autoimmune lymphoproliferative syndrome 279.49 Autoimmune disease, not elsewhere classified 281.0 Pernicious anemia 281.9 Unspecified deficiency anemia 283.0 Autoimmune hemolytic anemia 285.9 Anemia, unspecified 290.0 Senile dementia, uncomplicated 290.10–290.13 Presenile dementia 290.20–290.21 Senile dementia with delusional or depressive features 290.3 Senile dementia with delirium 293.0–293.1 Delirium 293.81–293.89 Transient organic mental disorders 294.8 Other specified organic brain syndromes 296.00–296.99 Affective psychoses 297.0 Paranoid state, simple 297.1 Paranoia 297.9 Unspecified paranoid state 298.3 Acute paranoid reaction 300.00–300.09 Anxiety states Agitation—other and unspecified special symptoms or syndromes, not 307.9 elsewhere classified 310.1 Organic personality syndrome 311 Depressive disorder, not elsewhere classified 327.00 Organic insomnia, unspecified 327.01 Insomnia due to medical condition classfied elsewhere 327.09 Other organic insomnia 327.29 Other organic sleep apnea 327.52 Sleep related leg cramp 327.8 Other organic sleep disorders 331.0–331.2 Alzheimer’s, pick’s disease, Senile degeneration of brain 331.83 Mild cognitive impairment, so stated PeaceHealth Laboratories | Medicare Coverage Policies 91 Thyroid Testing……con’t 84436, 84439, 84443, 84479 333.1 Essential and other specified forms of tremor 333.99 Other extrapyramidao diseases and abnormal movement disorders 354.0 Carpal Tunnel syndrome 356.9 Idiopathic peripheral neuropathy, unspecified polyneuropathy 358.1 Myasthenic syndromes in diseases classified elsewhere 359.5 Myopathy in endocrine diseases classified elsewhere 359.9 Myopathy, unspecified 368.2 Diplopia 372.71 Conjunctival hyperemia 372.73 Conjunctival edema 374.41 Lid retraction or lag 374.82 Eyelid edema 376.21 Thyrotoxic exophthalmos 376.22 Exophthalmic ophthlmoplegia 376.30–376.31 Exophthalmic conditions, unspecified and constant 376.33–376.34 Orbital edema or congestion, intermittent exophthalmos 378.50–378.55 Paralytic strabismus 401.0–401.9 Essential hypertension 403.00–403.91 Hypertensive kidney disease 404.00–404.93 Hypertensive heart and kidney disease 423.9 Unspecified disease of pericardium 425.7 Nutritional and metabolic cardiomyopathy 427.0 Paroxysmal supraventricular tachycardia 427.2 Paroxysmal tachycardia, unspecified 427.31 Atrial fibrillation 427.89 Other specified cardiac dysrhythmia 427.9 Cardiac dysrhythmia, unspecified 428.0 Congestive heart failure, unspecified 428.1 Left heart failure 429.3 Cardiomegaly 511.9 Unspecified pleural effusion 518.81 Acute respiratory failure 529.8 Other specified conditions of the tongue 560.1 Paralytic ileus 564.00-564.09 Constipation 564.7 Megacolon, other than Hirschsprung’s 568.82 Peritoneal effusion (chronic) 625.3 Dysmenorrhea 626.0–626.2 Disorders of menstruation 626.4 Irregular menstrual cycle Other current conditions in the mother, classifiable elsewhere, but complicating 648.10–648.14 pregnancy, childbirth, or the puerperium, thyroid dysfunction 676.20–676.24 Engorgement of breast associated with childbirth and disorders of lactation 698.9 Unspecified pruritic disorder 701.1 Keratoderma, acquired (dry skin) 703.8 Other specified diseases of nail (Brittle nails) 704.00–704.09 Alopecia PeaceHealth Laboratories | Medicare Coverage Policies 92 Thyroid Testing……con’t 84436, 84439, 84443, 84479 709.01 Vitiligo 710.0–710.9 Diffuse disease of connective tissue 728.2 Muscle wasting 728.87 Muscle weakness (generalized) 728.9 Unspecified disorder of muscle, ligament, and fascia 729.1 Myalgia and myositis, unspecified 729.82 Musculoskeletal cramp 730.30–730.39 Periostitis without osteomyelitis 733.02 Idiopathic osteoporosis 733.09 Osteoporosis, drug induced 750.15 Macroglossia, congenital 759.2 Anomaly of other endocrine glands 780.01 Coma 780.02 Transient alteration of awareness 780.09 Alteration of consciousness, other 780.50–780.52 Insomnia 780.60-780.66 Fever 780.71–780.79 Malaise and fatigue 780.8 Hyperhidrosis 780.93 Memory loss 780.94 Early satiety 780.96 Generalized pain 780.97 Altered mental status 780.99 Other general symptoms 781.0 Abnormal involuntary movements 781.3 Lack of coordination, ataxia 782.0 Disturbance of skin sensation 782.3 Localized edema 782.8 Changes in skin texture 782.9 Other symptoms involving skin and integumentary tissues 783.0 Anorexia 783.1 Abnormal weight gain 783.21 Abnormal loss of weight 783.6 Polyphagia 784.1 Throat pain 784.42 Dysphonia 784.43 Hypernasality 784.44 Hyponasality 784.49 Other voice and resonance disorders 784.51 Dysarthria 784.59 Other speech disturbance 785.0 Tachycardia, unspecified 785.1 Palpitations 785.9 Other symptoms involving cardiovascular system 786.09 Other symptoms involving respiratory system 786.1 Stridor 787.20–787.29 Dysphagia PeaceHealth Laboratories | Medicare Coverage Policies 93 Thyroid Testing……con’t 84436, 84439, 84443, 84479 787.91–787.99 Other symptoms involving digestive system 789.51 Malignant ascites 789.59 Other ascites Other nonspecific (abnormal) findings on radiological and other examination of 793.99 body structure 794.5 Thyroid, abnormal scan or uptake 796.1 Other nonspecific abnormal findings, abnormal reflex 799.21 Nervousness 799.22 Irritability 799.23 Impulsiveness 799.24 Emotional lability 799.25 Demoralization and apathy 799.29 Other signs and symptoms involving emotional state 990 Effects of radiation, unspecified V10.87 Personal history of malignant neoplasm of the thyroid V10.88 Personal history of malignant neoplasm of other endocrine gland V10.91 Personal history of malignant neuroendocrine tumor V12.21 Personal history of gestational diabetes V12.29 Personal history of other endocrine, metabolic, and immunity disorders V58.69 Long term (current) use of other medications V67.00-V67.9 Follow-up examination PeaceHealth Laboratories | Medicare Coverage Policies 94 Urinalysis Policy # L33034 Policy Type: LCD (Local Coverage Decision) CPT CODE(S) 81000 81001 81002 81003 81005 81007 81015 81020 TEST NAME Urinalysis non-auto w/scope Urinalysis auto w/scope Urinalysis non-auto w/o scope Urinalysis auto w/o scope Urinalysis Urine screen for bacteria Microscopic exam of urine Urinalysis glass test ICD-9 CODES ICD-9 DESCRIPTIONS 016.00-016.06 016.10-016.16 016.20-016.26 016.30-016.36 016.40-016.46 016.50-016.56 016.60-016.66 016.70-016.76 016.90-016.96 038.0-038.9 Tuberculosis of kidney Tuberculosis of bladder Tuberculosis of ureter Tuberculosis of other urinary organs Tuberculosis of epididymis Tuberculosis of other male genital organs Tuberculous oophoritis and salpingitis Tuberculosis of other female genital organs Unspecified genitourinary tuberculosis Septicemia Streptococcus infection in conditions classified elsewhere and of unspecified site Staphylococcus Pneumococcus infection in conditions classified elsewhere and of unspecified site Klebsiella pneumoniae E. Coli Hemophilus influenzae (H. Influenzae) infection in conditions classified elsewhere and of unspecified site Proteus (Mirabilis) (Morganii) infection in conditions classified elsewhere and of unspecified site Pseudomonas infection in conditions classified elsewhere and of unspecified site Other specified bacterial infections Helicobacter pylori [H. Pylori] Other specified bacterial infections in conditions classified elsewhere and of unspecified site other specified bacteria Bacterial infection unspecified in conditions classified elsewhere and of unspecified site Genital herpes 041.00-041.09 041.10-041.19 041.2 041.3 041.41-041.49 041.5 041.6 041.7 041.81-041.85 041.86 041.89 041.9 054.10-054.19 070.0-070.59, 070.70, 070.71 072.0 078.11 Hepatitis Mumps orchitis Condyloma acuminatum PeaceHealth Laboratories | Medicare Coverage Policies 95 81000, 81001, 81002, 81003, 81005, 81007, 81015, 81020 Urinalysis……con’t 078.88 079.81 079.82 079.88 079.89 079.98 087.0 087.1 095.4 098.0-098.39, 098.89 099.3 099.40 099.41 099.49 099.53 099.54 100.0 102.0 102.1 102.2 102.3 102.4 102.5 102.6 102.7 102.8 102.9 112.1 112.2 125.0 125.1 131.00 131.01 131.02 131.03 135 185 186.0 186.9 187.1 187.2 187.3 187.5 187.6 187.7 Other specified diseases due to chlamydiae Hantaviris infection Sars-associated coronavirus infection Other specified chlamydial infection Other specified viral infection Unspecified chlamydial infection Relapsing fever louse-borne Relapsing fever tick-borne Syphilis of kidney Gonococcal infection Reiter’s disease Other non-gonococcal urethritis unspecified Other non-gonococcal urethritis chlamydia trachomatis Other non-gonococcal urethritis other specified organism Other venereal diseases due to chlamydia trachomatis lower genitourinary sites Other venereal diseases due to chlamydia trachomatis other genitourinary sites Leptospirosis icterohemorrhagica Initial lesions of yaws Multiple papillomata due to yaws and wet crab yaws Other early skin lesions of yaws Hyperkeratosis due to yaws Gummata and ulcers due to yaws Gangosa Bone and joint lesions due to yaws Other manifestations of yaws Latent yaws Yaws unspecified Candidiasis of vulva and vagina Candidiasis of other urogenital sites Bancroftian filariasis Mayalan filariasis Urogenital trichomoniasis unspecified Trichomonal vulvovaginitis Trichomonal urethritis Trichomonal prostatitis Sarcoidosis Malignant neoplasm of prostate Malignant neoplasm of undescended testis Malignant neoplasm of other and unspecified testis Malignant neoplasm of prepuce Malignant neoplasm of glans penis Malignant neoplasm of body of penis Malignant neoplasm of epididymis Malignant neoplasm of spermatic cord Malignant neoplasm of scrotum PeaceHealth Laboratories | Medicare Coverage Policies 96 Urinalysis……con’t 187.8 188.0 188.1 188.2 188.3 188.4 188.5 188.6 188.7 188.8 188.9 189.0 189.1 189.2 189.3 189.4 189.8 189.9 198.0 198.1 203.00 203.01 203.02 222.2 223.0 223.1 223.2 223.3 223.81 223.89 233.4 233.7 233.9 236.5 236.7 236.90 236.91 236.99 249.00-249.91 250.00-250.93 253.5 253.6 271.4 272.2 272.3 81000, 81001, 81002, 81003, 81005, 81007, 81015, 81020 Malignant neoplasm of other specified sites of male genital organs Malignant neoplasm of trigone or urinary bladder Malignant neoplasm of dome of urinary bladder Malignant neoplasm of lateral wall of urinary bladder Malignant neoplasm of anterior wall of urinary bladder Malignant neoplasm of posterior wall of urinary bladder Malignant neoplasm of bladder neck Malignant neoplasm of ureteric orifice Malignant neoplasm of urachus Malignant neoplasm of other specified sites of bladder Malignant neoplasm of bladder part unspecified Malignant neoplasm of kidney except pelvis Malignant neoplasm of renal pelvis Malignant neoplasm of ureter Malignant neoplasm of urethra Malignant neoplasm of paraurethral glands Malignant neoplasm of other specified sites of urinary organs Malignant neoplasm of urinary organ site unspecified Secondary malignant neoplasm of kidney Secondary malignant neoplasm of other urinary organs Multiple myeloma, without mention of having achieved remission Multiple myeloma in remission Multiple myeloma, in relapse Benign neoplasm of prostate Benign neoplasm of kidney except pelvis Benign neoplasm of renal pelvis Benign neoplasm of ureter Benign neoplasm of bladder Benign neoplasm of urethra Benign neoplasm of other specified sites of urinary organs Carcinoma in situ of prostate Carcinoma in situ of bladder Carcinoma in situ of other and unspecified urinary organs Neoplasm of uncertain behavior of prostate Neoplasm of uncertain behavior of bladder Neoplasm of uncertain behavior of urinary organ unspecified Neoplasm of uncertain behavior of kidney and ureter Neoplasm of uncertain behavior of other and unspecified urinary organs Secondary diabetes mellitus Diabetes Diabetes insipidus Other disorders of neurohypophysis Renal glycosuria Mixed hyperlipidemia Hyperchylomicronemia PeaceHealth Laboratories | Medicare Coverage Policies 97 81000, 81001, 81002, 81003, 81005, 81007, 81015, 81020 Urinalysis……con’t 272.4 273.0 273.1 273.2 273.3 273.4 273.8 274.00 274.01 274.02 274.03 274.10 274.11 274.19 275.01 275.02 275.03 275.09 275.42 276.0 276.1 276.2 276.3 276.4 276.50 276.51 276.52 276.61 276.69 276.8 276.9 277.00-277.09 277.1 277.2 277.30 277.31 277.39 277.4 277.5 277.88 282.60 282.61 282.62 282.63 282.64 Other and unspecified hyperlipidemia Polyclonal hypergammaglobulinemia Monoclonal paraproteinemia Other paraproteinemias Macroglobulinemia Alpha-1-antitrypsin deficiency Other disorders of plasma protein metabolism Gouty arthropathy, unspecified Acute gouty arthropathy Chronic gouty arthropathy without mention of tophus (tophi) Chronic gouty arthropathy with tophus (tophi) Gouty nephropathy unspecified Uric acid nephrolithiasis Other gouty nephropathy Hereditary hemochromatosis Hemochromatosis due to repeated red blood cell transfusions Other hemochromatosis Other disorders of iron metabolism Hypercalcemia Hyperosmolality and/or hypernatremia Hyposmolality and/or hyponatremia Acidosis Alkalosis Mixed acid-base balance disorder Volume depletion, unspecified Dehydration Hypovolemia Transfusion associated circulatory overload Other fluid overload Hypopotassemia Electrolyte and fluid disorders not elsewhere classified Cystic fibrosis Disorders of porphyrin metabolism Other disorders of purine and pyrimidine metabolism Amyloidosis, unspecified Familial Mediterranean fever Other amyloidosis Disorders of bilirubin excretion Mucopolysaccharidosis Tumor lysis syndrome Sickle-cell disease unspecified HB-SS disease without crisis HB-SS disease with crisis Sickle-cell/HB-C disease without crisis Sickle-cell/HB-C disease with crisis PeaceHealth Laboratories | Medicare Coverage Policies 98 81000, 81001, 81002, 81003, 81005, 81007, 81015, 81020 Urinalysis……con’t 282.68 282.69 283.11 283.2 287.41 287.49 306.53 310.1 344.61 401.0 401.1 401.9 402.00 402.01 402.10 402.11 402.90 402.91 403.00 403.01 403.10 403.11 403.90 403.91 404.00-404.93 405.01 405.09 405.11 405.19 405.91 405.99 421.0 421.1 421.9 428.0 446.0 446.1 446.20 446.21 Other sickle-cell disease without crisis Other sickle-cell disease with crisis Hemolytic-uremic syndrome Hemoglobinuria due to hemolysis from external causes Post-transfusion purpura Other secondary thrombocytopenia Psychogenic dysuria Personality change due to conditions classified elsewhere Cauda equina syndrome with neurogenic bladder Malignant essential hypertension Benign essential hypertension Unspecified essential hypertension Malignant hypertensive heart disease without heart failure Malignant hypertensive heart disease with heart failure Benign hypertensive heart disease without heart failure Benign hypertensive heart disease with heart failure Unspecified hypertensive heart disease without heart failure Unspecified hypertensive heart disease with heart failure Hypertensive chronic kidney disease, malignant, with chronic kidney disease Stage I through Stage IV, or unspecified Hypertensive chronic kidney disease, malignant, with chronic kidney disease Stage V or end stage renal disease Hypertensive chronic kidney disease, benign, with chronic kidney disease Stage I through Stage IV, or unspecified Hypertensive chronic kidney disease, benign, with chronic kidney disease Stage V or end stage renal disease Hypertensive chronic kidney disease, unspecified, with chronic kidney disease Stage I through Stage IV, or unspecified Hypertensive chronic kidney disease, unspecified, with chronic kidney disease Stage V or end stage renal disease Hypertensive heart and chronic kidney disease Malignant renovascular hypertension Other malignant secondary hypertension Benign renovascular hypertension Other benign secondary hypertension Unspecified renovascular hypertension Other unspecified secondary hypertension Acute & subacute bacterial endocarditis Acute & subacute infective endocarditis in diseases classified elsewhere Acute endocarditis unspecified Congestive heart failure unspecified Polyarteritis nodosa Acute febrile mucocutaneous lymph node syndrome (MCLS) Hypersensitivity angiitis unspecified Goodpasture’s syndrome PeaceHealth Laboratories | Medicare Coverage Policies 99 81000, 81001, 81002, 81003, 81005, 81007, 81015, 81020 Urinalysis……con’t 446.29 446.3 446.4 446.5 446.6 446.7 447.3 447.4 447.5 447.6 456.4 457.0 457.1 570 571.40 571.41 571.42 571.49 571.5 571.6 571.8 572.2 573.0 573.1 573.2 573.3 580.0-580.9 581.0-581.9 582.0-582.9 583.0-583.9 584.5-584.9 585.1-585.9 586 587 588.0 588.1 588.81 588.89 589.0 589.1 589.9 590.00-590.11 590.2 590.3 590.80 Other specified hypersensitivity angiitis Lethal midline granuloma Wegener’s granulomatosis Giant cell arteritis Thrombotic microangiopathy Takayasu’s disease Hyperplasia of renal artery Celiac artery compression syndrome Necrosis of artery Arteritis unspecified Scrotal varices Postmasectomy lymphedema syndrome Other lymphedema Acute and subacute necrosis of liver Chronic hepatitis unspecified Chronic persistent hepatitis Autoimmune hepatitis Other chronic hepatitis Cirrhosis of liver without alcohol Biliary cirrhosis Other chronic non-alcoholic liver disease Hepatic encephalopathy Chronic passive congestion of liver Hepatitis in viral diseases classified elsewhere Hepatitis in other infectious diseases classified elsewhere Hepatitis unspecified Acute glomerulonephritis Nephrotic syndrome Chronic glomerulonephritis Nephritis and nephropathy not specified as acute or chronic Acute kidney failure Chronic kidney disease Renal failure unspecified Renal sclerosis unspecified Renal osteodystrophy Nephrogenic diabetes insipidus Secondary hyperparathyroidism (of renal origin) Other specified disorders resulting from impaired renal function Unilateral small kidney Bilateral small kidneys Small kidney unspecified Chronic/Acute pyelonephritis Renal and perinephric abscess Pyeloureteritis cystica Pyelonephritis unspecified PeaceHealth Laboratories | Medicare Coverage Policies 100 81000, 81001, 81002, 81003, 81005, 81007, 81015, 81020 Urinalysis……con’t 590.81 590.9 591 592.0 592.1 592.9 593.0 593.1 593.2 593.3 593.4 593.5 593.6 593.70-593.73 593.81 593.82 593.89 593.9 594.0 594.1 594.2 594.8 594.9 595.0-595.9 596.0 596.1 596.2 596.3 596.4 596.51 596.52 596.53 596.54 596.55 596.59 596.6 596.7 596.81 596.82 596.83 596.89 596.9 597.0 597.80 597.81 Pyelitis or pyelonephritis in diseases classified elsewhere Infection of kidney unspecified Hydronephrosis Calculus of kidney Calculus of ureter Urinary calculus unspecified Nephroptosis Hyperthrophy of kidney Cyst of kidney acquired Stricture or kinking of ureter Other ureteric obstruction Hydroureter Postural proteinuria Vesicoureteral reflux Vascular disorders of kidney Ureteral fistula Other specified disorders of kidney and ureter Unspecified disorder of kidney and ureter Calculus in diverticulum of bladder Other calculus in bladder Calculus in urethra Other lower urinary tract calculus Calculus of lower urinary tract unspecified Cystitis Bladder neck obstruction Intestinovesical fistula Vesical fistula not elsewhere classified Diverticulum of bladder Atony of bladder Hypertonicity of bladder Low bladder compliance Paralysis of bladder Neurogenic bladder NOS Detrusor sphincter dyssynergia Other functional disorder of bladder Rupture of bladder non-traumatic Hemorrhage into bladder wall Infection of cystostomy Mechanical complication of cystostomy Other complication of cystostomy Other specified disorders of bladder Unspecified disorder of bladder Urethral abscess Urethritis unspecified Urethral syndrome NOS PeaceHealth Laboratories | Medicare Coverage Policies 101 81000, 81001, 81002, 81003, 81005, 81007, 81015, 81020 Urinalysis……con’t 597.89 598.00 598.01 598.1 598.2 598.8 598.9 599.0 599.1 599.2 599.3 599.4 599.5 599.60 599.69 599.70 599.71 599.72 599.81 599.82 599.83 599.84 599.89 599.9 600.01 600.11 600.21 600.91 601.0 601.1 601.2 601.3 601.4 601.8 601.9 602.0 602.1 602.2 602.3 602.8 602.9 603.0 Other urethritis Urethral structure due to unspecified infection Urethral structure due to infective diseases classified elsewhere Traumatic urethral stricture Post-operative urethral stricture Other specified causes of urethral stricture Urethral stricture unspecified Urinary tract infection site not specified Urethral fistula Urethral diverticulum Urethral caruncle Urethral false passage Prolapsed urethral mucosa Urinary obstruction, unspecified Urinary obstruction, not elsewhere classified Hematuria unspecified Gross hematuria Microscopic hematuria Urethral hypermobility Intrinsic (urethral) sphincter deficiency (ISD) Urethral instability Other specified disorders of urethra Other specified disorders of urinary tract Unspecified disorder of urethra and urinary tract Hypertrophy (benign) of prostate with urinary obstruction and other lower urinary tract symptoms (LUTS) Nodular prostate with urinary obstruction Benign localized hyperplasia of prostate with urinary obstruction and other lower urinary tract symptoms (LUTS) Hyperplasia of prostate, unspecified, with urinary obstruction and other lower urinary symptoms (LUTS) Acute prostatitis Chronic prostatitis Abscess of prostate Prostatocystitis Prostatitis in diseases classified elsewhere Other specified inflammatory diseases of prostate Prostatitis unspecified Calculus of prostate Congestion or hemorrhage of prostate Atrophy of prostate Dysplasia of prostate Other specified disorders of prostate Unspecified disorder of prostate Encysted hydrocele PeaceHealth Laboratories | Medicare Coverage Policies 102 81000, 81001, 81002, 81003, 81005, 81007, 81015, 81020 Urinalysis……con’t 603.1 603.8 603.9 604.0 604.90 604.91 605 606.1 606.9 607.1 607.81 607.84 607.89 608.0 608.1 608.23 608.24 608.83 608.89 608.9 616.10 616.11 618.00 618.01 618.02 618.03 618.04 618.05 618.09 619.0 619.1 619.2 619.8 619.9 625.0 625.6 625.70 625.71 625.79 625.9 628.9 629.31 629.32 634.00-634.32 Infected hydrocele Other specified types of hydrocele Hydrocele unspecified Orchitis epididymitis and epididymo-orchitis with abscess Orchitis and epididymitis unspecified Orchitis and epididymitis in diseases classified elsewhere Redundant prepuce and phimosis Oligospermia Male infertility unspecified Balanoposthitis Balanitis xerotica obliterans Impotence of organic origin Other specified disorders of penis Seminal vesiculitis Spermatocele Torsion of appendix testis Torsion of appendix epididymis Vascular disorders of male genital organs Other specified disorders of male genital organs Unspecified disorder of male genital organs Vaginitis and vulvovaginitis unspecified Vaginitis and vulvovaginitis in diseases classified elsewhere Unspecified prolapse of vaginal walls Cystocele, midline Cystocele, lateral Urethrocele Rectocele Perineocele Other prolapse of vaginal walls without mention of uterine prolapse Urinary-genital tract fistula female Digestive-genital tract fistula female Genital tract-skin fistula female Other specified fistulas involving female genital tract Unspecified fistula involving female genital tract Dyspareunia Stress incontinence female Vulvodynia, unspecified Vulvar vestibulitis Other vulvodynia Unspecified symptom associated with female genital organs Infertility female of unspecified origin Erosion of implanted vaginal mesh and other prosthetic materials to surrounding organ or tissue Exposure of implanted vaginal mesh and other prosthetic materials into vagina Spontaneous abortion PeaceHealth Laboratories | Medicare Coverage Policies 103 81000, 81001, 81002, 81003, 81005, 81007, 81015, 81020 Urinalysis……con’t 635.00-635.32 636.00-636.32 637.00-637.32 638.0 638.1 638.2 638.3 639.0 639.1 639.2 639.3 642.00 642.01 642.02 642.03 642.04 642.10 642.11 642.12 642.13 642.14 642.20 642.21 642.22 642.23 642.24 642.30 642.31 642.32 642.33 642.34 642.40 642.41 642.42 642.43 642.44 642.50 642.51 Legally induced abortion Illegal abortion Unspecified abortion Failed attempted abortion complicated by genital tract and pelvic infection Failed attempted abortion complicated by delayed or excessive hemorrhage Failed attempted abortion complicated by damage to pelvic organs or tissues Failed attempted abortion complicated by renal failure Genital tract and pelvic infection following abortion or ectopic and molar pregnancies Delayed or excessive hemorrhage following abortion or ectopic and molar pregnancies Damage to pelvic organs and tissues following abortion or ectopic and molar pregnancies Kidney failure following abortion and ectopic and molar pregnancies Benign essential hypertension complicating pregnancy childbirth and the puerperium unspecified as to episode of care Benign essential hypertension with delivery Benign essential hypertension with delivery with postpartum complication Antepartum benign essential hypertension Postpartum benign essential hypertension Hypertension secondary to renal disease complicating pregnancy childbirth and the puerperium unspecified as to episode of care Hypertension secondary to renal disease with delivery Hypertension secondary to renal disease with delivery with postpartum complication Hypertension secondary to renal disease antepartum Hypertension secondary to renal disease postpartum Other pre-existing hypertension complicating pregnancy childbirth and the puerperium unspecified as to episode of care Other pre-existing hypertension with delivery Other pre-existing hypertension with delivery with postpartum complication Other pre-existing hypertension antepartum Other pre-existing hypertension postpartum Transient hypertension of pregnancy unspecified as to episode of care Transient hypertension of pregnancy with delivery Transient hypertension of pregnancy with delivery with postpartum complication Antepartum transient hypertension Postpartum transient hypertension Mild or unspecified pre-eclampsia unspecified as to episode of care Mild or unspecified pre-eclampsia with delivery Mild or unspecified pre-eclampsia with delivery with postpartum complication Mild or unspecified pre-eclampsia antepartum Mild or unspecified pre-eclampsia postpartum Severe pre-eclampsia unspecified as to episode of care Severe pre-eclampsia with delivery PeaceHealth Laboratories | Medicare Coverage Policies 104 Urinalysis……con’t 642.52 642.53 642.54 642.60 642.61 642.62 642.63 642.64 642.70 642.71 642.72 642.73 642.74 642.90 642.91 642.92 642.93 642.94 646.10 646.11 646.12 646.13 646.14 646.20 646.21 646.22 646.23 646.24 646.50 646.51 646.52 646.53 646.54 646.60 81000, 81001, 81002, 81003, 81005, 81007, 81015, 81020 Severe pre-eclampsia with delivery with postpartum complication Severe pre-eclampsia antepartum Severe pre-eclampsia postpartum Eclampsia complicating pregnancy childbirth or the puerperium unspecified as to episode of care Eclampsia with delivery Eclampsia with delivery with postpartum complication Eclampsia antepartum Eclampsia postpartum Pre-eclampsia or eclampsia superimposed on pre-existing hypertension complicating pregnancy childbirth or the puerperium unspecified as to episode of care Pre-eclampsia or eclampsia superimposed on pre-existing hypertension with delivery Pre-eclampsia or eclampsia superimposed on pre-existing hypertension with delivery with postpartum complication Pre-eclampsia or eclampsia superimposed on pre-existing hypertension antepartum Pre-eclampsia or eclampsia superimposed on pre-existing hypertension postpartum Unspecified hypertension complicating pregnancy, childbirth, or the puerperium unspecified as to episode of care Unspecified hypertension with delivery Unspecified hypertension with delivery with postpartum complication Unspecified antepartum hypertension Unspecified postpartum hypertension Edema or excessive weight gain in pregnancy unspecified as to episode of care Edema or excessive weight gain in pregnancy with delivery with or without antepartum complication Edema or excessive weight gain in pregnancy with delivery with postpartum complication Antepartum edema or excessive weight gain Postpartum edema or excessive weight gain Unspecified renal disease in pregnancy unspecified as to episode of care Unspecified renal disease in pregnancy with delivery Unspecified renal disease in pregnancy with delivery with postpartum complication Unspecified antepartum renal disease Unspecified postpartum renal disease Asymptomatic bacteriuria in pregnancy unspecified as to episode of care Asymptomatic bacteriuria in pregnancy with delivery Asymptomatic bacteriuria in pregnancy with delivery with postpartum complication Antepartum asymptomatic bacteriuria Postpartum asymptomatic bacteriuria Infections of genitourinary tract in pregnancy unspecified as to episode of care PeaceHealth Laboratories | Medicare Coverage Policies 105 Urinalysis……con’t 646.61 646.62 646.63 646.64 647.10 647.11 647.12 647.13 647.14 648.00 648.01 648.02 648.03 648.04 648.80 648.81 648.82 648.83 648.84 654.40 654.41 654.42 654.43 654.44 658.40 658.41 658.43 659.20 659.21 659.23 659.30 659.31 659.33 664.80 81000, 81001, 81002, 81003, 81005, 81007, 81015, 81020 Infections of genitourinary tract in pregnancy with delivery Infections of genitourinary tract in pregnancy with delivery with postpartum complication Antepartum infections of genitourinary tract Postpartum infections of genitourinary tract Gonorrhea of mother complicating pregnancy, childbirth, or the puerperium; unspecified as to episode of care Gonorrhea of mother with delivery Gonorrhea of mother with delivery with postpartum complication Antepartum gonorrhea Postpartum gonorrhea Diabetes mellitus of mother complicating pregnancy, childbirth, or the puerperium unspecified as to episode of care Diabetes mellitus of mother with delivery Diabetes mellitus of mother with delivery with postpartum complication Antepartum diabetes mellitus Postpartum diabetes mellitus Abnormal glucose tolerance of mother complicating pregnancy, childbirth, or the puerperium; unspecified as to episode of care Abnormal glucose tolerance of mother with delivery Abnormal glucose tolerance of mother with delivery with postpartum complication Abnormal glucose tolerance of mother antepartum Abnormal glucose tolerance of mother postpartum Other abnormalities in shape or position of gravid uterus and of neighboring structures unspecified as to episode of care Other abnormalities in shape or position of gravid uterus and of neighboring structures delivered Other abnormalities in shape or position of gravid uterus and of neighboring structures delivered with postpartum complication Other abnormalities in shape or position of gravid uterus and of neighboring structures antepartum Other abnormalities in shape or position of gravid uterus and of neighboring structures postpartum Infection of amniotic cavity unspecified as to episode of care Infection of amniotic cavity delivered Infection of amniotic cavity antepartum Unspecified type maternal pyrexia during labor unspecified as to episode of care Unspecified type maternal pyrexia during labor delivered Unspecified type maternal pyrexia antepartum Generalized infection during labor unspecified as to episode of care Generalized infection during labor delivered Generalized infection during labor antepartum Other specified trauma to perineum and vulva unspecified as to episode of care in pregnancy PeaceHealth Laboratories | Medicare Coverage Policies 106 Urinalysis……con’t 664.81 664.84 664.90 664.91 664.94 665.40 665.41 665.44 665.50 665.51 665.54 665.80 665.81 665.82 665.83 665.84 669.30 669.32 669.34 670.00 670.02 670.04 670.20 670.22 670.24 670.82 670.84 672.00 672.02 672.04 710.0 710.1 710.2 710.3 710.4 710.9 711.00-711.09 714.0 81000, 81001, 81002, 81003, 81005, 81007, 81015, 81020 Other specified trauma to perineum and vulva with delivery Other specified trauma to perineum and vulva postpartum Unspecififed trauma to perineum and vulva unspecified as to episode of care in pregnancy Unspecified trauma to perineum and vulva with delivery Unspecified trauma to perineum and vulva postpartum High vaginal laceration unspecified as to episode of care in pregnancy High vaginal laceration with delivery High vaginal laceration postpartum Other injury to pelvic organs unspecified as to episode of care in pregnancy Other injury to pelvic organs with delivery Other injury to pelvic organs postpartum Other specified obstetrical trauma unspecified as to episode of care Other specified obstetrical trauma with delivery Other specified obstetrical trauma delivered with postpartum condition or complication Other specified obstetrical trauma antepartum Other specified obstetrical trauma postpartum Acute kidney failure following labor and delivery, unspecified as to episode of care or not applicable Acute kidney failure following labor and delivery, delivered, with mention of postpartum complication Acute kidney failure following labor and delivery, postpartum condition or complication Major puerperal infection, unspecified, unspecified as to episode of care or not applicable Major puerperal infection, unspecified, delivered, with mention of postpartum complication Major puerperal infection, unspecified, postpartum condition or complication Puerperal sepsis, unspecified as to episode of care or not applicable Puerperal sepsis, delivered, with mention of postpartum complication Puerperal sepsis, postpartum condition or complication Other major puerperal infection, delivered, with mention of postpartum complication Other major puerperal infection, postpartum condition or complication Puerperal pyrexia of unknown origin unspecified as to episode of care Puerperal pyrexia of unknown origin delivered with postpartum complication Puerperal pyrexia of unknown origin postpartum Systemic lupus erythematosus Systemic sclerosis Sicca syndrome Dermatomyositis Polymyositis Unspecified diffuse connective tissue disease Pyogenic arthritis Rheumatoid arthritis PeaceHealth Laboratories | Medicare Coverage Policies 107 81000, 81001, 81002, 81003, 81005, 81007, 81015, 81020 Urinalysis……con’t 714.1 714.2 714.30 714.31 714.32 714.33 714.4 714.81 714.89 714.9 719.-40-719.49 724.2 724.5 752.51 753.0 753.10 753.11 753.12 753.13 753.14 753.15 753.16 753.17 753.19 753.3 753.4 753.5 753.6 753.7 753.8 753.9 780.02 780.09 780.2 780.33 780.4 780.60 780.61 780.62 780.63 780.64 780.65 780.66 780.79 780.91 Felty’s syndrome Other rheumatoid arthritis with visceral or systemic involvement Chronic or unspecified polyarticular juvenile rheumatoid arthritis Acute polyarticular juvenile rheumatoid arthritis Pauciarticular juvenile rheumatoid arthritis Monoarticular juvenile rheumatoid arthritis Chronic postrheumatic arthropathy Rheumatoid lung Other specified inflammatory polyarthropathies Unspecified inflammatory polyarthropathy Pain in joint Lumbago Backache unspecified Undescended testis Renal agenesis and dysgenesis Cystic kidney disease unspecified Congenital single renal cyst Polycystic kidney unspecified type Polycystic kidney autosomal dominant Polycystic kidney autosomal recessive Renal dysplasia Medullary cystic kidney Medullary sponge kidney Other specified cystic kidney disease Other specified anomalies of kidney Other specified anomalies of ureter Exstrophy of urinary bladder Congenital atresia and stenosis of urethra and bladder neck Congenital anomalies of urachus Other specified congenital anomalies of bladder and urethra Unspecified congenital anomaly of urinary system Transient alteration of awareness Alteration of consciousness other Syncope and collapse Post traumatic seizures Dizziness and giddiness Fever, unspecified Fever presenting with conditions classified elsewhere Post-procedural fever Post-vaccination fever Chills (without fever) Hypothermia not associated with low environmental temperature Febrile non-hemolytic transfusion reaction Other malaise and fatigue Fussy infant (baby) PeaceHealth Laboratories | Medicare Coverage Policies 108 81000, 81001, 81002, 81003, 81005, 81007, 81015, 81020 Urinalysis……con’t 780.97 780.99 782.3 783.5 785.59 787.01 787.03 787.91 788.0 788.1 788.20 788.21 788.29 788.30 788.31 788.32 788.33 788.34 788.35 788.36 788.37 788.38 788.39 788.41 788.42 788.43 788.5 788.61 788.62 788.63 788.64 788.65 788.69 788.7 788.8 788.91 788.99 789.00-789.09 789.36 789.51 790.21 790.22 790.29 790.7 790.93 Altered mental status Other general symptoms Edema Polydipsia Other shock without trauma Nausea with vomiting Vomiting alone Diarrhea Renal colic Dysuria Retention of urine unspecified Incomplete bladder emptying Other specified retention of urine Urinary incontinence unspecified Urge incontinence Stress incontinence male Mixed incontinence (male) (female) Incontinence without sensory awareness Post-void dribbling Nocturnal enuresis Continuous leakage Overflow incontinence Other urinary incontinence Urinary frequency Polyuria Nocturia Oliguria and anuria Splitting of urinary stream Slowing of urinary stream Urgency of urination Urinary hesitancy Straining on urination Other abnormality of urinary stream Urethral discharge Extravasation of urine Functional urinary incontinence Other symptoms involving urinary system Abdominal pain Abdominal or pelvic swelling mass or lump epigastric Malignant ascites Impaired fasting glucose Impaired glucose tolerance test (oral) Other abnormal glucose Bacteremia Elevated prostate specific antigen (PSA) PeaceHealth Laboratories | Medicare Coverage Policies 109 81000, 81001, 81002, 81003, 81005, 81007, 81015, 81020 Urinalysis……con’t 790.95 791.0 791.1 791.2 791.3 791.4 791.5 791.6 791.7 791.9 793.5 793.6 794.4 795.79 796.2 799.21 799.22 799.23 799.24 799.59 806.5 806.70 806.71 808.0 808.1 808.2 808.3 808.41 808.42 808.43 808.44 808.49 808.51 808.52 808.53 808.54 808.59 808.9 866.00 866.01 866.02 866.03 Elevated C-reactive protein (CRP) Proteinuria Chyluria Hemoglobinuria Myoglobinuria Biliuria Glycosuria Acetonuria Other cells and casts in urine Other non-specific findings on examination of urine Non-specific (abnormal) findings on radiological and other examination of genitourinary organs Non-specific (abnormal) findings on radiological and other examination of abdominal area, including retroperitoneum Non-specific abnormal results of function study of kidney Other and unspecified non-specific immunological findings Elevated blood pressure reading without diagnosis of hypertension Nervousness Irritability Implusiveness Emotional lability Other signs and symptoms involving cognition Open fracture of lumbar spine with spinal cord injury Open fracture of sacrum and coccyx with unspecified spinal cord injury Open fracture of sacrum and coccyx with complete cauda equina lesion Closed fracture of acetabulum Open fracture of acetabulum Closed fracture of pubis Open fracture of pubis Closed fracture of ilium Closed fracture of ischium Multiple closed pelvic fractures with disruption of pelvic circle Multiple closed pelvic fractures without disruption of pelvic circle Closed fracture of other specified part of pelvis Open fracture of ilium Open fracture of ischium Multiple open pelvic fractures with disruption of pelvic circle Multiple open pelvic fractures without disruption of pelvic circle Open fracture of other specified part of pelvis Unspecified open fracture of pelvis Unspecified injury to kidney without open wound into cavity Hematoma of kidney without rupture of capsule without open wound into cavity Laceration of kidney without open wound into cavity Complete disruption of kidney parenchyma without open wound into cavity PeaceHealth Laboratories | Medicare Coverage Policies 110 81000, 81001, 81002, 81003, 81005, 81007, 81015, 81020 Urinalysis……con’t 866.10 866.11 866.12 866.13 867.0 867.1 867.2 867.3 867.6 867.7 867.8 867.9 868.00 868.09 868.10 868.19 869.0 869.1 876.1 878.0-878.7, 878.9 879.3,879.5,879.7879.9 922.1 922.2 922.31 922.32 922.33 922.4 926.0 926.11 926.12 926.19 926.8 927.00 928.00 928.01 928.10 928.8 929.0 929.9 939.0 939.2 Unspecified injury to kidney with open wound into cavity Hematoma of kidney without rupture of capsule with open wound into cavity Laceration of kidney with open wound into cavity Complete disruption of kidney parenchyma with open wound into cavity Injury to bladder and urethra without open wound into cavity Injury to bladder and urethra with open wound into cavity Injury to ureter without open wound into cavity Injury to ureter with open wound into cavity Injury to other specified pelvic organs without open wound into cavity Injury to other specified pelvic organs with open wound into cavity Injury to unspecified pelvic organ without open wound into cavity Injury to unspecified pelvic organ with open wound into cavity Injury to unspecified intra-abdominal organ without open wound into cavity Injury to other and multiple intra-abdominal organs without open wound into cavity Injury to unspecified intra-abdominal organ with open wound into cavity Injury to other and multiple intra-abdominal organs with open wound into cavity Internal injury to unspecified or ill-defined organs without open wound into cavity Internal injury to unspecified or ill-defined organs with open wound into cavity Open wound of back complicated Open wound of penis, scrotum and testes, vulva, or vagina Open wound of abdominal wall, parts of trunk,& of unspecified site(s) Contusion of chest wall Contusion of abdominal wall Contusion of back Contusion of buttock Contusion of interscapular region Contusion of genital organs Crushing injury of external genitalia Crushing injury of back Crushing injury of buttock Crushing injury of other specified sites of trunk Crushing injury of multiple sites of trunk Crushing injury of shoulder region Crushing injury of thigh Crushing injury of hip Crushing injury of lower leg Crushing injury of multiple sites of lower limb Crushing injury of multiple sites not elsewhere classified Crushing injury of unspecified site Foreign body in bladder and urethra Foreign body in vulva and vagina PeaceHealth Laboratories | Medicare Coverage Policies 111 81000, 81001, 81002, 81003, 81005, 81007, 81015, 81020 Urinalysis……con’t 939.3 939.9 941.39 941.49 941.59 942.20 942.22 942.23 942.24 942.29 942.30 942.32 942.33 942.34 942.39 942.40 942.42 942.43 942.44 942.49 942.50 942.52 942.53 942.54 942.59 943.30 Foreign body in penis Foreign body in unspecified site in genitourinary tract Full thickness skin loss due to burn (third degree NOS) of multiple sites (except with eye) of face, head, and neck Deep necrosis of underlying tissues due to burn (deep third degree) of multiple sites (except with eye) of face, head and neck without loss of a body part Deep necrosis of underlying tissues due to burn (deep third degree) of multiple sites (except eye) of face, head, and neck with loss of a body part Blisters with epidermal loss due to burn (second degree) of unspecified site of trunk Blisters with epidermal loss due to burn (second degree) of chest wall excluding breast and nipple Blisters with epidermal loss due to burn (second degree) of abdominal wall Blisters with epidermal loss due to burn (second degree) of back (any part) Blisters with epidermal loss due to burn (second degree) of other and multiple sites of trunk Full thickness skin loss due to burn (third degree NOS) of unspecified site of trunk Full thickness skin loss due to burn (third degree NOS) of chest wall excluding breast and nipple Full thickness skin loss due to burn (third degree NOS) of abdominal wall Full thickness skin loss due to burn (third degree NOS) of back (any part) Full thickness skin loss due to burn (third degree NOS) of other and multiple sites of trunk Deep necrosis of underlying tissues due to burn (deep third degree) of trunk unspecified site without loss of body part Deep necrosis of underlying tissues due to burn (deep third degree) of chest wall excluding breast and nipple without loss of chest wall Deep necrosis of underlying tissues due to burn (deep third degree) of abdominal wall without loss of abdominal wall Deep necrosis of underlying tissues due to burn (deep third degree) of back (any part) without loss of back Deep necrosis of underlying tissues due to burn (deep third degree) of other and multiple sites of trunk without loss of body part Deep necrosis of underlying tissues due to burn (deep third degree) of unspecified site of trunk with loss of body part Deep necrosis of underlying tissues due to burn (deep third degree) of chest wall excluding breast and nipple with loss of chest wall Deep necrosis of underlying tissues due to burn (deep third degree) of abdominal wall with loss of abdominal wall Deep necrosis of underlying tissues due to burn (deep third degree) of back (any part) with loss of back Deep necrosis of underlying tissues due to burn (deep third degree) of other and multiple sites of trunk with loss of a body part Full thickness skin loss due to burn (third degree NOS) of unspecified site of upper limb PeaceHealth Laboratories | Medicare Coverage Policies 112 Urinalysis……con’t 943.39 943.40 943.49 943.50 943.59 946.2 946.3 946.4 946.5 947.1 947.2 947.3 947.4 947.8 948.21-948.88, 948.90-948.99 949.3 949.4 949.5 958.5 959.11 959.12 959.13 959.14 959.19 961.2 963.1 963.3 965.1 992.0 992.1 992.2 992.3 992.4 992.5 81000, 81001, 81002, 81003, 81005, 81007, 81015, 81020 Full thickness skin loss due to burn (third degree NOS) of multiple sites of upper limb except wrist and hand Deep necrosis of underlying tissues due to burn (deep third degree) of unspecified site of upper limb without loss of a body part Deep necrosis of underlying tissues due to burn (deep third degree) of multiple sites of upper limb except wrist and hand without loss of upper limb Deep necrosis of underlying tissues due to burn (deep third degree) of unspecified site of upper limb with loss of a body part Deep necrosis of underlying tissues due to burn (deep third degree) of multiple sites of upper limb except wrist and hand with loss of upper limb Blisters with epidermal loss due to burn (second degree) of multiple specified sites Full thickness skin loss due to burn (third degree NOS) of multiple specified sites Deep necrosis of underlying tissues due to burn (deep third degree) of multiple specified sites without loss of a body part Deep necrosis of underlying tissues due to burn (deep third degree) of multiple specified sites with loss of a body part Burn of larynx trachea and lung Burn of esophagus Burn of gastrointestinal tract Burn of vagina and uterus Burn of other specified sites of internal organs Burn (any degree) Full thickness skin loss due to burn (third degree NOS) unspecified site Deep necrosis of underlying tissue due to burn (deep third degree) unspecified site without loss of a body part Deep necrosis of underlying tissues due to burn (deep third degree) unspecified site with loss of a body part Traumatic anuria Other injury of chest wall Other injury of abdomen Fracture of corpus cavernosum penis Other injury of external genitals Other and unspecified injury of other sites of trunk Poisoning by heavy metal anti-infectives Poisoning by antineoplastic and immunosuppressive drugs Poisoning by alkalizing agents Poisoning by salicylates Heat stroke and sunstroke Heat syncope Heat cramps Heat exhaustion anhydrotic Heat exhaustion due to salt depletion Heat exhaustion unspecified PeaceHealth Laboratories | Medicare Coverage Policies 113 81000, 81001, 81002, 81003, 81005, 81007, 81015, 81020 Urinalysis……con’t 992.6 992.7 992.8 995.20 995.21 995.22 995.23 995.27 995.29 995.53 995.54 995.59 996.30 996.31 996.32 996.39 996.62 996.64 996.65 996.76 996.81 997.5 998.00 998.01 998.02 998.09 998.2 999.32 999.33 999.34 999.60 999.61 999.62 999.63 999.69 999.70 999.71 999.72 999.73 Heat fatigue transient Heat edema Other specified heat effects Unspecified adverse effect of unspecified drug, medicinal, and biological substance Arthus phenomenon Unspecified adverse effect of anesthesia Unspecified adverse effect of insulin Other drug allergy Unspecified adverse effect of other drug, medicinal, and biological substance Child sex abuse Child physical abuse Other child abuse and neglect Mechanical complication of unspecified genitourinary device implant and graft Mechanical complication due to urethral (indwelling) catheter Mechanical complication due to intrauterine contraceptive device Other mechanical complication of genitourinary device implant and graft Infection and inflammatory reaction due to other vascular device implant and graft Infection and inflammatory reaction due to indwelling urinary catheter Infection and inflammatory reaction due to other genitourinary device implant and graft Other complications due to genitourinary device implant and graft Complications of transplanted kidney Urinary complications not elsewhere classified Post-operative shock, unspecified Post-operative shock, cardiogenic Post-operative shock, septic Post-operative shock, other Accidental puncture or laceration during a procedure not elsewhere classified Bloodstream infection due to central venous catheter Local infection due to central venous catheter Acute infection following transfusion, infusion, or injection, of blood and blood products ABO incompatibility reaction, unspecified ABO incompatibility with hemolytic transfusion reaction not specified as acute or delayed ABO incompatibility with acute hemolytic transfusion reaction ABO incompatibility with delayed hemolytic transfusion reaction Other ABO incompatibility reaction RH incompatibility reaction, unspecified RH incompatibility with hemolytic transfusion reaction not specified as acute or delayed RH incompatibility with acute hemolytic transfusion reaction RH incompatibility with delayed hemolytic transfusion reaction PeaceHealth Laboratories | Medicare Coverage Policies 114 81000, 81001, 81002, 81003, 81005, 81007, 81015, 81020 Urinalysis……con’t 999.74 999.75 999.76 999.77 999.78 999.79 999.80 999.81 999.82 999.83 999.84 999.85 999.88 999.89 V10.46-V10.59 V13.00 V13.01 V13.02 V13.03 V13.09 V13.62 V15.51 V15.59 V21.0 V21.1 V21.2 V21.30 V21.31 V21.32 V21.33 V21.34 V21.35 V21.8 V21.9 V22.0 V22.1 V22.2 V23.0 V23.1 V23.2 V23.3 V23.41 V23.49 Other RH incompatibility reaction Non-ABO incompatibility reaction, unspecified Non-ABO incompatibility with hemolytic transfusion reaction not specified as acute or delayed Non-ABO incompatibility with acute hemolytic transfusion reaction Non-ABO incompatibility with delayed hemolytic transfusion reaction Other non-ABO incompatibility reaction Transfusion reaction, unspecified Extravasation of vesicant chemotherapy Extravasation of other vesicant agent Hemolytic transfusion reaction, incompatibility unspecified Acute hemolytic transfusion reaction, incompatibility unspecified Delayed hemolytic transfusion reaction, incompatibility unspecified Other infusion reaction Other transfusion reaction Personal history of malignant neoplasm Personal history of unspecified urinary disorder Personal history of urinary calculi Personal history, urinary (tract) infection Personal history, nephrotic syndrome Personal history of other specified urinary system disorders Personal history of other (corrected) congenital malformations of genitourinary system Personal history of traumatic fracture Personal history of other injury Period of rapid growth in childhood Puberty Other development of adolescence Unspecified low birth weight status Low birth weight status less than 500 grams Low birth weight status 500-999 grams Low birth weight status 1000-1499 grams Low birth weight status 1500-1999 grams Low birth weight status 2000-2500 grams Other specified constitutional states in development Unspecified constitutional state in development Supervision of normal first pregnancy Supervision of other normal pregnancy Pregnant state incidental Supervision of high-risk pregnancy with history of infertility Supervision of high-risk pregnancy with history of tropho blastic disease Supervision of high-risk pregnancy with history of abortion Supervision of high-risk pregnancy with grand multiparity Supervision of high-risk pregnancy with history of pre-term labor Supervision of high-risk pregnancy with other poor obstetric history PeaceHealth Laboratories | Medicare Coverage Policies 115 Urinalysis……con’t V23.5 V23.7 V23.81 V23.82 V23.83 V23.84 V23.89 V23.9 V42.0 V44.50 V44.51 V44.52 V44.59 V44.6 V45.11 V45.12 V58.0 V58.63 V58.64 V58.65 V58.69 V59.4 V67.51 V87.01 V87.09 V87.11 V87.12 V87.19 V87.2 V90.83 81000, 81001, 81002, 81003, 81005, 81007, 81015, 81020 Supervision of high-risk pregnancy with other poor reproductive history Supervision of high-risk pregnancy with insufficient prenatal care Supervision of high-risk pregnancy with elderly primigravida Supervision of high-risk pregnancy with elderly multigravida Supervision of high-risk pregnancy with young primigravida Supervision of high-risk pregnancy with young multigravida Supervision of other high-risk pregnancy Supervision of unspecified high-risk pregnancy Kidney replaced by transplant Cystostomy unspecified Cutaneous-vesicostomy Appendico-vesicostomy Other cystostomy Status of other artificial opening of urinary tract Renal dialysis status Non-compliance with renal dialysis Radiotherapy Long-term (current) use of antiplatelets/antithrombotics Long-term (current) us of non-steroidal anti-inflammatories Long-term (current) use of steroids Long-term (current) use of other medications Kidney donors Follow-up examination following completed treatment with high-risk medication not elsewhere classified Contact with and (suspected) exposure to arsenic Contact with and (suspected) exposure to other hazardous metals Contact with and (suspected) exposure to aromatic amines Contact with and (suspected) exposure to benzene Contact with and (suspected) exposure to other hazardous aromatic compounds Contact with and (suspected) exposure to other potentially hazardous chemicals Retained stone or crystalline fragments PeaceHealth Laboratories | Medicare Coverage Policies 116 Urine Culture, Bacterial/ Sensitivity Studies Policy Type: NCD (National Coverage Decision) CPT CODE(S) 87086 87088 87184 87186 ICD-9 CODES 003.1 038.0–038.9 276.2 276.4 286.6 288.00-288.09 288.8 306.53 306.59 518.82 570 580.0–580.9 583.0–583.9 585.6 590.00–590.9 592.0–592.9 593.0–593.9 594.0–594.9 595.0–595.9 597.0 597.80–597.89 598.00–598.01 599.0 599.70-599.72 600.00 600.01 600.10 600.11 600.20 600.21 600.90 600.91 601.0–601.9 602.0–602.9 TEST NAME Culture, bacterial, urine; quantitative, colony count Culture, bacterial; with isolation and presumptive identification of each isolates, urine. Sensitivity studies, antibiotic; disk method, per plate (12 or fewer disks) Sensitivity studies, antibiotic; microtiter, minimum inhibitory concentration (MIC), any number of antibiotics ICD-9 DESCRIPTIONS Salmonella Septicemia Septicemia Acidosis Metabolic acidosis/alkalosis Defibrination syndrome/disseminated intravascular coagulation Neutropenia Other specified disease of white blood cells including leukemoid reaction/leukocytosis Psychogenic dysuria Other psychogenic genitourinary malfunction Other pulmonary insufficiency, not elsewhere classified Acute and subacute necrosis of liver Acute glomerulonephritis Nephritis and Nephropathy, not specified as acute or chronic End stage renal disease Infections of kidney/pyelonephritis acute and chronic Calculus of kidney and ureter Other disorders of kidney and ureter (cyst, stricture, obstruction, reflux, etc) Calculus of lower urinary tract Cystitis Urethritis, not sexually transmitted and urethral syndrome Other urethritis Urethral stricture due to infection Urinary tract infection, site not specified Hematuria Hypertrophy (benign) of prostate without urinary obstruction Hypertrophy (benign) of prostate with urinary obstruction Nodular prostate without urinary obstruction Nodular prostate with urinary obstruction Benign localized hyperplasia of prostate without urinary obstruction Benign localized hyperplasia of prostate with urinary obstruction Hyperplasia of prostate, unspecified, without urinary obstruction Hyperplasia of prostate, unspecified, with urinary obstruction Inflammatory diseases of prostate Other disorders of prostate (calculus, congestion, atrophy, etc) PeaceHealth Laboratories | Medicare Coverage Policies 117 Urine Culture.. con’t 604.0–604.99 608.0–608.9 614.0–614.9 615.0–615.9 616.0 616.10–616.11 616.2–616.9 619.0–619.9 625.6 639.0 639.5 646.60–646.64 670.00–670.04 670.10 670.12 670.14 670.20 670.22 670.24 670.30 670.32 670.34 670.80 670.82 670.84 672.00–672.04 724.5 771.81-771.83 780.02 780.60-780.66 780.79 780.93 780.94 780.96 780.97 780.99 785.0 785.50–785.59 788.0–788.99 87086, 87088, 87184, 87186 Orchitis and epididymitis Other disorders of male genital organs (seminal vesiculitis, spermatocele, etc) Inflammatory disease of ovary, fallopian tube, pelvic cellular tissue, and peritoneum Inflammatory disease of uterus, except cervix Cervicitis and endocervicitis Vaginitis and vulvovaginitis Other inflammatory conditions of cervix, vagina and vulva Fistula involving female genital tract Stress incontinence, female Genital tract and pelvic infection complicating abortion, ectopic or molar pregnancies Shock complicating abortion, ectopic or molar pregnancies Infections of genitourinary tract in pregnancy Major puerperal infection Puerperal endometritis, unspecified as to episode of care or not applicable Puerperal endometritis, delivered, with mention of postpartum complication Puerperal endometritis, postpartum condition or complication Puerperal sepsis, unspecified as to episode of care or not applicable Puerperal sepsis, delivered, with mention of postpartum complication Puerperal sepsis, postpartum condition or complication *Puerperal septic thrombophlebitis, unspecified as to episode of care or not applicable Puerperal septic thrombophlebitis, delivered, with mention of postpartum complication Puerperal septic thrombophlebitis, postpartum condition or complication Other major puerperal infection, unspecified as to episode of care or not applicable Other major puerperal infection, delivered, with mention of postpartum complication Other major puerperal infection, postpartum condition or complication Pyrexia of unknown origin during the puerperium Backache, unspecified Other infection specific to the perinatal period Transient alteration of awareness Fever/chills Other malaise and fatigue Memory loss Early satiety Generalized pain Altered mental status Other general symptoms Tachycardia, unspecified Shock without mention of trauma Symptoms involving urinary system (renal colic, dysuria, retention of urine, incontinence of urine, frequency, polyuria, nocturia, oliguria, anuria, other abnormality of urination, urethral discharge, travasation of urine, other symptoms of urinary system) PeaceHealth Laboratories | Medicare Coverage Policies 118 Urine Culture.. con’t 789.00–789.09 789.60–789.7 790.7 791.0–791.9 799.3 939.0 939.3 V44.50–V44.6 V55.5–V55.6 V58.69 87086, 87088, 87184, 87186 Abdominal pain Abdominal tenderness Bacteremia Nonspecific findings on examination of urine (proteinuria, chyluria, hemoglobinuria, myoglobinuria, biliuria, glycosuria, acetonuria, other cells and casts in urine, other nonspecific findings on examination of urine) Debility, unspecified (only for declining functional status) Foreign body in genitourinary tract, bladder and urethra Foreign body in genitourinary tract, penis Artificial cystostomy or other artificial opening of urinary tract status Attention to cystostomy or other artificial opening of urinary tract Long-term (current) use of other medications PeaceHealth Laboratories | Medicare Coverage Policies 119 Vitamin D Assay Testing Policy # L32132 Policy Type: LCD (Local Coverage Decision) CPT CODE(S) 82306 TEST NAME VITAMIN D; 25 HYDROXY, INCLUDES FRACTION(S), IF PERFORMED 82652 VITAMIN D; 1, 25 DIHYDROXY, INCLUDES FRACTION(S), IF PERFORMED The following ICD-9 CM codes support the medical necessity of CPT code 82306 ICD-9 CODES ICD-9 DESCRIPTION 252.00 Hyperparathyroidism, unspecified 252.01 Primary hyperparathyroidism 252.02 Secondary hyperparathyroidism, non-renal 252.08 Other hyperparathyroidism 252.1 Hypoparathyroidism 261 Nutritional marasmus 262 Other severe protein-calorie malnutrition 268.0 Rickets active 268.2 Osteomalacia unspecified 268.9* Unspecified vitamin d deficiency 275.3 Disorders of phosphorus metabolism 275.40* Unspecified disorder of calcium metabolism 275.41 Hypocalcemia 275.42 Hypercalcemia 278.4 Hypervitaminosis d 571.9 Unspecified chronic liver disease without alcohol 579.0 Celiac disease 579.1 Tropical sprue 579.2 Blind loop syndrome 579.3 Other and unspecified postsurgical nonabsorption 579.4 Pancreatic steatorrhea 579.8 Other specified intestinal malabsorption 579.9 Unspecified intestinal malabsorption 585.3 Chronic kidney disease, stage iii (moderate) 585.4 Chronic kidney disease, stage iv (severe) 585.5 Chronic kidney disease, stage v 585.6 End stage renal disease 588.81 Secondary hyperparathyroidism (of renal origin) 733.00 Osteoporosis unspecified 733.01 Senile osteoporosis 733.02 Idiopathic osteoporosis 733.09 Other osteoporosis 733.90 Disorder of bone and cartilage unspecified 756.52 Osteopetrosis PeaceHealth Laboratories | Medicare Coverage Policies 120 Vit D Assay.. con’t 82306, 82652 268.9* If more than one LCD-listed condition contributes to Vit. D deficiency in a given patient and/or is improved by Vit. D administration, coders should use: ICD-9-CM 268.9 UNSPECIFIED VITAMIN D DEFICIENCY. This code should not be used for any other indication. 275.40* Use only for HYPERCALCIURIA The following ICD-9-CM codes support the medical necessity of CPT code 82652 ICD-9 CODES ICD-9 DESCRIPTION 268.0 Rickets active 268.2* Osteomalacia unspecified 275.40* Unspecified disorder of calcium metabolism 275.42* Hypercalcemia 592.0 Calculus of kidney 592.1 Calculus of ureter 592.9 Urinary calculus unspecified 268.2* Use only for tumor-induced osteomalacia 275.40* Use only for unexplained hypercalciuria 275.42* Use only for unexplained hypercalcemia PeaceHealth Laboratories | Medicare Coverage Policies 121 Medicare Coverage Policies Additional Coding Guidelines 190.12 – Urine Culture, Bacterial 1. Specific coding guidelines: a. Use CPT 87086 Culture, bacterial, urine; quantitative, colony count where a urine culture colony count is performed to determine the approximate number of bacteria present per milliliter of urine. The number of units of service is determined by the number of specimens. b. Use CPT 87088 where a commercial kit uses manufacturer defined media for isolation, presumptive identification, and quantitation of morphotypes present. The number of units of service is determined by the number of specimens. c. Use CPT 87088 where identification of morphotypes recovered by quantitative culture or commercial kits and deemed to represent significant bacteriuria requires the use of additional testing, for example, biochemical test procedures on colonies. Identification based solely on visual observation of the primary media is usually not adequate to justify use of this code. The number of units of service is determined by the number of isolates. d. Use CPT 87184 or 87186 where susceptibility testing of isolates deemed to be significant is performed concurrently with identification. The number of units of service is determined by the number of isolates. These codes are not exclusively used for urine cultures but are appropriate for isolates from other sources as well. e. Appropriate combinations are as follows: CPT 87086, 1 per specimen with 87088, 1 per isolate and 87184 or 87186 where appropriate. f. Culture for other specific organism groups not ordinarily recovered by media used for aerobic urine culture may require use of additional CPT codes (for example, anaerobes from suprapubic samples). g. Identification of isolates by non-routine, nonbiochemical methods may be coded appropriately (for example, immunologic identification of streptococci, nucleic acid techniques for identification of N. gonorrhoeae). h. While infrequently used, sensitivity studies by methods other than CPT 87184 or 87186 are appropriate. CPT 87181, agar dilution method, each antibiotic or CPT 87188, macrotube dilution method, each antibiotic may be used. The number of units of service is the number of antibiotics multiplied by the number of unique isolates. 2. ICD-9-CM code 780.02, 780.9 or 799.3 should be used only in the situation of an elderly patient, immunocompromised patient or patient with neurologic disorder who presents without typical manifestations of a urinary tract infection but who presents with one of the following signs or symptoms, not otherwise explained by another co-existing condition: increasing debility; declining functional status; acute mental changes; changes in awareness; or hypothermia. 3. In cases of post renal-transplant urine culture used to detect clinically significant occult infection in patients on long term immunosuppressive therapy, use code V58.69. PeaceHealth Laboratories | Medicare Coverage Policies 122 Medicare Coverage Policies Additional Coding Guidelines …(con’t) 190.13 – Human Immunodeficiency Virus (HIV) Testing (Prognosis Including Monitoring) 1. Specific coding guidelines: a. Temporary code G0100 has been superseded by code 87536 effective January 1, 1998. b. CPT codes for quantification should not be used simultaneously with other nucleic acid detection codes for HIV-1 (that is, 87534, 87535) or HIV-2 (that is, 87537, 87538). 2. Codes 647.60-647.64 should only be used for HIV infections complicating pregnancy. 190.14 - Human Immunodeficiency Virus (HIV) Testing (Diagnosis) 1. Specific coding guidelines: a. CPT 86701 or 86703 is performed initially. CPT 86702 is performed when 86701 is negative and clinical suspicion of HIV-2 exists. b. CPT 86689 is performed only on samples repeatedly positive by 86701, 86702, or 86703. c. CPT 87534 or 87535 is used to detect HIV-1 RNA where indicated. CPT 87537 or 87538 is used to detect HIV-2 RNA where indicated. 190.16 – Partial Thromboplastin Time (PTT) 1. When patients are being converted from heparin therapy to warfarin therapy, use code V58.61 to document the medical necessity of the PTT. 2. When coding for Disseminated Intravascular Coagulation (DIC), use 286.6 or code for the signs and symptoms clinically indicating DIC. 3. If a specific condition is known and is the reason for a pre-operative test, submit the clinical text description or ICD-9-CM code describing the condition with the order/referral. If a specific condition or disease is not known, and the pre-operative test is for pre-operative clearance only, assign code V72.84. 4. Assign codes 289.8 – other specified disease of blood and blood-forming organs only when a specific disease exists and is indexed to 289.8, (for example, myelofibrosis). Do not assign code 289.8 to report a patient on long term use of anticoagulant therapy (for example, to report a PTT value or re-check need for medication adjustment.) Assign code V58.61 to referrals for PTT checks or re-checks. (Reference AHA’s Coding Clinic, March-April, pg 12 – 1987, 2nd quarter pg 8 – 1989) 190.17 – Prothrombin Time (PT) 1. If a specific condition is known and is the reason for a pre-operative test, submit the text description or ICD-9-CM code describing the condition with the order/referral. If a specific condition or disease is not known, and the pre-operative test is for pre-operative clearance only, assign code V72.84. PeaceHealth Laboratories | Medicare Coverage Policies 123 Medicare Coverage Policies Additional Coding Guidelines ...(con’t) 2. Assign codes 289.8 – other specified disease of blood and blood-forming organs only when a specific disease exists and is indexed to 289.8 (for example, myelofibrosis). Do not assign code 289.8 to report a patient on long term use of anticoagulant therapy (e.g. to report a PT value or re-check need for medication adjustment.) Assign code V58.61 to referrals for PT checks or re-checks. (Reference AHA’s Coding Clinic, March-April, pg 12 – 1987, 2nd quarter pg 8 – 1989) 190.19 – Collagen Crosslinks, Any Method 1. When the indication for the test is long-term administration of glucocorticosteroids, use ICD-9-CM code V58.69. 190.20 – Blood Glucose Testing 1. A diagnostic statement of impaired glucose tolerance must be evaluated in the context of the documentation in the medical record in order to assign the most accurate ICD-9-CM code. An abnormally elevated fasting blood glucose level in the absence of the diagnosis of diabetes is classified to Code 790.6 - other abnormal blood chemistry. If the provider bases the diagnostic statement of impaired glucose tolerance” on an abnormal glucose tolerance test, the condition is classified to 790.2 -normal glucose tolerance test. Both conditions are considered indications for ordering glycated hemoglobin or glycated protein testing in the absence of the diagnosis of diabetes mellitus. 2. When a patient is under treatment for a condition for which the tests in this policy are applicable, the ICD-9-CM code that best describes the condition is most frequently listed as the reason for the test. 3. When laboratory testing is done solely to monitor response to medication, the most accurate ICD-9CM code to describe the reason for the test would be V58.69 -- long term use of medication. 4. Periodic follow-up for encounters for laboratory testing for a patient with a prior history of a disease, who is no longer under treatment for the condition, would be coded with an appropriate code from the V67 category -- follow-up examination. 5. According to ICD-9-CM coding conventions, codes that appear in italics in the Alphabetic and/or Tabular columns of ICD-9-CM are considered manifestation codes that require the underlying condition to be coded and sequenced ahead of the manifestation. For example, the diagnostic statement, “thyrotoxic exophthalmos (376.21),” which appears in italics in the tabular listing, requires that the thyroid disorder (242.0-242.9) is coded and sequenced ahead of thyrotoxic exophthalmos. Therefore, a diagnostic statement that is listed as a manifestation in ICD-9-CM must be expanded to include the underlying disease in order to accurately code the condition. PeaceHealth Laboratories | Medicare Coverage Policies 124 Medicare Coverage Policies Additional Coding Guidelines ...(con’t) 190.21 – Glycated Hemoglobin/Glycated Protein 1. A diagnostic statement of impaired glucose tolerance must be evaluated in the context of the documentation in the medical record in order to assign the most accurate ICD-9-CM code. An abnormally elevated fasting blood glucose level in the absence of the diagnosis of diabetes is classified to Code 790.6 - other abnormal blood chemistry. If the provider bases the diagnostic statement of impaired glucose tolerance” on an abnormal glucose tolerance test, the condition is classified to 790.2 -normal glucose tolerance test. Both conditions are considered indications for ordering glycated hemoglobin or glycated protein testing in the absence of the diagnosis of diabetes mellitus. 190.22 – Thyroid Testing 1. When a patient is under treatment for a condition for which the tests in this policy are applicable, the ICD-9-CM code that best describes the condition is most frequently listed as the reason for the test. 2. When laboratory testing is done solely to monitor response to medication, the most accurate ICD-9CM code to describe the reason for the test would be V58.69 - long term use of medication. 3. Periodic follow-up for encounters for laboratory testing for a patient with a prior history of a disease, who is no longer under treatment for the condition, would be coded with an appropriate code from the V67 category -- follow-up examination. 4. According to ICD-9-CM coding conventions, codes that appear in italics in the Alphabetic and/or Tabular columns of ICD-9-CM are considered manifestation codes that require the underlying condition to be coded and sequenced ahead of the manifestation. For example, the diagnostic statement “thyrotoxic exophthalmos (376.21),” which appears in italics in the tabular listing, requires that the thyroid disorder (242.0-242.9) is coded and sequenced ahead of thyrotoxic exophthalmos. Therefore, a diagnostic statement that is listed as a manifestation in ICD-9-CM must be expanded to include the underlying disease in order to accurately code the condition. 5. Use code 728.9 to report muscle weakness as the indication for the test. Other diagnoses included 728.9 do not support medical necessity. 6. Use code 194.8 (Malignant neoplasm of other endocrine glands and related structures, other) to report multiple endocrine neoplasia syndromes (MEN-1 and MEN-2). Other diagnoses included in 194.8 do not support medical necessity. 190.26 – Carcinoembryonic Antigen 1. To show elevated CEA, use ICD-9-CM 790.99 (Other nonspecific findings on examination of blood) only if a more specific diagnosis has not been made. If a more specific diagnosis has been made, use the code for that diagnosis. PeaceHealth Laboratories | Medicare Coverage Policies 125 Medicare Coverage Policies Additional Coding Guidelines ...(con’t) 190.31 – Prostate Specific Antigen 1. To show elevated PSA, use ICD-9-CM code 790.93 (Elevated prostate specific antigen). If a more specific diagnosis code has been made, use the code for that diagnosis. L33034 – Urinalysis 1. Contractors may specify Bill Types to help providers identify those Bill Types typically used to report this service. Absence of a Bill Type does not guarantee that the policy does not apply to that Bill Type. Complete absence of all Bill Types indicates that coverage is not influenced by Bill Type and the policy should be assumed to apply equally to all claims. 012x Hospital Inpatient (Medicare Part B only) 013x Hospital Outpatient 014x Hospital – Laboratory Services provided to non-patients 022x Skilled Nursing – Inpatient (Medicare Part B only) 023x Skilled Nursing – Outpatient 085x Critical Access Hospital 2. Contractors may specify Revenue Codes to help providers identify those Revenue Codes typically used to report this service. In most instances Revenue Codes are purely advisory; unless specified in the policy services reported under other Revenue Codes are equally subject to this coverage determination. Complete absence of all Revenue Codes indicates that coverage is not influenced by Revenue Code and the policy should be assumed to apply equally to all Revenue Codes. 030X Laboratory – General Classification 031X Laboratory Pathology –General Classification PeaceHealth Laboratories | Medicare Coverage Policies 126
© Copyright 2024